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 Abstract 
Coronary artery disease (CAD) is a leading killer of human life worldwide. 
Clinically, stent implantation with percutaneous coronary intervention has 
become a standard and effective method to treat coronary artery disease. A large 
amount of research work has been carried out to investigate the mechanical, 
degradation and fatigue behavior for permanent metallic stents, but not for 
bioresorbable polymeric stents. Such research gaps are urgently required to be 
addressed, as bioresorbable polymeric stents are regarded as the next 
generation medical devices, even replacing metallic stents. In this thesis, 
pioneering efforts have been made to systematically study the mechanical 
behavior of polymeric stents using finite element method, which are novel and 
have not been reported in literature yet. Specifically, four commercially available 
bioresorbable polymeric stents (Absorb, Elixir, Igaki-Tamai and RevaMedical 
stents) were chosen to explore the effects of design on the mechanical 
performance of stent during the full deployment process. Fatigue behavior of 
implanted stents was also investigated for the Elixir stent subjected to pulsatile 
blood pressure. In particular, the change of stent material properties has been 
calibrated over degradation times and further applied to quantify the stent-artery 
interaction during long-term degradation process. Finally, both experimental and 
simulation work has been conducted to study the time-dependent material 
behavior and also the effect of loading rate on stent expansion. 
Comparative study between four bioresorbable polymeric stents (i.e., Absorb, 
Elixir, Igaki-Tamai and RevaMedical stents) showed that stent with larger U-bend 
amplitude and axial strut spacing has better flexibility and less stress 
concentration, but with higher recoiling effect. The radial stiffness and strength 
of stent are highly dependent on strut thickness, and thicker struts can 
significantly enhance the radial properties. Simulation of stent deployment in 
stenotic artery showed that stents exhibited dogbone shapes and achieved 
 smaller diameters due to the existence of plaque and artery. Stress 
concentrations were generated at the corner regions of U-bend struts, also on 
the plaque and artery. Also, stents gained slightly larger diameters and 
experienced less recoiling and dog-boning effects in simulations without 
considering crimping-caused residual stresses. Fatigue study showed that U-
bend regions of stent, with stress concentrations, had high risks of fatigue failure 
under pulsatile systolic-diastolic blood pressure. Over degradation times, stress 
variation on stent tended to increase firstly and then decrease gradually, 
corresponding to the change of yield stress for the stent material; whereas the 
stress on the plaque and arterial layers showed a continuous decrease. In 
addition, significant stress loss was observed for stent, plaque and artery in the 
simulations with the consideration of plaque regression. Experimental study of 
PLA/PBS blends showed that the crystallinity and brittleness of pure PLA can be 
improved by blending with ductile PBS, but with a sacrifice of mechanical 
stiffness and strength. The rate-dependent plastic deformation nature of 
PLA/PBS blends was also studied, which was found to influence stent expansion 
behaviour based on simulations. 
These findings offer a more thorough understanding of the mechanical behavior 
of polymeric stents during and after deployment and also a connection with 
clinical outcomes. Moreover, these research results can inform manufactures to 
improve stent performance in terms of optimal designs and material processing. 
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Chapter 1 - Introduction 
Cardiovascular diseases (CVDs) are the most common causes of global death. 
There were approximately 17.5 million people died from CVDs in 2012. This 
equals to 31% of the numbers of deaths worldwide, including 7.4 million caused 
by coronary heart disease and 6.7 million caused by stroke (World health 
organization, 2016). Disease of the heart and circulatory system is also one of 
most common causes of death in the UK. Statistically, there were 155,000 deaths 
in 2014 (Townsend, 2015). In 2015, NHS reported that there were approximately 
2.3 million people struggling with coronary heart disease. Also, 2 million patients 
were affected by chest pain in the UK. Since Puel and Sigwart deployed the first 
coronary stent in human to open the blocked coronary arteries in 1986, stenting, 
via the percutaneous transluminal coronary angioplasty (PTCA), has attracted 
considerable attention and become a standard surgical procedure to treat 
coronary artery disease (Newsome, 2006). Commercially, drug-eluting stent 
systems had a market value of approximately $1874 million in the United States 
in 2011. The sale of bioresorbable stent systems, reported by Medtech Insight 
(2013), was approximately $56.3 million in 2016. 
1.1 Coronary artery disease 
Coronary artery disease (CAD), also called coronary heart disease (CHD), is the 
most common type of heart diseases. Also, CAD is the major cause of heart 
attacks. In addition, CAD is a leading killer of human life worldwide. CAD is 
mainly caused by the build-up of cholesterol, calcium and other fatty substances 
(called plaque) on inner walls of coronary arteries. The plaque narrows the 
arteries and prevents blood flow between the heart and arteries. The process is 
also referred as atherosclerosis. As shown in Figure 1.1, coronary arteries are 
located on the surface of the heart, mainly supplying oxygen-rich blood to the 
2 
 
heart. The build-up and growth of the plaque limit the blood flow through the 
arteries, leading to angina (chest pain) or heart attack. Furthermore, CAD may 
weaken the heart muscle and cause the heart failure or arrhythmias over time. 
 
Figure 1.1, Coronary artery disease.  
(Source: http://medzul.com/coronary-artery-disease-and-its-treatment-in-india/ ) 
The treatment for coronary artery disease depends on where and how serious 
the atherosclerosis is, and what risks it may cause. Generally, coronary artery 
disease can be treated with pharmacologic therapy or surgical intervention. 
When the atherosclerosis is in the early stage, pharmacologic therapy is used. 
Statins and cholesterol-lowering medications are very effective in preventing the 
build-up of plaque in the arteries. Angiotensin-converting-enzyme (ACE) 
inhibitors, Beta blockers and Nitro-glycerine can deal with high blood pressure or 
angina. But in the case of severe atherosclerosis, surgical intervention is required, 
such as coronary artery bypass graft (CABG) surgery and percutaneous 
coronary intervention (PCI). CABG surgery was first performed by Kolesov and 
Favaloro in the 1960s, and then quickly developed as a principal technique for 
invasive treatment of CAD (Konstantinov, 1997). Although CABG offers complete 
3 
 
revascularization, there were some complications occurred due to its highly 
invasive nature, such as graft infection and chest wound infection (Reul, 2005). 
Gruntzig introduced an alternative and less invasive percutaneous coronary 
intervention (PCI) procedure after a decade. PCI has then developed from 
balloon angioplasty to bare-metal stent (BMS) technology and drug-eluting stent 
(DES) technology over the last several decades (Ded, 2013; Stefanini, 2013). 
Actually, since the first metallic stent (Palmaz-Schatz) was clinically evaluated 
and commercialized in the early 1990s, stent implantation with PCI has become 
the most widely used treatment for coronary artery diseases (Bhatia, 2010). 
1.2  What is a stent? 
In the technical vocabulary of medicine, a stent is a mesh 'tube' inserted into a 
natural passage or conduit in the body to prevent or counteract a disease-
induced, localized flow constriction (Basu, 2012). In other words, a typical 
coronary stent is regarded as a mesh tubular device, manufactured from metallic 
or polymeric materials, such as stainless steels, nickel-titanium alloy, cobalt-
chrome alloy and Poly (l-lactic acid) (PLLA), to help blood flow through blocked 
arteries. Moreover, a stent is not only used in coronary artery to treat heart 
disease, but also can be used to open the following passageways such as brain 
aneurysm, bile duct and bronchi in the lungs.  
Figure 1.2 shows the implantation procedure of coronary stent. It is achieved by 
the inflation and deflation of balloon attached to a catheter. Specifically, the 
manufactured stent is crimped onto a balloon catheter firstly, and then inserted 
into the site of diseased artery through a guide wire with the help of X-ray 
visualization technique. Afterwards, the balloon-stent system is expanded 
significantly to compress the atherosclerotic plaque and open up the blocked 
arterial lumen. Finally, the balloon catheter is withdrawn and the stent is 
permanently left in the artery. 
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Figure 1.2, The stenting procedure for the treatment of coronary artery 
diseases. (Source: http://theheartcenter.in/disease/coronery-artery-disease/) 
1.3 Aim and objectives 
The aim of this PhD project is to study the mechanical behaviour of bioresorbable 
polymeric stents during and after deployment, using the finite element method. 
This PhD research focuses on the effect of design, fatigue and degradation on 
the stent performance. In order to fulfil this aim, the following five objectives are 
identified: 
• To investigate the effect of stent designs on their performance during 
crimping and free expansion; 
• To compare the mechanical behaviour of polymeric stents with varied 
designs and their interactions with the plaque-artery system during their 
deployment in the stenotic artery; 
• To evaluate the fatigue behaviour of the selected polymeric stent after its 
deployment in the stenotic artery, under the pulsatile systolic-diastolic 
blood pressure; 
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• To simulate the stent-artery interaction by considering the material 
property change over degradation, and the plaque regression during 
vessel remodelling; 
• To model the process of stent crimping and expansion by considering the 
rate-dependent plastic behaviour of stent determined from experimental 
tests. 
The overall thesis structure is demonstrated in Figure 1.3. The thesis has been 
divided into 9 Chapters, based on the aim and objectives identified above. 
Chapter 2: Literature review is given, in terms of the development of stents, the 
materials for bioresorbable polymeric stents, and the existing experimental 
studies and computational analyse for stents. 
Chapter 3: A general methodology for the finite element modelling is 
demonstrated. Finite element models for stents, tri-folded balloon and plaque-
artery system, as well as the corresponding constitutive material models, are 
described. The simulation procedures for stent deployment are also introduced, 
with a mesh sensitivity study for stent and plaque-artery systems. 
Chapter 4: A comparative study is presented to investigate the mechanical 
behaviour of bioresorbable polymeric stents with four different designs, using the 
finite element method. 
Chapter 5: Stent deployment in stenotic artery is simulated to study the 
mechanical behaviour of both the stent and plaque-artery system. 
Chapter 6: Fatigue behaviour of polymeric stent is simulated by applying the 
pulsatile systolic-diastolic blood pressure. 
Chapter 7: The stent-artery interaction over degradation and during vessel 
remodelling is modelled, by considering the change of material property and the 
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regression of plaque. 
Chapter 8: Experimental work is presented, regarding the mechanical behaviour 
of PLA/PBS blend. The effect of rate-dependent material behaviour on stent 
behaviour is also evaluated using the finite element modelling. 
Chapter 9: Conclusions of this thesis are given, and further work is identified. 
 
Figure 1.3, The thesis structure. 
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Chapter 2 - Literature Review 
2.1 Development of stents 
2.1.1 Bare metal stents (BMSs) 
Over the last three decades, there has been rapid and effective development in 
stent designs, coatings and materials. The first generation of stents is called 
bare-metal stents (BMSs). The initial BMSs were balloon expandable or self-
expandable, made of 316L stainless steel or nitinol wire coils with various 
designs (Serruys, 2006). The first FDA-approved stent, called Palmaz-Schatz 
(Johnson & Johnson), was developed by Schatz and his colleges in 1987 (Gerg, 
2010). It was the first stainless steel, balloon-expandable, slotted tube stent 
which was approved for the treatment in the peripheral arteries in 1991 and in 
coronary arteries in 1994. It remained as one of the most widely studied and used 
device in 1990s. Ellis et al. (1992) presented the initial clinical results after the 
placement of Palmaz-Schatz stent in 206 consecutive patients, and their results 
showed that the overall incidence of restenosis was 30% for single stent 
placement and 64% for multiple overlapping stents placement. In 1993, two 
landmark clinical trials were carried out to evaluate the clinical efficacy of Palmaz-
Schatz stent. The North American Stent Restenosis Study (STRESS) showed 
that patients treated with stents had a lower rate of restenosis (31.6% vs 42.1%) 
and target vessel revascularization (10.2% vs 15.4%) than those treated with 
balloon angioplasty (Fischman, 1994). The Belgium Netherlands Stent Arterial 
Revascularization Therapies Study (BENESTENT) showed an even lower rate 
of restenosis (22% vs 32%) in stent treated groups when compared with balloon 
angioplasty treated group (Serruys, 1994).  
Another FDA-approved BMS is balloon-expandable Gianturco-Roubin stent, 
which is manufactured by wrapping flat 316L stainless steel wire coil to a single 
longitudinal strut. Dean et al. (1997) reported that complications, such as 
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thrombosis (7.3%), ejection (58%) and abrupt closure (20.3%), were found in the 
initial treatment of 350 patients who received the Gianturco-Roubin stent 
implantations. Subsequently, many other types of BMSs were developed in early 
1990s, i.e., Flexstent (Cook), Cordis (Cordis), Wiktor (Medtronic) and Multi-link 
(Advanced Cardiovascular systems), and they were all made of stainless steel. 
These BMSs were initially developed to reduce the severe elastic recoil and 
restenosis generally encountered for balloon angioplasty, but showed a high risk 
of acute stent thrombosis and mid- or long-term in-stent restenosis (Serruys, 
1991). Recently, cobalt-chromium alloys emerged as a new material choice of 
BMSs, allowing the development of stents with much thinner struts. The most 
recent BMSs include Vision (Abbott Vascular), Driver (Medtronic), Coroflex (B-
Braun), made of cobalt-chromium alloys, and Omega stent (Boston Scientific), 
made of platinum-chromium alloy. However, long-term complications, especially 
stent thrombosis and in-stent restenosis, occurred with the use of these BMSs. 
The in-stent restenosis and target vessel revascularization were found to be very 
high, which was in the range of 50-60% and 30-50%, respectively, when 
implanted in patients with small vessels or long and bifurcation lesions (Yokol, 
1996). 
2.1.2 Drug-eluting stents (DESs) 
In order to deal with the complications associated with BMS implantation, drug-
eluting stents (DESs) were developed by coating a BMS platform with a thin layer 
containing drugs and carrier materials. Figure 2.1 shows the different 
generations of drug-eluting stents. The first generation of DESs include the 
Cypher stent (Cordis) and the Taxus stent (Boston Scientific), both made of 
stainless steel. The Cypher stent combines the poly (ethylene-co-vinyl acetate) 
(PEVA) and poly (n-butyl methacrylate) (PBMA) as polymer coating that carries 
140 µg/ cm2 sirolimus drug, and approximately 80% of drug is designed to 
release within 30 days after stent deployment (Moses, 2003). The Cypher 
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sirolimus-eluting stent was the first DES approved by EU CE and US FDA in April 
2002 and April 2003, and since then they have been implanted in more than 3 
million patients globally. The Taxus stent is coated with triblock copolymer poly 
(styrene-b-isobutylene-b-styrene) (SIBS) for the enhanced delivery of paclitaxel 
drug (100 µg/ cm2), which is released at a fast rate in the initial 48 hours and a 
relatively slow rate in the following 10 days (Stone, 2004). The drug paclitaxel 
was proved effective to minimize in-stent restenosis. The Taxus paclitaxel-eluting 
stent also received the approval of CE and FDA in 2002 and 2004. 
The second generation includes the Xience stent (Abbott Vascular) and the 
Endeavor stent (Medtronic Cardio Vascular), both made of Cobalt-Chromium 
alloy. The Endeavor stent is made of MP35N Cobalt-Chromium alloy with 
significantly thinner strut (91 µm), and was approved by CE and FDA in July 2005 
and February 2008, respectively. The coating for Endeavor stent is biocompatible 
PC copolymer which carries 100 µg/ cm2 of drug zotarolimus, designed to have 
95% release within 15 days after stent deployment (Meredith, 2005). The Xience 
stent is L-605 Cobalt-Chromium balloon expandable stent with advanced design 
features (i.e., high flexibility and deliverability, acceptable recoil and better 
compliance), which was approved by CE and FDA in January 2006 and July 2008, 
respectively. It has even thinner strut (81 µm), utilizing biocompatible polymer 
PBMA with PVDF-HFP as coating layer to carry everlimus drug of 100 µg/ cm2. 
The drug dose is designed to be released by approximately 80% within 30 days 
after stent deployment (Serruys, 2005). 
Both first and second generations of DESs have been used in various clinical 
studies to evaluate their efficacy and safety after the deployment in patients, 
since they were approved and commercialized. Table 2-1 and  
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Table 2-2 summarized the results from clinical trials of first-and second- 
generation DESs compared with BMSs. These clinical results suggested that the 
DESs showed significantly clinical safety and efficacy during the short- and mid-
term follow-up compared to BMSs. 
 
Figure 2.1, Different generations of drug-eluting stents. 
However, with the wide clinical use of DESs, some long-term safety issues were 
identified, such as late stent thrombosis and severe inflammation. Generally, 
stent thrombosis is regarded as a potentially fatal adverse event which usually 
leads to myocardial infarction death, which usually happens very late (>12 
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months) after the deployment of drug eluting stent (Martin, 2011). Stone et al. 
(2007) reported that the stent thrombosis rates at 4 years were 1.2% and 1.3% 
for Cypher sirolimus-eluting stent and Taxus paclitaxel-eluting stent groups, 
respectively, compared to 0.6 % and 0.9% in bare-metal stent groups. Daemen 
et al. (2007) addressed that both early and late stent thrombosis were observed 
with the deployment of Cypher and Taxus stents, and late stent thrombosis 
happened steadily at a constant rate of 0.6% each year up to 3 years after stent 
deployment. Wenaweser et al. (2008) also assessed the risk of late stent 
thrombosis in a long-term follow-up study, and found that late stent thrombosis 
occurred steadily at an annual rate of 0.4%-0.6% up to 4 years. Tada et al. (2013) 
compared the risk of stent thrombosis among patients implanted with BMSs, first 
generation DESs and second generation DESs, and their results showed that 
stent thrombosis rate was 1.5% for BMSs, 2.2% for the first generation DESs 
and 1.0% for the second generation DESs at 3 years. 
The exact cause of stent thrombosis is not fully understood yet, but the use of 
non-bioresorbable polymer coatings may be the possible factors associated with 
the risk of stent thrombosis. Joner et al. (2008) addressed that the non-erodible 
polymer coatings with DES impair stent strut endothelialisation and may cause 
late sensitivity reactions and subsequent stent thrombosis. John et al. (2008) 
identified that delayed healing and incomplete endothelial strut coverage may 
increase the risk of stent thrombosis. Nakazawa et al. (2008) pointed out that the 
delayed arterial healing was extremely possible to increase the risk of thrombotic 
complications in patients treated with DESs. Consequently, these safety issues 
prompted the efforts towards development of bioreosrbable polymers, polymer-
free metal platform and even completely resorbable DES platforms. 
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Table 2-1, Clinical trials of first generation DES vs BMS. 
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Table 2-2, Clinical trials of second generation DES vs BMS. 
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2.1.3 Bioresorbable stents (BRSs) 
Bioresorbable stents (BRSs) are made of materials that may dissolve or be 
absorbed in the body, so they can provide the mechanical support and then 
disappear within a specific period of time. There are several bioresorbable stents 
available during different stages of development, i.e., Dreams stent (Biotronik), 
Igaki-Tamai stent (Kyoto Medical), Reva stent (Reva Medical), Absorb stent 
(Abbott Vascular) and Elixir stent (Elixir Medical), as shown in Figure 2.2. 
Biotronik introduced the first bioresorbable magnesium stent (Dreams), but the 
clinical trial showed that significant restenosis rate occurred due to the 
accelerated absorption time and insufficient radial strength (Iqbal, 2013). The 
Igaki-Tamai stent is a fully bioresorbable, first in-human PLLA scaffold with no 
coating or drugs, which received CE approval for use in treatment of peripheral 
artery disease in 2007 and has already been available in the European market 
since 2009. The Reva stent, made of proprietary polymer, has a unique feature 
that can be visualized by X-ray during the deployment and early follow-up. 
However, so far, only Absorb and Elixir bioresorbable stents got CE approval for 
use in coronary artery disease. The Absorb stent is made of PLLA and coated 
with a layer of PDLLA controlling the release of drug everolimus, but its strut 
thickness was designed as 150 µm to provide sufficient mechanical support. It 
has two versions, i.e., BVS 1.0 and BVS 1.1. The BVS 1.1 has an improved 
design to enhance radial strength, mechanical integrity and drug release kinetics. 
The Elixir, with PLLA platform, 150 µm strut thickness and resorption time of 1 
year, has an advantage of greater expansion and reduced strut fracture risk 
compared to other bioresorbable stents (Haude, 2013). 
These bioresorbable stents also have been widely evaluated in a range of clinical 
trials for a comparative study of their safety and efficacy with DESs/BMSs. Table 
2-3 summarizes the past and current clinical trials for bioresorbable stents, 
providing evidence supporting their use in clinical practise. Generally, most 
15 
 
clinical data were obtained from small or non-randomized trials, evaluating 
patients with relatively stable coronary artery disease or de novo lesions. 
Therefore, further studies are needed to evaluate the safety and efficacy of 
bioresorbable stents in treatments of diseases in more complex lesions. 
 
Figure 2.2, Summary of currently existing bioresorbable stents. 
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Table 2-3, Summary of clinical trials of bioresorbable stents.   
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Regarding a range of clinical trials, BRSs showed some potential advantages 
against DESs. BRSs provide mechanical support for an adequate time period 
and then disappear to prevent long-term side effects, such as stent thrombosis, 
bleeding complication and inflammation caused by permanent metallic stent. 
Also, BRSs allow the use of non-invasive imaging techniques for follow-up 
studies, such as computer tomography (CT) and magnetic resonance imaging 
(MRI) (Brie, 2016). However, there are still some challenges in the development 
of bioresorbable stents. As shown in the Figure 2.1 and Figure 2.2, conventional 
metallic stents have an approximately 80 µm thickness of strut while the strut 
thickness for BRSs is around 150-200 µm. The almost double thicker struts of 
BRSs may cause severe vessel injury, platelet deposition, nonlaminar flow and 
poor deliverability (Wiebe, 2014). It is well known that polymers have weaker 
material properties compared to metal, and therefore the mechanical behaviour 
of bioresorbable polymeric stents are limited during deployment at high pressure 
conditions. Also, there are high risks of strut fracture and stent failure during the 
over-dilatation of bioresorbable polymeric stents, due to their limited radial 
strength (Wayangankar, 2015). Therefore, further development of BRSs is highly 
required. 
2.1.4 Conclusion 
Coronary artery disease is one of major killers of human life all over the world. 
Percutaneous coronary intervention (PCI) with stenting has been established as 
a standard treatment for the coronary heart disease. Over the past two decades, 
stents have been rapidly developed from bare-metal stents (BMSs), to drug-
eluting stents (DESs) and bioresorbable stents (BRSs). BRSs have a unique 
feature that they can disappear within a period of time after providing the 
essential mechanical lumen support in the diseased arteries and reduce long-
term clinical complications, because they are made of materials that can dissolve 
and be absorbed in the human bodies. The current clinical studies showed that 
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bioresorbable stents showed comparable clinical safety and efficacy with 
permanent metallic stents, and therefore they have large potential to be the next-
generation stents for treatment of coronary artery disease. However, the 
bioresorbable stents face the challenge of stent designs and manufacturing due 
to the relatively weak mechanical properties of polymer PLLA. Further clinical 
studies and research work are still required. 
2.2 Materials for Bioresorbable Stents 
As summarized in the Section 2.1, most bioresorbable stents are made of 
biodegradable poly-L-lactic acid (PLLA) or corrodible magnesium alloy. In fact, 
bioresorbable polymeric materials have already been widely used in medical field, 
such as tissue scaffolds, vascular grafts, vascular stents, sutures and temporary 
bone fixation devices. This section aims to review existing and potential material 
candidates used for bioresorbable stents. 
2.2.1 Corrodible metallic alloys 
The bioresorbable metallic stents attract much interest, due to their similar 
mechanical properties to permanent metallic stents. Two types of metal alloys, 
i.e., iron alloy and magnesium alloy, are currently being studied and evaluated 
as material candidates for bioresorbable scaffold application. 
2.2.1.1 Iron alloy 
Iron plays an important role in acting as cytochromes, oxygen-binding molecules 
(e.g., haemoglobin and myoglobin) and many enzymes, to deal with cellular 
respiration and oxidation in plants, animals and human body. Mueller et al. (2006) 
reported that iron ions can reduce the proliferation rate of vascular smooth 
muscle cells by influencing growth-related gene expansion, which may help 
antagonize restenosis in vivo. Iron also has good mechanical property, i.e., high 
elastic modulus, radial strength and ductility, which enables thinner-strut stents 
and hence easier stent expansion within plastic deformation region (Moravej, 
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2011). Therefore, iron becomes an attractive material for the bioresorbable stents. 
Peuster et al. (2001) evaluated the safety and efficacy of first bioresorbable iron 
stent (Armco iron) in descending aorta of white rabbits. The 6-18 months follow-
up study showed that no thromboembolic complications, such as adverse events, 
significant inflammatory response or systemic iron toxicity, were observed. In 
2006, another study was performed to evaluate and compare the safety of iron 
stent with commercially available 316L stainless steel stent, in the descending 
aorta of 29 mini pigs (Peuster, 2006). Their results showed no significant 
difference was observed between iron and 316L stent regarding neointimal 
proliferation, and there was no evidence for iron overload or iron-related toxicity. 
But the iron stents didn’t corrode completely during the follow-up times in these 
two studies, due to the slow degradation rate of iron. Waksman et al. (2008) 
implanted iron stent and cobalt chromium stent in porcine coronary arteries to 
compare their safety and efficacy. Again, no significant difference was found in 
the measured results. Observation results showed the iron stent started to show 
signs of degradation at 28 days, but without occurrence of stent particle 
embolization or thrombosis. These studies suggested the safety of iron stent, but 
a faster degradation rate was desirable. 
2.2.1.2 Magnesium alloy 
Magnesium alloy is another metallic material candidate for bioresorbable stents 
because it has low thrombogenicity and good biocompatibility. Pure magnesium 
degrades rapidly in aggressive chloride environment such as human body, with 
various degradation rates in a range of 2 to 12 months by alloying with rare earth 
elements (Kitabata, 2014). There are two Mg alloys widely investigated for 
bioresorbable stents, i.e., AE21 (2 wt. % Al and 1 wt. % rare earth elements) and 
WE43 (4 wt. % Y and 3 wt. % RE). Generally, magnesium and its alloys have 
lower mechanical properties compared to 316L stainless steel. For instance, pure 
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magnesium has yield strength of only 20 MPa and WE43 Mg alloy has an 
elongation of only 2%, as shown in  
Table 2-4. In vivo degradation studies revealed that a prolonged degradation rate 
was desirable for Mg alloy stents (Allen, 1998). 
 
Table 2-4, Summary of properties for corrodible metal compared to SS 316L. 
 
Bioresorbable magnesium stents have been evaluated in various preclinical and 
clinical studies. Heublein et al. (2003) firstly investigated bioresorbable AE21 Mg 
alloy stent and implanted them in porcine coronary arteries, and results showed 
there were no thromboembolic events. However, a problem was found that the 
degradation rate of AE21 stent was faster than expected, with a significant loss 
of mechanical integrity. Waksman et al. (2006) evaluated the safety and efficacy 
of bioresorbable WE34 Mg alloy stents in porcine coronary arteries, and the 3-
month follow-up report showed no occurrence of stent particle embolization, 
thrombosis, excess inflammation or fibrin deposition. Moreover, Peeters et al. 
(2005) implanted the Mg alloy stents in 20 patients with critical limb ischemia, 
and no symptoms of allergic or toxic reactions were observed in preliminary 3-
month follow-up. Bosiers et al. (2005) reported the long-term follow-up outcome 
for the same stent, and results showed the stent had a continuous absorption 
progress, leading to a completely invisibility of stent material at 12 months. 
Theses preclinical and clinical results suggested that the development of new 
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magnesium alloy is required regarding mechanical property, drug elution and 
degradation rate. Recently, a modified drug-eluting bioresorbable WE43 Mg alloy 
stent, called Dreams, has been developed and evaluated in patients with 
coronary artery disease, as summarized in the previous section. 
 
2.2.2 Biodegradable polymers 
Biodegradable polymer is a specific type of polymer that breaks down to natural 
by-products (i.e., water, gases (CO2 and N2), biomass and inorganic salts) after 
its intended purpose (Bastioli, 2005). Biodegradable polymeric materials consist 
of aliphatic polyesters, polyorthoesters, polyanhydrides and polyurethanes, and 
aliphatic polyesters are the most commonly investigated and used material for 
bioresorbable medical devices. Aliphatic polyesters, including poly-L-lactic acid 
(PLLA), poly-D-lactic acid (PDLA), poly-D, L-lactic acid (PDLLA), poly-Ɛ-
caprolactone (PCL), poly-L-glycolide (PGA), and copolymers poly-D, L-lactide-
co-glycolide (PLGA), have also been studied as potential materials for 
bioresorbable stents (Eberhart, 2003). 
2.2.2.1 Poly-lactic acid (PLA) 
Chemical compositions and thermal properties 
Poly-lactic acid (PLA), as a member of aliphatic polyester family, is a 
biodegradable and bioactive material derived from renewable resources, i.e., 
corn starch, tapioca roots and sugarcane. There are two lactic acid monomers 
(L-lactic acid and D-lactic acid) used for the synthesis of PLA. Polymerization of 
these two monomers forms three different types of lactide, such as L-lactide, D-
lactide and Meso-lactide, as shown in Figure 2.3. Therefore, PLA can exist in 
three different stereo chemical forms: PLLA, PDLA and PDLLA.  There are three 
synthesis methods for PLA, including the conventional polycondensation, 
dehydration condensation of lactic acids and ring-opening polymerization of 
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lactides. Ring-opening polymerization of lactide is the most common method to 
obtain PLA with high molecular weight (Nampoothiri, 2010). 
 
Figure 2.3, Lactic acid monomer and stereoforms of lactide (Nampoothiri, 2010). 
The morphology of PLA can be amorphous or semi-crystalline, depending on the 
chemical composition, temperature, processing time and molecular weight. 
Generally, pure PLLA and PDLA are semi-crystalline due to the stereo regular 
chain microstructure, while PDLLA is optically amorphous because of stereo 
complex mixture of monomers (Tesfamariam, 2016). Crystallinity, melting 
temperature (Tm) and glass transition temperature (Tg) are most commonly used 
to characterize thermal properties of polymer. The degree of crystallinity can be 
obtained from the equation: 
 𝐶𝑟𝑦𝑠𝑡𝑎𝑙𝑙𝑖𝑛𝑖𝑡𝑦 % = ∆H. − ∆H093.1 ∗ 100 (2.1) 
where ∆𝐻8  is measured as heat of fusion and ∆𝐻9  is enthalpy of cold 
crystallization. The enthalpy of fusion for 100% crystalline PLLA or PDLA 
homopolymers is 93.1 J/g. The glass transition is defined as a reversible 
transition in amorphous materials or amorphous regions from a hard and 
relatively brittle state into a rubber-like state. Pure PLLA has a glass transition 
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temperature between 60-65°C, a melting temperature of 173-178 °C and a 
crystallinity of approximately 37% (Nampoothiri, 2010). Thermal properties play 
an important role in the degradable and mechanical properties of polymer. 
Biodegradation behaviour 
Generally, degradation of polymer occurs by the way of hydrolysis and 
chemical/enzymatic oxidation. During chemical/enzymatic oxidation, oxygen 
species (i.e., superoxide 𝑂;<  and hydrogen peroxide 𝐻;𝑂; ) generated by 
inflammatory cells cause polymer chain to fracture, which then leads to their 
degradation. In hydrolysis, water catalyzes chain scissions at ester bonds and 
converts polymer into simple monomers, followed by loss of molecular weight, 
reduction of mechanical integrity and loss of mass (Tesfamariam, 2016). The 
mechanism of degradation can be classified as bulk degradation and surface 
erosion mechanism. Bulk degradation is identified as the hydrolysis of chemical 
bonds in the chain of polymeric biomaterial, and typically leads to an empty shell 
but not change geometries. Surface erosion occurs at the interface between 
polymer and suspension, and results in thinner surface but maintains bulk 
integrity (Tamada, 1993). Corresponding to these two different degradation 
mechanisms described above, there are two types of degradation-monitoring 
techniques, i.e., surface analysis (i.e., X-ray photoelectron spectroscopy) and 
bulk analysis (measurement of the changes in molecular weight, weight loss, 
temperature transitions and mechanical properties). 
The hydrolytic degradation process can be divided into three stages, as shown 
in Figure 2.4. During the initial stage, the polymer undertakes water via gradual 
diffusion, which leads to a very slight loss of molecular weight but with no change 
in mass and mechanical strength. At the second stage, a significant reduction of 
molecular weight is observed due to the hydration of polymer, while the change 
of mechanical strength is limited. At the third stage, both mechanical strength 
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and mass reduce significantly as a result of scission of the amorphous tie chains. 
 
Figure 2.4, Hydrolytic degradation of semi-crystalline biodegradable 
polyester (Ang, 2016). 
The degradation behaviour of PLA has been widely characterized and is affected 
by multiple factors, i.e., chemical composition, crystallinity, molecular weight, 
temperature, pH level and catalytic additives (enzymes, bacteria or inorganic 
fillers) (Park, 2009). Duek et al. (1999) studied the in vitro degradation behaviour 
of PLLA pins in a phosphate buffer solution (PBS) (pH=7.4), with different 
degrees of crystallinity. Results showed that the PLLA pins with extensive 
crystallinity underwent faster degradation during 6-month incubation time. It was 
reported that PLA can be recycled back to lactic acid monomer by hydrolysis of 
boiling water or steam, which can benefit the recycling between raw material and 
post-manufactured products. For example, PLLA could be hydrolysed to obtain 
L-lactic acid at temperature of 180-350°C for approximately 30 minutes (Auras, 
2004). Xu et al. (2011) addressed that the pH level and temperature had a large 
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effect on degradation rate of PLA brushes obtained from ring-opening 
polymerization of L-lactide, and the brushes degraded very slowly in acidic 
solution. Gorrasi et al. (2013) investigated the hydrolysis process of various 
commercial grades of PLA films (i.e., 4060D, 2002D and 4032D), with different 
morphologies (D-lactide content), in bidi stilled water at 58°C. Results showed 
that PLA underwent a polymeric chain breakdown with the reduction of molecular 
weight and mass loss, which were faster for PLA sample with more D-lactide 
contents. Liu et al. (2014) studied the biodegradation behaviour of PLLA, 
PLLA/pearl powder scaffolds in PBS for up to 200 days, and typical degradation 
behaviours were observed, such as change of molecular weight, pH level, weight 
and mechanical properties. They concluded that the PLLA/powder scaffolds had 
slower rate of degradation than PLLA. Li et al. (2017) investigated the in vitro 
degradation behaviour of pure PLA and its composite PLA/MAO-MAWs, and 
reported that the PLA/MAO-MAWs had a lower degradation rate than that of pure 
PLA due to the synergic function of Mg2+ ions. They also found that the high 
temperature and external compression stress could accelerate the degradation 
of PLA and its composites.  
Mechanical properties 
It was reported that semicrystalline PLA has an approximately tensile modulus of 
3 GPa, tensile strength of 50-70 MPa, and elongation of 4% at break (Sodergard, 
2002). Tensile properties of PLA, such as tensile modulus, elongation at break 
and ultimate strength, are most commonly studied to support its widespread 
application or in comparison to other polymers. Figure 2.5 highlights the tensile 
properties of PLLA in comparison with some metallic materials used for stents. It 
shows that further improvement of mechanical properties is highly required for 
bioresorbabale polymeric materials. Generally, the mechanical properties of PLA 
vary from soft and elastic material to stiff and high strength plastics, which is 
highly dependent on thermal properties (i.e., crystallinity and molecular weight), 
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degradation, material processing and polymer blending. 
 
Figure 2.5, Comparison of mechanical and degradation properties of polymeric 
and metallic materials (Ang, 2016). 
A number of studies have been conducted to investigate the effect of polymer 
blending on the mechanical properties of PLA/PLLA. Nijenhuis et al. (1996) 
studied the mechanical properties of blend PLLA/PEO with up to 20 wt. % of 
PEO, and reported that the elongation at break of the blend was significantly 
increased to 180%, but with a compromise of tensile strength. Bhatia et al. (2007) 
characterized the tensile properties of PLA/PBS with different weight ratios, and 
results showed the tensile strength decreased gradually from 60 MPa (pure PLA) 
to 25 MPa, and Young’ modulus decreased from 1200 MPa (pure PLA) to 600 
MPa for 50/50 PLA/PBS blend, whereas no significant difference was found for 
the elongation at break. Lu et al. (2007) investigated the effect of PES on the 
tensile properties of PLLA/PES blend, and reported that the Young’s modulus 
decreased slightly from 1980 MPa to 1490 MPa and 1380 MPa for PLLA/PBS 
blends with 0 %, 40 % and 60 % weight ratios of PES, respectively. Significant 
increase was obtained for the elongation at break of the blend, i.e., 15% for 
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PLLA/PES (80/20) and 140% for PLLA/PES (60/40) compared to 5% for pure 
PLLA. Yang et al. (2008) addressed that the tensile strength and elongation at 
break of PLA could be improved by blending with polycarbodiimide (CDI), but not 
very significant. Ning et al. (2008) used poly (1, 3-butylene adipate) (PBA) as a 
plasticiser for PLA, and found that the elongation at break of PLA/PBA could be 
increased to 600% with 30 wt. % of PBA content. Liang et al. (2013) studied the 
tensile properties of PLLA/PCL/nano-CACO3 composites with different weight 
ratios of PCL, and found that the tensile modulus and strength at failure for the 
composites reduced nonlinearly with the increase of PCL weight ratio, while the 
elongation at break for the composite increased significantly with over 60% 
weight ratio of PCL. Homklin and Hongsriphan (2013) evaluated the influence of 
nucleating agents (Nano-sized calcium carbonate (NPCC) and sodium benzoate 
(SB)) on the mechanical properties of PLA/PBS blends, and reported that both 
tensile strength and elongation at break of the blends were reduced with the 
added filler of NPCC and SB. Navarro-Baena et al. (2016) studied the tensile 
stress-strain behaviours for PLA/PCL blends, and they concluded that the tensile 
modulus and yield stress were decreased but the elongation at break was 
dramatically increased for the blends with  30 wt. % of PCL content. Malinowski 
(2016) investigated the mechanical properties of PLA/PCL blends containing 
triallyl isocyanurate (TAIC) agent, and results showed that tensile modulus and 
strength of the blends were improved, but not the elongation at break, with the 
increase of agent dose. 
Thermal properties of PLA, such as molecular weight, crystallinity and stereo 
chemical structure, also play an important role in depicting its mechanical 
properties. Meijer and Govaert (2005) addressed that the averaged molecular 
weight determines the mechanical strength of polymer, and high molecular 
weight enhances mechanical properties like strain at break and impact 
resistance. Nunes et al. (1982) reviewed a large amount of literature on the 
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mechanical properties of polymer as a function of molecular weight and 
distribution, and concluded generally the mechanical properties of polymer 
increase as the molecular weight increases. They also reported that polymers 
with molecular weight above 100 kDa have enough chains entanglements to 
exhibit more ductile behaviour. For example, tensile modulus of PLA can be 
increased by a factor of 2 with an increase of molecular weight from 50 to 100 
kDa, and tensile strength can be improved from 15.5 MPa to 80 and 150 MPa 
when the molecular is 50, 150 and 200 kDa, respectively (Farah, 2016). 
Perego et al. (1996) characterized mechanical properties of PLA with different 
molecular weights and degrees of crystallinity, and their results showed that 
crystalline PLLA with high molecular weight had more interesting tensile and 
flexural properties. They also pointed out that crystallization significantly 
improved stiffness and strength of PLLA. Liu et al. (2014) figured out that 
crystallization mediation offered the simplest and most practical approach to 
enhance the properties of PLA, because PLA followed the basic structure and 
property relationship, i.e., crystallization benefits the rigidity, stiffness and thermal 
resistance. Sarasua et al. (2005) prepared PLLA, PDLA and PLLA/PDLA 
samples by various annealing methods and studied the effect of crystallinity and 
chemical composition on the mechanical behaviour of material. They found that 
the ductility decreased with crystallinity degree for pure PLLA and PDLA, while 
PLLA/PDLA blend showed high stiffness than that of pure components. Cocca et 
al. (2011) reported that the mechanical properties of PLLA films were influenced 
by both crystallinity degree and crystal structure. The Young’s modulus of PLLA 
films increased from 3 GPa to 4 GPa when the crystallinity degree increased 
from 30% to 45%, while the elongation at break reduced from 3% to 2%. 
Hartmann (1998) also addressed that the stereo chemical structure of PLA could 
be modified by controlling the polymerization of L- or D-lactides to obtain high 
mechanical strength. For example, the ultimate tensile strength was 31 MPa for 
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pure PLLA, but increased to 50 MPa for the 1:1 stereo complex PDLLA. 
2.2.2.2 Other polymers 
Poly-Ɛ-caprolactone (PCL) 
PCL is semicrystaline linear polyester and obtained from ring-opening 
polymerization of relatively cheap Ɛ-caprolactone, with good biodegradability and 
biocompatibility. Generally, PCL has a low melting temperature of approximately 
55-60°C and glass transition temperature of -60°C, which makes it easy for the 
material to be processed and blended with other polymers. PCL mainly 
undergoes hydrolytic degradation because of the existence of hydrolytically labile 
aliphatic ester linkages, but it has a shorter degradation time (2-3 years) 
compared to PLLA due to its lower crystallinity degree (Nair, 2007). Furthermore, 
it was reported that PCL has a low tensile strength (about 23 MPa) but an 
extemely high elongation at break (>700%) (Gunatillake, 2006). 
PCL has been widely investigated for applications in different delivery systems 
in form of microspheres, nanospheres and implants, due to its slow degradation 
rate, high permeability to drugs and non-toxicity (Sinha, 2004). Mondrins et al. 
(2006) studied on pure PCL and PCL/Calcium phosphate (PCL-CaP) scaffolds, 
fabricated by SFF-based injection moulding process, for tissue engineering. 
They revealed that scaffolds made of PCL and PCL-CaP displayed in vitro 
cytocompatibility and interesting mechanical properties (i.e. compressive 
modulus and ultimate compressive strength) for hard tissue repair. Recently, 
Khoshroo et al. (2017) evaluated the in vitro safety and efficacy of PCL 
microsphere/TNT composite scaffolds for bone tissue. The in vitro biological 
results showed that the PCL/TNT (0.5 wt. %) had better biocompatibility and 
bioactivity than pure PCL scaffolds, and constituted a good substrate for cell 
differentiation. Mechanical testing results also revealed that PCL/TNT (0.5 wt. %) 
exhibited higher compressive modulus and strength than others. 
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Poly-L-glycolide (PGA) 
PGA is another biodegradable synthetic polymer candidate for biomedical 
applications, and it can be synthetized by polymerization of glycolic acid, ring-
opening polymerization of glycolide or reaction of formaldehyde with carbon 
monoxide in the presence of acid (Wypych, 2016). It has a glass transition 
temperature of 35-40°C, melting temperature of 225-230°C, and a high 
crystallinity of 35-55%. Due to the high crystallinity, homopolymer PGA exhibits 
greater strength and stiffness than PLA, and was reported to achieve a modulus 
of 12.8 GPa. However, PGA degrades very rapidly, leading to the loss of strength 
in 1-2 months, and its breakdown products cause inflammation in the 
surrounding tissues (Maurus, 2004). 
PGA was firstly used for bioresorbable suture (DEXON) in 1960 due to its 
excellent processing capability (Wypych, 2016). Then, Terasaka et al. (2006) 
evaluated the efficacy of PGA nonwoven fabric composite used as a novel 
biocompatible substitute. The material exhibited excellent closing ability without 
requiring suture, suggesting PGA’s potential alternative for biological tissue. 
Furthermore, PGA was also investigated for application as bone internal fixation 
devices, called Biofox, because of its good initial mechanical properties (Valentin, 
2013). 
Poly-D, L-lactide-co-glycolide (PLGA) 
PLGA is a FDA-approved biodegradable polymer that is physically strong and 
highly biocompatible, and have been widely investigated for applications as 
carriers delivering drugs, proteins and other macromolecules (Makadia, 2011). It 
is a copolymer synthesized from ring-opening polymerization of PLA and PGA, 
and exhibits a wide range of properties with different composition ratios of PLA 
and PGA. However, a linear relationship doesn’t exist between properties and 
composition ratios for copolymer PLGA. For example, PLGA (50/50) has a faster 
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degradation rate than pure PLA and PGA (Middleton, 2000). 
PLGA has been extensively developed for use as medical devices and drug 
delivery systems. PLGA with composition ratio of 90/10 was initially considered 
in the development of multifilament suture Vicryl and Vicryl Rapid, a revised 
version of Vicryl to increase the degradation rate (Domb, 2014). Zhai et al. (2015) 
evaluated the safety and efficacy of PLGA/alginate composite microspheres for 
hydrophilic protein delivery, and their results suggested that PLGA/alginate 
composite microspheres might be useful device for the sustained release of 
hydrophilic biomolecules. 
2.2.3 Conclusion 
In this section, existing and potential materials for bioresorbable stents have 
been discussed, including corrodible metallic alloys and biodegradable polymers. 
Generally, each material has its own advantages and limitations. Corrodible 
metallic alloys (i.e., iron alloy and magnesium alloy) possess comparable 
mechanical properties with permanent metallic materials and have been widely 
applied for biomedical scaffolds in animals, but face the problems of either too 
fast or too slow degradation rate. Biodegradable polymers, especially PLLA and 
its copolymers, have attracted much interest for bioresorbable stents application. 
Firstly, it is because that they can break down to natural by-products (i.e., water, 
biomass and inorganic salts) after the intended purpose. Secondly, polymer 
PLLA has been widely investigated and used in medical devices (i.e., sutures 
and tissue scaffolds), with appropriate degradation rate. However, it is generally 
known that polymers have significantly weaker mechanical properties compared 
to metals, which leads to a problem of balancing the degradation rate and 
mechanical property for PLLA in stent application. Therefore, further studies are 
needed regarding further development of both material processing and stent 
technology. 
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2.3 Arteries and atherosclerotic plaques 
Stent implantations are mechanical procedures, and therefore their performance 
is influenced by applied pressure, geometries of stent-balloon-artery-plaque 
system, and their mechanical properties. In this section, studies on artery and 
plaque are reviewed, including histological structures and mechanical 
behaviours. 
2.3.1 Histological structures 
2.3.1.1 Histological structure of normal artery 
Generally, there are two types of arteries, i.e., elastic and muscular, and the 
elastic arteries are usually located close to the heart with relatively large 
diameters while the muscular arteries are mainly located in the periphery. Figure 
2.6 shows the histological structure of elastic arteries. Basically, a normal arterial 
wall is composed of three layers, i.e., intima, media and adventitia.  
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Figure 2.6, Histological structure of normal arterial wall (Gasser, 2006). 
Intima 
Intima is the inner layer of artery, in direct contact with flowing blood, and 
composed of an endothelial cell layer and a subendothelial tissue layer. The 
endothelial cells are lined by tight junctions of intercellular cohesion and gap 
junctions of intercellular electrochemical coupling. However, the endothelial layer 
doesn’t contribute significantly to the load-bearing capability of the whole arterial 
wall (Camare, 2017). The subendothelial layer constitutes connective tissue 
basement membrane with embedded elastic fibres, and its thickness varies from 
almost zero up to geometrically dominant size. The orientation of fibres is proven 
to be non-uniform throughout the thickness of the subendothelial layer (Gasser, 
2006). Furthermore, the subendothelial layer makes contributions to the load-
bearing capability of the whole arterial wall. 
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Media 
Media is the middle layer of artery, which is separated from the intima layer and 
the adventitia layer by internal and external elastic lamina, respectively. It mainly 
consists of smooth muscle cells, elastin and collagen fibres. The smooth muscle 
cells, elastin and bundles of collagen fibres interconnect with each other to 
constitute a continuous fibrous helix which is almost circumferentially oriented 
within the media layer. Through polarized light microscopy, Canham et al. (1989) 
revealed that the collagen fibres and smooth muscle cells are consistently and 
coherently aligned along circumferential direction in the media layer, and 
suggested that this arrangement can resist high loads in circumferential direction. 
Adventitia 
Adventitia is the outer layer of artery, and mainly composed of elastic and 
collagen fibres and connective tissues. The thickness of the adventitia layer is 
strongly dependent on its topographical sites and physiological functions. The 
structure of adventitia layer was shown to be helically arranged by two families 
of collagen fibres, and the individual collagen fibre has a significant deviation 
from their mean orientation (Canham, 1989). Moreover, the collagen fibres play 
an important role in maintaining the stability and strength of the whole arterial 
wall. However, Shekhonin et al. (1985) addressed that there is no big difference 
in the distribution of collagen fibres in the media and adventitia layers between 
normal artery and atherosclerotic artery.  
2.3.1.2 Atherosclerotic plaque  
Atherosclerosis is one of the most common cardiovascular diseases, and can be 
characterized by symmetric/asymmetric thickening of arterial walls compared to 
their normal conditions. An atherosclerotic plaque forms on the inner arterial wall, 
and mainly consists of accumulated lipids, cells, calcium, collagen and 
inflammatory infiltrates (Naghavi, 2003). The classification of plaque 
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compositions is generally based on histological or morphological methods such 
as Magnetic Resonance Imaging (MRI), ultrasound imaging techniques, R-Ray 
and Fourier Transform Infrared (FTIR). 
Kragel et al. (1989) studied the composition of atherosclerotic plaques obtained 
from coronary arteries in 27 patients using a computerized morphometry system. 
Their results showed that plaque compositions included dense fibrous tissue, 
loose fibrous tissue, cellular fibrous tissue, heavily calcified tissue, pultaceous 
debris, foam cells and inflammatory infiltrates.  Lee et al. (1991) performed 
histological study on human atherosclerotic plaques, which were classified as 
cellular, hypocellular and calcified based on the various fibrous caps, as shown 
in Figure 2.7. Maher et al. (2009) classified fresh human carotid atherosclerotic 
plaques as calcified, echolucent and mixed by using routine Duplex ultrasound 
with grey scale imaging, which was determined by a clinician. 
 
Figure 2.7, Photomicrographs showing morphological distinguishable subtypes 
of fibrous caps from atherosclerotic plaque: (A) Cellular plaque, (B) 
Hypocellular plaque and (C) Calcified plaque (Lee, 1991). 
2.3.2 Mechanical behaviour 
2.3.2.1 Experimental studies on arteries and plaques 
In real life condition, the arterial walls are subjected to complex loading conditions, 
such as simultaneous cyclic inflation, axial extension and even twist. To study 
the mechanical properties of coronary arteries, in vivo test is preferable but very 
difficult due to limitations of arterial samples and experimental setup. Therefore, 
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some in vitro experiments were performed instead. Van Andel et al. (2003) 
studied the circumferential and axial stress-strain behaviours of human coronary 
arteries, in comparison with those of porcine arteries, as shown in Figure 2.8. 
The results showed that the porcine arteries were far more elastic in both 
circumferential and axial directions than human arteries. It also suggested that 
the mechanical behaviour of human arteries was anisotropic, exhibiting different 
properties in circumferential and axial directions.  
Karimi et al. (2013) investigated the mechanical properties of both healthy and 
atherosclerotic coronary arteries by uniaxial tensile testing method. The authors 
found that the atherosclerotic coronary arteries showed a significantly higher 
stiffness than healthy arteries whereas the healthy arteries exhibited 2.9 times 
higher maximum elastic modulus than atherosclerotic arteries. 
Holzapfel et al. (2005) firstly studied the mechanical response of individual layers 
of human coronary arteries, and characterized both circumferential and 
longitudinal behaviour of three arterial layers by carrying out uniaxial cyclic 
tensile testing, as shown in Figure 2.9. Results revealed that all specimens had 
small hysteresis and exhibited strong nonlinear and anisotropic behaviour. The 
intima is the stiffest layer and the media is the softest layer in longitudinal 
direction. Teng et al. (2009) studied the ultimate strength of the adventitia and 
media layers for human atherosclerotic carotid arteries in circumferential and 
axial directions. It was reported that the adventitia layer had a mean ultimate 
strength of 1996 kPa and 1800 kPa in the axial and circumferential directions 
respectively while the corresponding values for the media layer were 520 kPa 
and 1230 kPa, respectively. 
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Figure 2.8, Circumferential /axial stress versus circumferential strain behaviours 
for human coronary arteries and porcine arteries (Van Andel, 2003). 
Similarly, experimental work was also carried out to study the mechanical 
behaviour of atherosclerotic plaques. Born and Richardson (1990) studied the 
tensile properties of human coronary plaques, and addressed that there was no 
significant difference for the stress-strain response in axial and circumferential 
directions, but with a large variation between different samples. Loree et al. (1994) 
conducted tensile testing on 26 human aortic intimal plaque specimens to extract 
their stress-strain behaviour. The specimens were histologically classified as 
cellular, hypocellular and calcified, and their stress-strain curves were shown in 
Figure 2.10. Again, a large variation was observed from the stress-strain curves 
of the three types of plaque. The hypocellular plaques were about twice stiffer 
than cellular plaques. The tangential modulus exhibited an increase with the 
increase of applied tensile stress for all 26 specimens. Moreover, the 
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atherosclerotic plaques showed strongly nonlinear behaviour. 
 
Figure 2.9, Uniaxial tensile stress-stretch responses for intima, media and 
adventitia samples in circumferential (A) and longitudinal (B) directions 
(Holzapfel, 2005). 
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Figure 2.10, Tensile stress-strain curves for cellular, hypocellular and calcified 
specimens (Loree, 1994). 
2.3.2.2 Constitutive models for arteries and plaques 
The histological structure and mechanical response of arterial wall and 
atherosclerotic plaque are extremely complex, including incompressibility, 
anisotropy and non-linearity. So far, there have been several constitutive models 
developed to describe and predict the mechanical behaviour of artery and 
atherosclerotic plaque. 
Mooney-Rivlin model 
The Mooney-Rivlin model is described in the general form of strain energy 
function (Walter, 1998): 
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 𝑊 = 𝐶>? 𝐼A − 3 > 𝐼; − 3 ? + 𝐷 𝐽 − 1 ;?>  (2.2) 
 𝐼A = 𝜆A; + 𝜆;; + 𝜆F; (2.3) 
 𝐼; = 𝜆A;𝜆;; + 𝜆A;𝜆F; + 𝜆;;𝜆F; (2.4) 
 𝐼F = 𝜆A;𝜆;;𝜆F; (2.5) 
where 𝐼>(𝑖 = 1,2,3) and 𝜆>(𝑖 = 1,2,3) are the strain invariants and stretches in 
three principal directions, respectively, and 𝐶>?(𝑖, 𝑗 = 1,2,3) and 𝐷 are material 
constants associated with distortional r and volumetric response, respectively. 
When the material is incompressible, we have 𝐽 = 1. 
A specific form of the Mooney-Rivlin model, which is suitable for an 
incompressible isotropic material, was widely used in computational studies of 
arteries and plaques (Lally, 2003; Lee, 2003; Pericevic, 2009). The function is 
given by: 
 𝑊 = 𝐶AL 𝐼A − 3 + 𝐶LA 𝐼; − 3 + 𝐶;L 𝐼A − 3 ;+ 𝐶AA 𝐼A − 3 𝐼; − 3 + 𝐶FL 𝐼A − 3 F (2.6) 
This model was calibrated by fitting to uniaxial and biaxial tensile test data of 
porcine arterial tissues, with model coefficients were summarized in . 
Table 2-5. 
Table 2-5, Coefficients used for the Mooney-Rivlin model (Pericevic, 2009). 
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Ogden model 
The Ogden hyperelastic strain energy potential is presented by (Ogden, 1972): 
 𝑊 = 2µ>𝛼>; (𝜆AOP + 𝜆;OP + 𝜆FOP − 3)Q>RA + 1𝐷> (𝐽 − 1);>
Q
>RA  (2.7) 
where µ>, 𝛼> and 𝐷> are the hyperelastic material model constants, ( µ> and  𝛼> represent the material shear behaviour, and 𝐷> describes compressibility of 
the material), 𝜆> are the deviatoric principle stretches, 𝐽 is the elastic volume 
strain, and 𝑁 is the order of the equation. 
Generally, the material behaviour of three-layered artery is defined by taking the 
third order Ogden hyperelastic constitutive equation, whereas atherosclerotic 
plaque is modelled by the first order Ogden equation. The material model 
constants were determined by fitting the tensile testing data of human coronary 
artery (in circumferential direction) (Holzapfel, 2005) and hypercellular plaque 
(Loree, 1994), as shown in Table 2-6.  This model has been widely used in 
computer simulations of the interaction between arteries and stents 
(Zahedmanesh, 2009; Zahedmanesh, 2010; Schiavone, 2014).   
Table 2-6, Constitutive constants of Ogden model (Zahedmanesh, 2009). 
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The Mooney-Rivlin and Ogden models are isotropic and nonlinear, largely used 
to model rubber-like materials that are considered as isotropic hyperelastic 
materials. They have good capabilities for capturing large deformation behaviour 
of materials. 
Holzapfel-Gasser-Ogden (HGO) model 
HGO model is an anisotropic hyperelastic model, which has the capability of 
modelling materials that exhibit highly anisotropic and nonlinear elastic behaviour, 
such as biomedical soft tissues and fibre-reinforced elastomers. Based on the 
work of Holzapfel et al. (2000) and Gasser et al. (2006), a general form of HGO 
model (also available in Abaqus), with the consideration of collegen fibre 
orientations, is given as:  
 
W = CAL IA − 3 + 1D (J);2 − ln[
+ kA2k; exp k; Ea ; − 1baRA  
(2.8) 
 Ea = κ IA − 3 + (1 − 3κ) Id(aa) − 1  (2.9) 
where CAL  ,  D  , 	kA  ,  k;  and κ  are temperature-dependent material 
parameters, N is the number of fibre families (N ≤ 3), IA is the first deviatoric 
strain invariant, J is the elastic volume ratio,  Id(aa) is the invariant of Cauchy-
Green deformation tensor and Ea  represents the deformation of the fibre 
families. The operator <> stands for the Macaulay bracket. 
The model assumes that the directions of the collagen fibres are dispersed about 
a mean preferred direction for each fibre family. The parameter κ represents the 
level of dispersion in the fibre directions. The first two terms in the expression of 
the strain energy function describe the distortional and volumetric contributions 
of the non-collagenous isotropic ground material, and the third term represents 
the contribution from the different families of collagen fibres by taking dispersion 
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effect into account. 
2.3.3 Conclusion 
In this section, the histological structure of artery and atherosclerotic plaque were 
discussed, and they played an important role in depicting the overall mechanical 
behaviour of the healthy and diseased vessels. The experimental and 
computational studies of tissue mechanical behaviour were also reviewed, 
including tensile stress-strain behaviour and constitutive models. In summary, 
the three-layer artery and atherosclerotic plaque are biological soft tissues that 
exhibit nonlinear, anisotropic hyperelastic behaviour, which need to be 
considered in studying the mechanical interaction between stents and diseased 
arteries. 
2.4 Experimental studies on stents 
Stents, as medical devices used in human bodies, impose difficulties and 
challenges for experimental studies due to their tiny and complex designs. 
However, researchers also developed various methods to investigate the 
behaviours of stents experimentally, which are reviewed in this section. 
2.4.1 Mechanical behaviour studies 
2.4.1.1 Metallic stents  
Experimental studies have been carried out to investigate the radial and 
longitudinal flexibility of metallic stents by means of in-vitro expansion, 
compression and bending tests. Schmidt et al. (2009) investigated and compared 
the mechanical performance characteristics (i.e., pushability, trackability and 
crossability) of seven drug-eluting stent systems (i.e., Biosensors Biomatrix, 
Conor Costar, Cordis Cypher, Medtronic Endeavor, Boston Scientific Taxus, 
Guidant Xience V and Braun Coroflex Please) using a standardized in-vitro 
model. The in-vitro model had a guide wire (Guidant HI-Torque Balance Middle 
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Weight 0.014”), a guide catheter (Cordis Vista brite tip 6F JL3.5 0.067”) and mock 
coronary vessels that were produced based on typical vessel anatomy. Results 
showed that the pushability, defined as the ratio of distal force and proximal push 
force, varied from 18.53% for Braun Coroflex Please stent to 38.66% for Conor 
Costar stent. The trackability, expressed by mean track force, increased from 
0.551 N for Biosensors Biomatrix stent to 1.137 N for Cypher stent. The 
crossability, measured by the mean crossing forces in a 1.4 mm stenosis model, 
also showed a range from 0.038 N for Xience stent up to 0.103 N for Braun 
Coroflex Please stent. Also, they studied the stent profile (outer diameter of stent) 
and bending stiffness of these stents in crimped configurations, and differences 
were observed again. The Xience stent had the smallest profile with an outer 
diameter of 1.055 mm while Cypher showed the largest profile with an outer 
diameter of 1.198 mm. Bending stiffness ranged from 17.22 Nmm2 for Taxus to 
47.20 Nmm2 for Endeavor. 
Ormiston et al. (2000) conducted three-point bending tests to investigate the 
longitudinal flexibility of 13 stents with various designs, including 2 coil, 2 modular 
zigzag and 9 slotted tube designs, by assessing their stiffness before and after 
balloon expansion. As shown in Figure 2.11, all stents became stiffer after 
expansion with a 3.5 mm balloon at 12 atm. The stiffness of 13 stents varied in 
a wide range, from 0.5 to 91.5 g force/mm, regardless of unexpanded or 
expanded state. The Wiktor and Crossflex stents with coil designs showed the 
lowest stiffness, which were 0.5 g force/mm and 0.6 g force/mm, respectively. 
The measured stiffness of AVE GFX and Bard XT stents with modular zigzag 
designs had a value of 4.0 and 4.3 g force/mm, respectively. The NIR (69.7 g 
force/mm) and Crown (91.5 g force/mm) stents, with a slotted tube design, were 
the stiffest scaffolds while the MultiLink Duet and MultiLink showed the most 
flexibility. 
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Figure 2.11, Stent stiffness for 13 designs in unexpanded and expanded (to 3.5 
mm) states (Ormiston, 2000). 
Lim et al. (2013) studied the mechanical performance of a novel stent, designed 
by Chonnam National University Hospital (CNUH) (Figure 2.12) by radial 
compression and three-point bending tests. They compared histopathological 
results of the novel stent with that of a commercial cobalt-chromium coronary 
stent in porcine coronary model. Their results showed that the CNUH stent had 
a radial force of 2.65 N, 35.1 N and 0.52 N for the flat plate radial compression, 
segmental compression and three-point bending tests, respectively. The 
foreshortening and recoil were measured as 1.94% and 4.29% in the expansion 
test of stent. Moreover, the CNUH stent exhibited similar histological outcomes 
when compared with the commercial cobalt-chromium coronary stent in a 
porcine restenosis model. 
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Figure 2.12, CNUH stent design in form of flat (A) and tube (B) (Lim, 2013). 
Two years later, Bae et al. (2015) modified the strut designs of the CNUH stents 
to improve their mechanical performance. As shown in Figure 2.13, U-bend was 
changed to a concaved shape to inhibit shear stress of stent, and an additional 
strut was added between two U-bends in longitudinal direction to enhance its 
flexibility. Similarly, they performed radial compression and three-point bending 
tests on the modified CNUH stent and four commercialized stents (i.e., PROMUS 
Element, Cypher, Resolute Integrity and Xience PRIME), with results 
summarized in Table 2-7. The CNUH stent showed the lowest radial forces (2.40 
N, 1.27 N and 0.46 N) for flat plate compression, segmental compression and 
three-point bending, which suggested lower capability against external pressures 
but higher flexibility. For the foreshortening and recoil, there was no significant 
difference observed between CNUH stent and four commercialized stents. 
These studies characterized and compared the mechanical behaviour of metallic 
stents, especially longitudinal and radial flexibility, by considering the effect of 
stent designs. Their results showed that designs played an important role in the 
mechanical behaviour of stents. 
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Figure 2.13, 2D CNUH stent with modified strut designs (Bae, 2015). 
Table 2-7, Results of mechanical testing on different stents. 
 
2.4.1.2 Polymeric stents  
Also, some experimental studies have been conducted to investigate the 
mechanical behaviour of polymeric stents. Grabow et al. (2007) studied the 
expansion behaviour of a biodegradable slotted tube stent, made of PLLA and 
PHB, by stent bench testing. As shown in Figure 2.14, the crimped stent was 
mounted on a balloon catheter, and then expanded by balloon inflation. All stents 
were expanded successfully without the occurrence of strut fracture, and Figure 
2.15 showed the stent diameter change as a function of balloon pressure. The 
stent initially expanded rapidly at a balloon pressure of 1-2 bars and then 
achieved full expansion at a pressure of 6 bars. The measured recoil effect and 
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collapse pressure were 4.2% and 1.1 bars, respectively. Their results revealed 
that the PLLA/PHB slotted tube stent exhibited adequate mechanical properties 
during rapid expansion process. 
 
Figure 2.14, Stent in crimped and deployed configurations (Grabow, 2007). 
 
 
Figure 2.15, Stent diameter change against balloon pressure during expansion 
(Grabow, 2007). 
 
49 
 
Later, Grabow and his colleges (2007) used the same method to investigate the 
mechanical properties of biodegradable balloon-expandable stent made of PLLA 
and PLLA/PCL/TEC. As a result, all stents were expanded successfully by 
balloon inflation to a pressure of 8 bars, but differences were observed for 
expansion behaviour of these two stents, diameter change against balloon 
pressure, elastic recoil and shortening, as shown in Figure 2.16a. The PLLA 
/PCL/TEC stent expanded immediately with the balloon inflation while the pure 
PLLA stent started to expand at a balloon pressure of ~2 bars. As a result, the 
pure PLLA stent achieved a smaller diameter (6.0 mm) than that of 
PLLA/PCL/TEC stent (6.7mm) at peak balloon pressure. Moreover, the pure 
PLLA stent exhibited smaller elastic recoil (2.4%) and larger shortening (3.4%) 
compared to PLLA/PCL/TEC stent (8.8% and 2.3%, respectively). These results 
suggested that material properties affected the mechanical behaviours of stents. 
Zou et al. (2014) investigated both compressive and tensile properties of 
bioresorbable ureteral stents with varying braided structures and braided 
components (PLGA and PGA). Figure 2.17 showed the compressive and tensile 
results for five braided stents compared to those of a commercial polyurethane 
stent. Obviously, a big difference was found for the compressive resistance, 
tensile strength and elongation at break for theses stents. They addressed that 
stent with design C (PGA and PLGA 2 ply yarn) exhibited the optimal 
compressive and tensile properties.   
Schmidt and his co-workers (2016) characterized the in vitro mechanical 
performance of bioresorbable scaffolds (i.e., Absorb GT1, Elixir DESlove and 
Biotronik Dreams 2G) using the same method described above. The crimped 
stent had an outer diameter of 1.38 mm, 1.39mm and 1.44 mm for Absorb GT1, 
Elixir DESlove and Dreams 2G, respectively. The Dreams 2G exhibited a 
pushability of 45.41% compared to 33.77% for Absorb GT1 and 36.27% for Elixir 
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DESolve, but no significant difference was found for trackability of the three 
stents which were 0.68N, 0.75N and 0.64N for Dreams 2G, Absorb GT1 and 
Elixir DESlove stents respectively. Moreover, they examined and compared 
expansion behaviour of the three stents within a mock vessel and a rigid vessel 
model. The elastic recoil after stent expansion was shown in Figure 2.18. The 
Dreams 2G showed smaller recoil (5.6% and 5.0%) in both two cases without 
change over time, while Absorb GT1 and Elixir DESolve stents showed time-
dependent recoil. These results highlighted the differences between metallic and 
polymeric bioreosrbable stents due to different material properties and designs. 
 
Figure 2.16, Stent diameter change against balloon pressure (a), elastic recoil 
(b) and stent shortening (c) (Grabow, 2007). 
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Figure 2.17, Compressive and tensile results for five braided stents compared 
to commercial polyurethane stent (Zou, 2014). 
Ormiston et al. (2015) performed expansion and post-dilatation experiments for 
two commercially available bioresorbable stents (Absorb and DESolve) and 
compared to typical metallic drug-eluting stent Xience Xpedition. They examined 
the mechanical characteristics, such as crossing profile, recoil and radial strength, 
by imaging and intravascular ultrasound techniques. The crossing profile had a 
diameter of 1.14 mm, 1.43 mm and 1.44 mm for Xpedition, Absorb and DESolve, 
respectively. The radial strength of stent, measured in terms of pressure required 
to reduce 25% of cross-sectional area, was found to be 1.6 atm for Xpedition, 
1.4 atm for Absorb and 1.1 atm for DESolve. All three stents showed elastic recoil 
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after expansion with a slight change over time, as shown in Figure 2.19. Initially, 
all three stents significantly recoiled by approximately 0.1mm. Afterwards, 
Absorb and Xpedition continued slight recoiling whereas the diameter of 
DESolve showed an increase (self-correction). Their results revealed that the 
metallic stent had thinner strut with smaller profile but greater radial strength 
compared to polymeric stents. 
 
Figure 2.18, Acute recoil and time-dependent recoil (after 1 hour) of 
bioresorbable stents after expansion within a rigid vessel model (a) and mock 
vessel (b) (Schmidt, 2016). 
. 
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Figure 2.19, Elastic recoils of stents at different time points (Ormiston, 2015). 
Welch et al. (2014) studied the effect of thermal annealing on the mechanical 
behaviour of helical coiled PLLA stents. The stents were annealed at a 
temperature of 70, 80 and 90°C for 25 mins after manufacturing, and then 
expanded by balloon catheter up to a pressure of 12 atm. Experimental results 
showed that the stent had progressively high stiffness and greater collapse 
resistance with the increase of annealing temperature, whereas the elastic recoil 
had a decrease. Probably, thermal annealing induced some changes in 
crystalline structure of PLLA, and then the stress -strain behaviour and stent 
expansion behaviour were affected. 
These experimental works mainly studied the expansion behaviour of polymeric 
stents, such as stent diameter change against inflation pressure, recoil and 
shortening effect, and their results indicated that stent materials and designs 
affected their mechanical performance. Therefore, further research, especially 
for stent material characterization and design modifications, is required to 
improve the stent performance. 
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2.4.2 Degradation behaviour studies 
One of key features for polymeric stents is their degradation behaviour over time. 
There were some experimental studies available in terms of characterization of 
stent degradation in vitro and in vivo. Xu et al. (2008) also evaluated in vitro and 
in vivo degradation behaviour of biodegradable tubular stents, made of PLGA 
with five different molar weight ratios of LA/GA (50/50, 60/40, 71/29, 80/20 and 
88/12), for application in common bile duct (CBD) repair and reconstruction. For 
in vitro test, stents were placed in bile degradation medium (pH=7.2-7.6). 
Morphological results showed that the stents slightly expanded, deformed and 
then cracked meanwhile their colour changed from initially transparent to yellow 
and opaque due to the bile and water absorption, as shown in Figure 2.20. 
Weight loss, molecular weight change and water uptake were also observed, 
indicating the PLGA stents exhibited different degradation rates due to different 
composition ratios, as shown in Figure 2.21. For in vivo test, PLGA (71/29) stents 
were implanted in the rat CBDs. Results showed that the polymeric stents can 
provide the same biomedical functions as typical T tubes and completely 
disappeared after 5 weeks. 
 
Figure 2.20, Optical images of PLGA stents in different degradation stages 
(days) in bile at 37°C in vitro: (a) LA/GA=50/50, (b) 60/40, (c) 71/29, (d) 80/20 
and (e) 88/12 (Xu, 2014). 
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Figure 2.21, Weight loss (a) and molecular weight change (b) of PLGA stents 
as a function of degradation time in bile at 37°C in vitro (Xu, 2014). 
Hadaschik et al. (2008) investigated the degradation behaviour of a new 
biodegradable ureteral stent (Uriprene) made of copolymer PLGA (LA/GA=80/20) 
using porcine models. Uriprene stents were implanted in 20 pigs while standard 
biostable stents were implanted in 16 pigs as a control. Compared to control 
stents, Uriprene stents caused significantly less ureteral dilatation and urinary 
tract infections, as shown in Figure 2.22. Their results also showed that the 
Uriprene stents began degradation at week 3, and completely degraded at week 
10. The novel stent was proved to be biocompatible in vivo. 
 
Figure 2.22, Values in Uriprene and control stented pigs with time, (a) body 
weight, (b) urine pH and (c) ureter dimensions (Hadaschik, 2008). 
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Yang et al. (2017) carried out degradation experiments on a novel biodegradable 
PGLA ureteral stent, with multilayer design immersed by microsphere zein and 
BaSO4, in human urine in vitro. The SEM results showed that the novel stent 
started degradation at week 2 and fully degraded after 4 weeks, and the 
degradation happened layer by layer from outer to inner surface. Moreover, 
weight loss and change of mechanical strength were characterized for the stent 
at different degradation time points, as shown in Figure 2.23. Stent groups A-D 
were classified by different zein concentrations. These curves indicated that the 
stent weight and mechanical strength (i.e. tensile strength, elastic recovery and 
radial compression load) showed a decrease over the degradation time. 
 
Figure 2.23, Property changes for stents over degradation (Yang, 2017). 
These experimental results showed that the degradation rate of polymeric stents 
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varied with different material compositions. Therefore, it is of importance to 
characterize and understand the degradation behaviour of polymeric stents, to 
make sure they can provide the desirable functions. 
2.4.3 In vivo efficacy studies of polymeric stents 
A large amount of in vivo studies have been carried out to evaluate the safety 
and efficacy of polymeric stents in human bodies or animals. Clinical trials for 
bioresorbable vascular scaffolds, such as Igaki-Tamai, RevaMedical, Absorb and 
Elixir stents, have already been reviewed in section 1 regarding their safety and 
efficacy, and reported their clinical outcomes (i.e., major adverse cardiac event, 
late thrombosis, target lesion revascularization, restenosis and lumen failure). 
Here, review focused on in vivo studies of polymeric stents for biliary applications. 
Biodegradable polymeric stents have advantages in the treatment of bile duct 
disease and intestinal obstruction. Some in vivo studies have been carried out to 
evaluate the safety and efficacy of biliary/intestinal polymeric stents in animals. 
Meng et al. (2006) carried out in vivo study to evaluate a self-expandable PLLA 
helical biliary stent for the treatment of biliary stricture in canines, and reported 
that the stent could fully expanded to support the duct, and there were no duct 
stricture or dilation observed at week 2 after stent implantation. But the SEM 
images showed that micro holes and cracks were found at the stent surface. 
Laukkarinen et al. (2007) investigated the performance of a novel braided 
biodegradable biliary stent, made of PLA, for the treatment of bile duct 
obstruction in a large animal model. The novel stent seemed easy to insert and 
dissolves safely in animal model, and larger anastomosis inner diameter was 
achieved with the use of stent in the 18-month follow up. Fan et al. (2011) 
evaluated the safety and efficacy of biodegradable stent, made of a mixture of 
PLLA and PLGA, in bile duct of dogs.  After 3 months, there were no 
inflammation complication, bile leakage or anastomotic stoma stenosis observed 
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based on pathological results, which suggested that this stent had a relative long 
degradable period (> 3 months) and good compatibility. Son et al. (2013) 
fabricated a biodegradable fibrous tube by electrospinning of PLGA and gelatin 
for the application of intestinal stent, and they inspected the in vivo behaviour of 
the scaffold implanted in rat models. Results showed that the PLGA/Gelatin 
fibrous tube could degrade 14 days after surgery, and no inflammation was 
observed surrounding the suture area. It indicated that the PLGA/Gelatin 
biodegradable scaffold was biocompatible and beneficial in surgery technique as 
additional removal of the intestinal stent was not required in rat models.  
2.4.4 Conclusion 
This section reviewed existing experimental studies on both metallic and 
polymeric stents, including the investigation on degradation behaviour, tensile 
and compressive properties and expansion behaviour. These studies showed 
that stent performance was affected by materials and designs. However, 
experimental research on stents was still limited and the majority tests were 
performed under in vitro environment or in animal models. To complement 
experimental work, finite element simulations were largely used to study the stent 
performance during expansion, which is reviewed in the next section. 
  
59 
 
2.5 Computational work 
Computational methods have been widely used to investigate the mechanical 
performance of stents during expansion, fatigue and degradation, which are 
reviewed in this section. 
2.5.1 Stent expansion modelling 
2.5.1.1 Metallic stents 
A large amount of computational work has been conducted for metallic stents to 
study stent expansion behaviour with or without presence of artery (i.e., stent-
artery interaction). The recoiling, foreshortening and dog-boning are generally 
used as comparable parameters to evaluate the expansion behaviour of stents. 
Recoiling represents the radial change of stent diameter after expansion, which 
occurs after the removal of balloon inflating pressure. Dog-boning refers to the 
dog-bone shape on stent caused by validation of expansion along the stent, with 
minimal expansion in the middle and increased expansion towards the ends of 
stent. It usually happens with the presence of stenotic plaque. Foreshortening 
means the decrease of stent length caused by stent expansion from crimped 
state to deployed state. Moreover, stress state in the plaque-artery system is 
often used to evaluate the injury of arterial vessel caused by stenting. 
On one hand, a large number of computational studies were conducted to 
investigate the free expansion of stents by using internal pressure or balloon 
inflation. For instance, Chua et al. (2002) modelled the expansion of a stainless 
steel slotted stent by directly applying pressure to the inner surface of stent. Two 
simulations were carried out by using two different loading speeds, i.e., 400 
MPa/ms and 11.3 MPa/ms, and significant difference was found for stent 
expansion behaviour in terms of radial displacement, foreshortening and von 
Mises stress distribution. The stent exhibited greater expansion with lower 
loading speed and the maximum radial displacement was computed to be 6.72 
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mm, compared to 5.6 mm for higher loading speed. Less foreshortening but 
higher stresses were developed for the stent with higher loading speed. Their 
results indicated that stent expansion behaviour can be influence by the speed 
of applied pressure, and the maximum target diameter can be achieved by 
controlling the applied pressure. In order to make the simulation more realistic, 
Chua et al. (2003) applied a balloon model in the simulation of stent expansion. 
In this modelling, interaction between stent and balloon was considered, and the 
stent was expanded by applying pressure on the inner surface of balloon. The 
stent was dilated from 3 mm to 4.5 mm I diameter under a pressure of 0.4 MPa, 
and the maximum foreshortening was approximately 0.5 mm after the process of 
stent expansion. Stress distribution results showed that higher stresses were 
mostly located at the corners of stent struts. However, there was no experimental 
validation of the modelling results. Later, Migliavaccca et al. (2005) predicted the 
mechanical behaviour of a newer stent (Cordis BX Velocity) by finite element 
method, which was compared with experimental results. The stent was 
expanded by balloon inflation, and the diameter change of stent under an 
inflating pressure of 0.5 MPa, was similar to the experimental data. After removal 
of balloon pressure, the elastic recoiling and foreshortening obtained was 1.18 % 
and 8.22 %, respectively.  The maximum von Mises stress occurred at the 
corner of curvature struts, which was around 520 MPa. The maximum equivalent 
plastic deformation was observed at the inner surface of strut corner in simulation, 
in agreement with scanning electron microscopy image results. 
On the other hand, finite element studies were also carried out to investigate the 
stent-artery interaction during stent deployment. Chua et al. (2004) investigated 
the expansion behaviour of a slotted tube stent with the diseased artery using 
ANSYS. In the simulation, stent was expanded in the artery by balloon inflation. 
Results showed that the maximum von Mises stress were located at the corners 
of slots while the minimum stress was found at the middle of connecting struts, 
61 
 
and the stress in plaque-artery system exhibited a gradual increase from inner 
surface of plaque to outer surface of arterial wall. The recoiling after balloon 
deflation was higher (20.5%) for stent deployed in diseased artery, leading to a 
final diameter of 5.1 mm, compared to a recoiling of 16.5% and a final diameter 
of 5.9 mm for free stent expansion. Liang et al. (2005) also developed a complete 
stenting system, including balloon, stent, plaque and artery, for the finite element 
analysis. Dog-bone shape occurred to the deployed stent due to the existence of 
plaque. Stress concentration was generated at the corners of V-link struts, and 
higher stresses were also found at the area of plaque that was in strong contact 
with the stent, which suggested V-peaks of stent strut might penetrate the plaque 
during stenting. They also analysed the recoiling rate with varying components 
in the model, such as balloon-stent, balloon-plaque-artery and balloon-stent-
plaque-artery models, and results showed that the balloon-stent model exhibited 
the smallest recoiling of 3.1%, compared to 22.9% for balloon-plaque-artery 
model and 12.3% for balloon-stent-plaque-artery model. It indicated that stent 
implantation can provide greater luminal support than traditional balloon 
angioplasty. Lally et al. (2005) analysed the stress state on the arterial wall during 
stent deployment in diseased artery by considering two different stent designs 
(NIR stent and S7 stent). Their results showed that the slotted tube NIR stent 
caused higher stress to the arterial wall than the modular S7 stent, which showed 
a direct correlation with clinical results of restenosis rates caused by these two 
stent designs (The reported restenosis rate is 19% for the NIR stent and 10.1% 
for the S7 stent at 6-month follow-up). Zahedmanesh and Lally (2009) simulated 
the deployment of Multilink stent, with different strut thicknesses, in diseased 
artery. When expanded to the same maximum diameter, the stent with thinner 
strut recoiled more severely, leading to a smaller luminal gain. In contrast, the 
stent with thicker strut exhibited a lower recoiling, resulting in a larger luminal 
gain, but also inducing higher stress in the arterial wall. 
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Stent-artery interaction can be affected by various parameters of plaque-artery 
system, including the plaque type, artery geometry and applied material models. 
Pericevic et al. (2009) modelled the deployment of Driver stent in an idealised 
stenotic artery by considering three different types of plaque, i.e., hypercellualr, 
cellular and calcified plaques.  Results showed that plaque type had a 
significant effect on both the stresses and enlargement of arterial wall. Lower 
stress was observed in the arterial wall with calcified plaque, and higher stress 
was generated in the arterial wall with cellular plaque. Larger displacement was 
predicted for the arterial wall with hypercellular plaque during stenting, followed 
by cellular plaque and calcified plaque. Wu et al. (2007b) simulated stent 
expansion by balloon inflation in curved and straight vessels. The curved vessel 
was straightened at the middle segment due to stent expansion. The straight 
vessel reached a final lumen area of 6.28 mm2, whereas only 6.10 mm2 lumen 
area was achieved for the curved vessel. The stress distribution in the straight 
vessel was more uniform compared to that in the curved vessel, and the stress 
concentration occurred at the inner curvature of curved vessel. The maximum 
stresses on both plaque and vessel were higher in straight vessel than those in 
curved vessel. Specifically, the maximum stress on the plaque and vessel was 
0.51 MPa and 2.78 MPa, respectively, for straight vessel model, while 0.17 MPa 
and 2.42 MPa were obtained for the plaque and vessel in curved vessel model. 
Morlacchi et al. (2013) simulated stent deployment using two patient-specific 
arterial bifurcation models. Their results showed that the patient-specific arterial 
wall could be straightened by overlapping stent implantation, which was in 
agreement with experimental studies. And higher mechanical stresses were 
generated on the overlapping area of stent and arterial wall, which might lead to 
stent and arterial failures. Schiavone and Zhao (2016) modelled the deployment 
of Xience stent (made of Co-Cr alloy L605) in diseased artery. Two different 
constitutive material models, an isotropic hyperelastic Ogden model and an 
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anisotropic hyperelastic Holzapfel-Gasser-Ogden (HGO) model, were used to 
describe the behaviour of three individual arterial layers. Difference was found 
for the two different constitutive models, in terms of stent diameter change 
against inflating pressure, recoiling effect, dog-boning behaviour and stress state 
in the stent and plaque-artery system. The stent reached a diameter of 3.85 mm 
at peak pressure and stabilized at 3.56 mm after recoil for anisotropic model, 
whereas a maximum diameter of 4.08 mm was obtained at peak pressure and a 
stabilized diameter of 3.90 mm was achieved after recoil for isotropic model. The 
computed recoiling was 10.6% and 13% for anisotropic and isotropic models, 
respectively, while the dog-boning was similar (~22%) for both cases. The von 
Mises stresses generated on stent, plaque and artery after deployment were 
higher for isotropic model than those for anisotropic model, as shown in Figure 
2.24. Their results highlighted the importance of considering vessel anisotropy in 
stent deployment simulations.  
 
Figure 2.24, Comparison of contour plots of von Mises stress for (a) stent, (b) 
plaque and (c) artery after deployment of Xience stent in case of isotropic and 
anisotropic arterial models (Schiavone and Zhao, 2016). 
2.5.1.2 Polymeric stents 
The computational study of polymeric stents is very limited. Very recently, 
Schiavone et al. (2016) compared the mechanical behaviour of metallic 
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stent (Xience) and polymeric stent (Absorb) during crimping and deployment in 
diseased artery using finite element method. The Absorb stent exhibited a lower 
expansion rate and a higher recoiling and dog-boning effects than Xience, due 
to the difference in stent design and material property. However, the Absorb stent 
caused significantly lower stress on the plaque and arterial layers than Xience, 
which benefited clinically in terms of less injury generated on vessels. They also 
evaluated the effect of plaque eccentricity, and found that higher stress was 
generated in the media and adventitia layers of artery in case of plaque with high 
eccentricity. Debusschere et al. (2015) investigated the effect of expansion rate 
on the mechanical behaviour of bioresorbable Absorb stent during free 
expansion process, considering the viscoplastic behaviour of stent material PLLA. 
They modelled the stent expansion by linearly increasing inflation or stepwise 
inflation methods, and results showed that more stress concentration areas were 
generated on the U-bend struts of stent in case of linear inflation procedure, both 
at peak inflating pressure and after balloon deflation. Short term effects of 
inflation rate were observed for stent during balloon inflation process, i.e., stent 
diameter change against pressure and dog-boning behaviour, but no significant 
difference was found after balloon deflation. Wang et al. (2017) studied the 
mechanical deformation of a PLLA biodegradable coronary stent using 
experimental and computational methods. They modelled the crimping of stent 
to an outer diameter of 1.41 mm and subsequent expansion to different inner 
diameters. Stent deformation profiles were in good agreement with experimental 
ones during both crimping and expansion processes, and large deformation 
occurred at sharp curvature of struts in all cases. The radial recoil ratio showed 
a decrease trend with the increase of stent expansion, which was 4.19%, 2.92% 
and 1.81% obtained for stent with expanding to 3.1mm, 3.7 mm and 3.92 mm, 
respectively. They also modelled re-crimping of the expanded stent to evaluate 
the radial strength and stiffness, and calculated radial strength and stiffness was 
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1.46 N/mm (close to the experimental value of 1.55 N/mm) and 1.40%, 
respectively. Shanahan et al. (2017) developed a viscoelastic material model for 
a biodegradable polymeric braided stent, and evaluated the time-dependent 
viscoelastic behaviour using finite element method. They simulated the crimping 
of stent by enforcing radial displacement on 8 rigid plates, and the linear 
viscoelastic material model was validated against their experimental data. 
However, no significant difference was observed for the crimping behaviour of 
braided stent modelled as either linear elastic or viscoelastic material. 
2.5.2 Effects of stent designs  
Stent design parameters, such as U-bend radius, strut thickness and bridge strut 
shape, affect stent behaviour during expansion. Some computational studies 
have been performed to evaluate the influence of stent design parameters on 
stent performance, especially for metallic stents. Hsiao et al. (2012) carried out 
a stent parametric analysis to evaluate the effects of stent design parameters 
(i.e., strut thickness and width, crown radius) on key mechanical behaviour (i.e., 
equivalent plastic strain, von Mises stress, radial strength and recoil) of a 
standard cobalt-chromium stent. Results revealed that the crown radius played 
an important role in the plastic deformation and recoil behaviour of stent, while 
strut thickness and width had a significant effect on the radial strength of stent. 
Azaozi et al. (2013) studied the effect of bridge strut geometry (see Figure 2.25) 
on the behaviour of stainless steel 316L stent under loading conditions of 
bending, torsion and expansion using finite element method. Results showed 
that the stent with unsymmetrical N-shaped bridge struts exhibited better 
mechanical behaviour, such as less elastic recoil, enhanced flexibility and 
increased radial strength, which indicated that the geometry of bridge strut 
played an important role in the mechanical behaviour of stent.   
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Figure 2.25, Geometry of connecting bridge strut (Azaozi, 2013). 
Wu et al. (2011) simulated expansion of biodegradable magnesium alloy stents 
with three different ring designs (see Figure 2.26) in arterial vessels. Stent A was 
extracted from the existing Magic stent, stent B was a design-optimized model 
based on stent A, and stent C was a patented stent from Institute of Metal 
Research. Results showed that the stress concentration areas were observed at 
different location of stent strut due to the difference of stent design, and stent B 
exhibited more uniform stress distribution then the other two designs. Specifically, 
the maximum principal stress was 183 MPa, 163 MPa and 230 MPa for stent A, 
B and C, respectively. The stent recoiling also had a difference, which was 8.1 % 
for stent A, 7.0% for stent B and 12.6% for stent C. Li et al. (2014) also carried 
out finite element analysis for design optimization of common biodegradable 
magnesium alloy stent, with a focus on optimizing the strut with gradual width 
between peak and valley units. Comparison results showed that no significant 
difference was found for recoil, and radial strength between the common stent 
and the optimized stent. But the maximum principal strain and residual stress 
after expansion were significantly different, which were 0.155 and 208 MPa for 
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the common stent compared to 0.092 and 177 MPa for the optimized stent. 
 
Figure 2.26, Magnesium alloy stent with three different designs (Wu, 2011). 
Also, computational studies have been carried out to evaluate mechanical 
performance of commercial available metallic stents with different designs. Imani 
et al. (2013) modelled deployment of two commercially available stents (Palmaz-
Schatz and Multi-Link stents) in arteries, and compared their behaviour in terms 
of stress distribution, dog-boning behaviour and stent diameter change. Results 
showed that high stress regions were located at the corners or curvatures of stent 
struts in both cases, and the maximum von Mises stress was similar, which was 
257.5 MPa and 249 MPa for the Palmaz-Schatz and Multi-Link stents, 
respectively. The Palmaz-Schatz stent achieved a diameter of 3.7 mm (middle 
section) at a pressure of 0.4 MPa while the Multi-Link stent required 0.3 MPa to 
obtain that diameter, which meant the Multi-Link stent is more flexible. The dog-
boning was 0.6 for the Palmaz-Schatz stent, which was higher than that of Multi-
Link stent (0.47). Moreover, the von Mises distribution in arterial wall showed a 
difference in two cases, and the maximum stress was 0.282 MPa when 
expanded by Palmaz-Schatz stent and 0.244 MPa if inflated by Multi-Link stent. 
Schiavone et al. (2014) focused on four commercial metallic stents (i.e., Palmaz-
Schatz, Cypher, Endeavor and Xience) to compare their expansion behaviour. 
The change of stent diameter during expansion was distinctly different due to 
different designs and material properties. The recoiling and dog-boning effects 
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were 1.6% and 22.4% for Palmaz-Schatz, 5% and 10.4% for Cypher, 31.1% and 
36.8% for Endeavor and 21.8% and 17.7% for Xience. High stress 
concentrations were found at the corners of U-bend stent struts in all cases (see 
Figure 2.27), which suggested the U-bend design played an important role in 
controlling the structural behaviour of stent. 
 
Figure 2.27, The von Mises stress distribution on the Palmaz-Schatz, Cypher, 
Endeavor and Xience stents after deployment (Schiavone, 2014). 
Recently, Pauck and Reddy (2015) investigated the effect of three distinct 
geometries (see Figure 2.28) on the radial properties of polymeric stents (made 
of PLLA) using finite element modelling. The first design S1 was based on the 
commercial BVS stent, S2 was extracted from typical metallic stent design with 
high ring wave amplitude and strut spacing, and S3 represented a design with 
reduced bend radius and wave amplitude. The obtained radial properties (i.e., 
radial strength and stiffness) were different for three different designs. The radial 
strength was 92 mmHg, 57 mmHg and 83 mmHg, and the radial stiffness was 
1.12 MPa, 0.5 MPa and 1.2 MPa for the design S1, S2 and S3, respectively. The 
measured recoiling was also different for three designs, which was 15.1%, 24.3% 
and 8.4% for design S1, S2 and S3, respectively.  
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Figure 2.28, FE stent models with three distinct geometries (Pauck and Reddy, 
2015). 
2.5.3 Methods for modelling stent expansion 
The modelling strategy for stent expansion also has an influence on both stent 
and artery in the simulation of stent expansion. De Beule et al. (2008) modelled 
free expansion of a balloon-expandable 316L stainless steel stent by applying 
three different expanding approaches, including I) applying pressure directly on 
stent inner surface, II) enforcing radial displacement on a rigid cylindrical balloon 
and III) applying pressure on the inner surface of a tri-folded balloon. The results 
(see Figure 2.29) showed that the stent shape during expansion is dependent on 
the applied expanding approach. They also compared the simulated expansion 
behaviour of stent with manufacturer’s data, and only the tri-folded balloon 
expansion approach showed good agreement with experimental data. Gervaso 
et al. (2008) also evaluated these three different expanding approaches in the 
simulation of expansion of Cordis BX-Velocity stent in artery. They found similar 
results in terms of expansion behaviour. Moreover, the stress distribution in 
arterial wall was compared along radial, circumferential and axial directions, 
which showed that the radial and circumferential stresses in arterial wall are more 
dependent on the applied expanding approach than the axial stress. The use of 
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tri-folded balloon led to more spread distribution of radial and circumferential 
stresses. The pressure-diameter diagram obtained from tri-folded balloon model 
showed better agreement with manufacturer’s data, which suggested that the 
method used for stent expansion simulation should be properly chosen in order 
to accurately estimate the stress state and associated injury level of arterial wall 
caused by stenting. 
 
Figure 2.29, Expanded stent simulated using different inflation approaches: (I) 
no balloon (left; applying internal pressure directly), (II) cylindrical balloon 
(middle) and (III) tri-folded balloon (right) (De Beule, 2008). 
Zahedmanesh et al. (2010) carried out a realistic simulation of stent deployment 
in a human atherosclerotic coronary artery by implementing a realistic tri-folded 
balloon model, and compared stent expansion behaviour to that without a balloon 
(applying direct pressure on stent). Results showed that the stent could achieve 
a diameter of 3.5 mm at a pressure of 15 atm when using tri-folded balloon, 
whereas only 3 mm of diameter was obtained for stent expanded by applying 
direct pressure on the inner surface. Also, significant difference was observed 
for the dog-boning and foreshortening behaviour of stent. After recoil, the dog-
boning was approximately 8% and 19% for stent expanded by tri-folded balloon 
and directly applied pressure. The foreshortening was -10% for stent expanded 
by a tri-folded balloon, while elongation as obtained for the stent expanded by 
direct internal pressure. However, the von Mises stress distribution in arterial wall 
was very similar for the two cases. Martin and Boyle (2013) investigated the 
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effect of folded configuration of balloon on stent behaviour during free expansion 
and expansion in artery, including an idealised non-folded model A, an idealised 
folded model B and a semi-compliant folded model C. In the three cases, similar 
equivalent stress distribution was shown on the stent, and stress concentrations 
were observed at the curvatures of stent.  However, the equivalent stress 
distribution in the artery showed significant difference (see  
Figure 2.30), and the peak stress and average stress in artery was lower for 
balloon model C than those for balloon models A and B. The stent diameter 
change against inflating pressure was also different, and the stent inflated by 
balloon model A showed rapid expansion at a pressure of 0.3 MPa compared to 
0.4-0.5 MPa for balloon models B and C. Moreover, significantly smaller dog-
boning effect was obtained for stent inflated by balloon model C. These results 
indicated that balloon configuration had an influence on the mechanical 
behaviour of stent and artery during expansion process. 
 
Figure 2.30, Equivalent stress distribution in the artery at unloading of (a) 
balloon A, (b) balloon B and (c) balloon C (Martin and Boyle, 2013). 
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2.5.4 Modelling of stent fatigue behaviour 
Stents are subjected to pulsatile blood pressure due to heat beating, and 
therefore it is essential to evaluate stent fatigue behaviour after implantation. 
Generally, there are two approaches to perform fatigue lifetime prediction, i.e. the 
classical stress/strain-life (S-N) approach and the fracture-mechanics based 
approach.  
Finite element modelling has been used for the fatigue assessment of metallic 
stents. Marrey et al. (2006) carried out a fatigue life prediction study for a 
cardiovascular L-605 Co-Cr stent by combining the stress-life approach and 
fracture mechanics method. They modelled the stent deployment in a cylindrical 
tube, and then applied cyclic pressure on inner surface of the tube to simulate 
the systolic-diastolic blood pressure within arterial vessels. The calculated stress 
result showed that all elements on the stent were located in the safe zone 
according to the Goodman Diagram. By considering small cracks, they found that 
stents with flaws smaller than 90 µm had little chance of fatigue failure. Pelton et 
al. (2007) conducted fatigue test on diamond-shaped samples (processed form 
Cordis SMART Nitinol stent), and applied the testing data in the simulation of 
stent deformation under pulsatile loading condition. According to strain-life curve, 
the Nitinol stent can survive up to 107 cycles with a strain amplitude limit of 0.4%. 
Hsiao et al. (2012) modelled the fatigue of cobalt-chromium stent by applying 
180-80 mmHg pulsatile systolic-diastolic pressure, and the simulated stress 
amplitude were all within the safe zone of Goodman’s Diagram in terms of 4×108 
life cycles, suggesting the safety of stent. They also addressed that the thickness 
of strut influenced the fatigue behaviour of stent. Azaouzi et al. (2013) also used 
stress-based Goodman’s Diagram to perform fatigue life assessment of balloon-
expandable stainless steel stent under cardiac pulse pressure by considering the 
effect of stent design. The obtained stress amplitude and mean stress showed 
significant difference due to the different strut dimensions, which indicated that 
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the strut dimensions (e.g., strut radius, length, width, thickness) had a noticeable 
influence on the fatigue life of stent. Kumar et al. (2013) analysed fatigue 
behaviour of a new Nitinol mitral valve stent by considering the cyclic cardiac 
muscle loading, blood pressure and cyclic calve-leaflet forces in finite element 
modelling. The strain-based Goodman’s Diagram was used to evaluate the 
fatigue behaviour, and results shows that the calculated strain amplitudes were 
all located in the safe zone, indicating that the new stent was able to survive the 
4×108 life cycles under complex loading conditions. They also pointed out that 
the highest risk of fatigue fracture might occur at the inter curvatures of stent strut. 
Auricchio et al. (2015) carried out fatigue analysis for classical stainless steel 
coronary stent by applying cyclic systolic-diastolic pressure on inner surface of 
artery. The Dang Van criterion was used to predict the crack initiation of stent, 
based on elastic and plastic shakedown concepts. The most critical location of 
crack initiation was identified at the inter-ring connectors.  
On the other hand, material models were also developed and applied to assess 
fatigue behaviour of metallic stents. Dos Santos et al. (2012) applied a two-scale 
plasticity-damage numerical model in the fatigue life assessment of balloon-
expandable stainless steel stents (i.e., Palmaz-Schatz and Cypher). This method 
is based on a two-scale continuum damage mechanics model, and the fatigue 
failure criterion is extracted from the Soderberg relation. Results revealed that 
the obtained stress-life results showed a limited fatigue life for both stents. And 
the modelled stress-life curve of Palmaz-Schatz stent showed good agreement 
with the experimental data in high-cycle fatigue regime. Sweeney et al. (2012) 
presented a micromechanical framework to assess the fatigue behaviour of a 
316L stainless steel stent, with random polycrystalline microstructure, with the 
assistance of finite element simulation. This micromechanical model combined 
kinematic-isotropic hardening crystal plasticity with a microstructure sensitive 
crack initiation parameter. The predicted locations of crack initiation were at the 
74 
 
corners of stent strut, and the predicted number of life cycle varied from 4×106 
up to infinite life. However, the simulated results were not validated due to the 
lack of experimental data. Recently, Guerchais et al. (2016) introduced another 
approach, based on micromechanical model incorporated with probabilistic 
methodology, to conduct high-cycle fatigue life prediction of stent with 
polycrystalline microstructure (made of 316L stainless steel). The prediction of 
survival probability was accomplished for the whole stent, which showed a good 
agreement with experimental data. In addition, they found that the amplitude of 
arterial pressure played an important role in the fatigue strength of the stent. 
2.5.5 Stent degradation modelling 
Bioresorbable stents have advantages in overcoming clinical complications (e.g. 
restenosis and stent thrombosis) associated with permanent metallic stents due 
to their biodegradation characteristics. Degradation is another factor that 
influences the mechanical performance of bioresorbable stents after deployment, 
but the studies were very limited.  
Generally, constitutive models are required to describe the mechanical response 
of stent materials during the process of degradation. For instance, Soares et al. 
(2010) applied a thermodynamically consistent constitutive model to predict 
degradation behaviour of PLLA stents. By considering that polymer degradation 
led to the material loses its ability to store, a degradation-dependent Helmholtz 
potential and a specific form of rate of dissipation energy were chosen to describe 
the degradation mechanisms. The general constitutive model was formed by a 
constitutive relation for the Cauchy stress: 
 T=-p1+ρ𝜕𝜓𝜕𝐅 𝐅n (2.10) 
with the Helmholtz potential of the degradable network: 
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 ψ = ψ(F, d) (2.11) 
and the functional form of the rate of dissipation: 
 𝜉 = 𝜉（𝐅, 𝑑, 𝑑） (2.12) 
in the above equations, T is the Cauthy stress, p is the Lagrange multiplier for 
the imposition of the incompressibility constant, F is the deformation gradient, r 
is the density, and d represents the state of degradation. The governing equation 
for the degradation process has the following form: 
 −	𝜌 uvuw 𝑑 = ξ (2.13) 
Considering material frame indifference, isotropy and material properties change 
caused by degradation, a specific constitutive model that described the 
mechanical response of biodegradable poly (L-lactic acid) was particularized as 
a specific form of the Helmholtz potential: 
 ρψ 𝐼x, d = λ d e< z{<F 𝐼x − 3+ 𝜇(𝑑) ln 1 + 𝑎(𝐼x − 3)  (2.14) 
with material properties: 
 λ 𝑑 = λL(1 − 𝑑) (2.15) 
 
 𝜇 𝑑 = µL(1 − 𝑑) (2.16) 
and a specific form of the equation governing the process of degradation: 
 𝑑 = (1 − 𝑑)𝑘(𝐅) (2.17) 
where a is a material constant, λLand 𝜇L are constants relating to the response 
of the nondegraded material, 𝜏  is a characteristic time of degradation. The 
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deformation-dependent rate was given by: 
 𝑘 𝐅 = 𝑘 𝑰𝑩, 𝑰𝑰𝑩= 1𝜏 (𝑰𝐁 − 3); + (𝐼𝐼 − 3)	; 	A/; (2.18) 
This model was suitable for simulating deformation-induced degradation, 
especially for biodegradable PLLA. The model is based on a degradation-
dependent Helmholtz potential (material properties decrease as a function of 
degradation) and the rate of dissipation. Degradation of three different stent 
designs was modelled, and results showed that high risk of degradation was 
mainly observed at the bends of stent rings and junction points.  
Luo et al. (2014) developed a numerical model to study the degradation 
behaviour of bioabsorbable PLLA stent. The exponential function used to 
describe the degradation degree D was given by: 
 D = D ε, t = a(b + c×𝜀)×𝑡8 (2.19) 
where e is strain, t is time, and a, b, c, n, m are material constants obtained by 
fitting experimental results. This model is a phenomenologically based model. 
The constitutive degradation model combined the degree of degradation with 
pre-stretched deformation, and the degree of degradation was used to describe 
the change of material property as a function of degradation time. The 
degradation model was validated against experimental tensile data at different 
degradation times. Results showed that degradation happened throughout the 
whole stent over 30 days, but the degradation rate was not uniform (see Figure 
2.31). The maximum degradation was observed at the inner surface of U-bend 
strut where the stress concentration/maximum strain occurred during stent 
expansion, which was in good agreement with experimental result. This indicated 
that the degradation rate of material was influenced by the initial deformation. 
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Figure 2.31, Degradation degree distribution on the stent over time (Luo, 2014). 
2.5.6 Conclusion 
In this section, computational studies on metallic and polymeric stents were 
reviewed, in terms of stent expansion, stent-artery interaction, effects of stent 
design and balloon model, stent fatigue and material degradation. Most studies 
focused on metallic stents, probably due to their longer history and widespread 
applications. Bioresorbable polymeric stents, as a new generation of stent, only 
received attention in the last couple of year. Therefore, further research is 
required for a better understanding of the mechanical performance of polymeric 
stents, including expansion during deployment, and fatigue/degradation 
behaviour after deployment. 
2.6 Research gaps 
Based on the literature review so far, several main research gaps can be 
identified for bioresorbable polymeric stents in terms of the stent expansion, 
stent-artery interaction during deployment, as well as stent fatigue and 
degradation after deployment. 
Computational studies on metallic stents showed that stent design had a 
significant effect on the stent behaviour, and finite element method can be used 
to carry out comparative studies on stents with different designs to evaluate their 
mechanical behaviour during expansion process. It is well known that the 
bioresorbable polymeric stents have different designs from metallic permanent 
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stents, such as thicker strut thickness, due to the distinct material property of 
biodegradable polymer. However, there is little literature available focusing on 
the bioresorbable polymeric stents to investigate their performance during 
crimping and expansion processes. 
The stent performance should be assessed and modelled by considering its full 
interaction with diseased artery, in terms of stent diameter change, radial 
recoiling and the shape of stent (dog-boning) after deployment. This allows for a 
realistic study of the mechanical behaviour of stent during its deployment process. 
Again, there is a lack of such research for polymeric stents, as most studies were 
limited to free expansion by neglecting the plaque and artery.  
Coronary stents, as medical devices serviced in coronary arteries, are subjected 
to pulsatile diastolic-diastolic blood pressure (up to 107 cycles each year) due to 
the heat beating. It is of importance to evaluate stent fatigue behaviour prior to 
their implantation in arteries. According to the literature review, computational 
studies have been performed on Co-Cr stent, Nitinol stent and stainless steel 
stent to assess their fatigue behaviour under cyclic blood pressure loading. 
However, fatigue studies are extremely scarce for the bioresorbable polymeric 
stents due to the lack of experimental data. 
The bioresorbable polymeric stents show advantages against metallic 
permanent stents because they can degrade and disappear after providing 
mechanical support to the arterial lumen without causing clinical complications 
including stent thrombosis, in-stent restenosis and inflammation. Material 
property of biodegradable polymer shows a difference during degradation, and 
therefore mechanical behaviour of polymeric stents is also influenced by stent 
degradation. Several studies have been carried out to predict the degradation 
behaviour of polymeric stents by developing constitutive models for degradable 
material. Study on stent-artery interaction during degradation is necessary to 
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evaluate the safety and efficacy of polymeric stents, but little work is available in 
the literature. 
Finally, bioresorbable polymeric stents, as the latest generation of stent, are 
mostly made of biodegradable polymer PLLA. It is well known that PLLA has low 
mechanical strength and poor elongation compared to metal, which limits its 
application for stents. Based on literature review, a number of experimental 
studies have been performed to investigate and improve the mechanical 
behaviour of PLA, including adding plasticizers to PLA and blending PLA with 
ductile biodegradable polymers. Also, different constitutive material models (e.g., 
elastic-plastic model and viscoelastic model) were applied to model the 
deformation of PLLA stent. However, there is little research on modelling the 
deformation of biodegradable polymeric stent by considering the effect of rate 
dependence for stent material.  
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2.7 Conclusions 
In this chapter, literature review is presented, in terms of the current research 
status for stents, plaque and artery. Stents have been developed from bare-metal 
stent, to drug-eluting stent and then bioresorbable stents to prevent various 
complications and improve their clinical efficacy. Materials are also extended 
from metal (e.g., stainless steel and cobalt-chromium alloy) to biodegradable 
polymer (PLLA). The histological composition of plaque and artery has been 
characterized, and their mechanical behaviour has also been analysed to help 
investigate the stent behaviour during and post deployment.  
Experimental studies have been conducted to investigate the radial and 
longitudinal flexibility of both metallic and polymeric stents using in vitro 
experimental setups, and result showed stent designs and materials played an 
important role in the stent behaviour during expansion. Degradation behaviour of 
polymeric stents was also characterized by in vitro and in vivo methods, physical 
properties (e.g. mass weight and molecular weight) and mechanical properties 
(e.g., tensile strength and elastic modulus) showed a difference during stent 
degradation. A large number of clinical trials in human indicated the safety and 
efficacy of polymeric stents in treatment of coronary artery disease, and a series 
of in vivo studies in animals also showed that the polymeric stents offered the 
benefits for the treatment of biliary disease. However, experimental studies are 
still limited due to the microscale geometry of stent and complex environment of 
human artery. 
Computational approaches, i.e., finite element analysis and numerical modelling, 
have been widely used to study the stent and artery performance during 
expansion, fatigue and degradation, especially for metallic stents. Expansion 
behaviour, including recoiling, dog-boning and stress distribution on stents, were 
analysed by simulation of stent expansion with and without the consideration of 
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plaque-artery system. Fatigue studies on metallic stents were reviewed, and 
results showed that stent fatigue behaviour was influenced by stent design and 
blood pressure. Also, the predicted crack initiation was located at the corners of 
U-bend stent struts due to the occurrence of stress concentration during stent 
deformation. Constitutive material models were developed to predict the 
degradation behaviour of polymeric stent, by combining the degradation and 
deformation parameters. 
Finally, research gaps regarding the current status of research in polymeric 
stents were identified. Currently, the development of bioresorbable polymeric 
stents is still ongoing, and further research is urgently required. 
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Chapter 3 - Methodology for Finite Element 
Simulation 
3.1 Finite element models  
3.1.1 Stent models 
Four different bioresorbable polymeric stent designs were considered in this 
research, and they are the Absorb (Abbott Vascular), Elixir (Elixir Medical), Igaki-
Tamai (Kyoto Medical) and RevaMedical (REVA Medical) stents. The Absorb and 
Elixir stents have already obtained CE mark to treat coronary artery disease, 
while the Igaki-Tamai stent obtained the CE mark to treat peripheral artery 
disease. According to Bedoya et al. (2006), stent geometry is usually defined by 
three parameters, i.e., axial strut spacing (bridge strut), U-bend amplitude and 
U-bend radius. In this research, Absorb, Elixir and RevaMedical stents, have the 
same radius and amplitude for the U-bend struts, while the Igaki-Tamai has larger 
amplitude and smaller radius for U-bend struts. The connective axial strut 
spacing is also similar for Absorb, Elixir and RevaMedical stents, while the Igaki-
Tamai stent has larger axial strut spacing. The geometries and strut thickness of 
these four stents were obtained from various open resources, summarized in 
Table 3-1.  
Table 3-1, Summary of parameters and dimensions for four stents. 
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Geometries of these four stents were generated in the expanded shapes using 
Abaqus 6.14 CAE. Generally, the diameter of stent is designed to be around 3 
mm in expanded shape, and the length is chosen to be around 12 mm. Here, the 
Absorb stent was taken as an example to describe how the finite element model 
was created step by step. The Absorb stent, with 12.66 mm in length, has 13 ring 
units connected by bridge struts, and each ring has 6 peaks and 6 valleys. 
Dimensions of the Absorb stent were measured using OGP flash 200 Microscope. 
The thickness of strut is 150 μm, and the width of strut is 200 μm. To create the 
3D model, three steps are required: (i) creating the flat pattern of stent, (ii) 
partitioning and meshing the flat model and (iii) wrapping the meshed flat part to 
produce tubular model.  
 
Figure 3.1, Diagram showing the procedure of creating flat stent model 
In step i, a series of single rings were built as shown in Figure 3.1 (a), (b) and (c), 
respectively, which were subsequently merged to form a flat model by line pattern 
tool (Figure 3.1d). In step ii, partition was performed using face and cell partition 
tools, and then the partitioned flat model was meshed using 3D 8-node 
hexahedral elements with reduced integration (C3D8R). In step iii, wrapping-up 
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tool was used to revolve the flat model into the 3D tubular stent. The diameter of 
stent was determined by the length of ring unit, which is approximately 3.12 mm 
for the Absorb stent. 
Following the same procedure, models for the other three stents were also 
created according to the images in open resources (see Figure 3.2).  It is clear 
that each stent consists of several ring units connected by bridge struts, and each 
ring unit is made of several U-bends. The U-bends have the same geometry for 
the Absorb, Elixir and RevaMedical stents, and therefore these three stents have 
the same diameter of 3.12 mm. The Igaki-Tamai stent has a different geometry, 
and its diameter is around 3.06 mm. It should be noted that the bridge struts are 
different for each design.  
 
Figure 3.2, 3D stent models of (a) Absorb, (b) Elixir, (c) Igaki-Tamai and (d) 
RevaMedical stents. 
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3.1.2 Tri-folded balloon model 
 
 
Figure 3.3, Diagram for describing the creation of folded balloon using NX. 
NX 8.5 (Siemens PLM Software, UK) was used to create one-third of the tri-
folded balloon model in this research, as shown in Figure 3.3. The tri-folded 
balloon was created in the folded configuration. Specifically, four projected 
curves were created on four uniformly distributed datum planes (Figure 3.3a), 
and the projected curve 4 had a radius of 0.6 mm. These cross-sectional 
sketches were further extruded to produce the 3D shell using swept tool, as 
shown in Figure 3.3b. Then the 3D shell was imported into Abaqus CAE to 
produce the final geometry of tri-folded balloon model (Figure 3.4) by circular 
pattern method. The length of tri-folded balloon is 16 mm for the major part, and 
the fully inflated diameter is approximately 3 mm, corresponding to the target 
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expansion diameter of stent. The 4-node quadrilateral membrane element 
(M3D4R) was chosen to mesh the balloon, because membrane elements are 
generally used to represent thin surfaces in space which have in-plane strength 
but not out-of-plane bending stiffness (e g. a balloon or an airbag). The tri-folded 
balloon model has 12012 elements in total. 
 
Figure 3.4, 3D Finite element model for the tri-folded balloon with meshes. 
3.1.3 Three-layered artery and plaque model 
A three-layer artery was considered, with an inner diameter of 3 mm and a length 
of 40 mm. The overall thickness of arterial wall is 1 mm, including 0.38 mm for 
adventitia layer, 0.33 mm for media layer and 0.29 mm for intima layer. Plaque 
was modelled as a symmetric wall inside the arterial wall, with a length of 10 mm 
and a stenosis of 50% (inner diameter is 1.5 mm). Hexahedral element with 
reduced integration (C3D8R) was used to mesh the artery and plaque. In the 
radial direction, the artery was meshed with 4 layers of elements for each arterial 
layer and the plaque was meshed with 8 layers of elements. In the longitudinal 
direction, the element size along the artery was increasing from the middle to 
both ends using single bias method. The plaque-artery system has 107640 
elements in total. Figure 3.5 shows the mesh and geometry for plaque-artery 
system. 
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Figure 3.5, FE mesh for the plaque-artery system. 
 
3.2 Material constitutive models 
3.2.1 Constitutive models for stent and balloon 
From literature, the Absorb, Elixir and Igaki-Tamai stents are made of Poly (lactic-
L-acid) (PLLA) (Wiebe, 2014), and the RevaMedical stent is made of 
polycarbonate (Garcia-Garcia, 2014). But in this study, biodegradable polymer 
PLLA was taken as the material for all stents. The mechanical property for PLLA 
was obtained from uniaxial tensile tests conducted by Pauck and Reddy (2015), 
and stress-strain curve of PLLA was shown in Figure 3.6. The density of material 
PLLA is 1.4×10-6, Young’s Modulus is 2200 MPa and Poisson Ratio is 0.3. 
Tri-folded balloon was modelled as an isotropic and linear-elastic material, with 
Young’s Modulus of 900 MPa and Poisson Ratio of 0.3, according to literature 
(Gervaso, 2008). 
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Figure 3.6, Stress-strain behaviour for stent material PLLA used in simulation. 
3.2.2 Constitutive models for plaque and artery 
For the three-layer artery, the Holzapfel-Gasser-Ogden (HGO) model was used 
to describe the anisotropic behaviour of the arterial layers with collagen fibres, 
and the strain energy potential function is expressed by: 
 
U = CAL IA − 3 + 1D (J);2 − ln[
+ kA2k; exp k; Ea ; − 1baRA  
(3.1) 
 Ea = κ IA − 3 + (1 − 3κ) Id(aa) − 1  (3.2) 
where U is the strain energy per unit of reference volume,  CAL ,  D , 	kA ,  k; and κ are temperature-dependent material parameters, N is the number of 
fibre families (N ≤ 3), IA is the first deviatoric strain invariant, J is the elastic 
volume ratio, Id(aa) is the invariant of Cauchy-Green deformation tensor and Ea 
represents the deformation of the fibre families. The operator <> stands for the 
Macauley bracket. 
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The model assumes that the directions of the collagen fibres are dispersed about 
a mean preferred direction within each fibre family. The parameter κ represents 
the level of dispersion in the fibre directions. The first two terms in the expression 
of the strain energy function describe the distortional and volumetric contributions 
of the non-collagenous isotropic ground material, and the third term represents 
the contribution from the different families of collagen fibres by taking dispersion 
effect into account. 
In this study, it is assumed that there are two families of collagen fibres 
embedded in a soft incompressible ground matrix within each arterial layer, and 
so here we have 𝑁 = 2. The constitutive model was calibrated by fitting the 
average stress-stretch curves that were obtained from 13 patients (Holzapfel, 
2005), and the calibrated parameter values for the HGO model were given in 
Table 3-2. Figure 3.7 presents the simulated longitudinal and circumferential 
stress-stretch responses of three layers, which were in very good agreement with 
the experimental results. 
Table 3-2, Parameter values of the anisotropic hyperelastic GHO model. 
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For hypocellular plaque, the constitutive behaviour was defined in form of 
hyperelastic Ogden strain energy potential (Ogden, 1972), which is represented 
by: 
 𝑈 = 2𝜇>𝛼>; 𝜆AOP + 𝜆;OP + 𝜆FOP − 3 + 1𝐷> 𝐽 − 1 ;>Q>RA
Q
>RA  (3.3) 
where 𝜆A  , 𝜆;  and 𝜆F denotes the deviatoric stretches in three principle 
directions, 𝜇> , 𝛼> and 𝐷> represent material parameters, and 𝑖 is the order of 
the function. The first order Ogden function was used for the hypocellular plaque, 
and the material parameters were calibrated against experimental data 
(Zahedmanesh and Lally, 2009), as shown in Table 3-3. The stress-strain curve 
modelled with these parameters was shown in Figure 3.8, compared to 
experimental data in the literature (Loree, 1994). Two symbolic plots 
(experimental data 1 & 2) refer to the measured stress-strain behaviour of 
hypocellular plaque specimens, and the modelling result turned to be in good 
agreement. 
Table 3-3, Material parameter values for the Ogden model. 
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Figure 3.7, Longitudinal and circumferential stress-stretch responses 
comparing simulation results with experimental data. 
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Figure 3.8, Stress-strain curves for hypocellular plaque predicted from Ogden 
model, compared to experimental data. 
3.3 Finite element simulation setup 
3.3.1 Simulation procedures 
It is well known that the manufactured stent is in the expanded configuration, and 
therefore crimping procedure is required prior to the stent deployment. In reality, 
a purposely-designed machine (as shown in Figure 3.9) is generally used for 
crimping a stent onto a balloon. Specifically, the stent-balloon catheter assembly 
is mounted on a mandrel and inserted into the space between the crimp head, 
and then the stent is crimped to a target diameter under the loading of crimp 
head. Particularly, the crimp head consists of 12 loading segments, and the 
crimping procedure is realised by controlling the radial displacement or force of 
loading segments. The crimped stent and balloon catheter system is obtained 
after the removal of crimp head. 
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Figure 3.9, A stent crimping machine. 
To model the crimping process of stent, two steps, i.e., crimping and spring back, 
were created in the simulation. The stent-balloon-rigid plate assembly is shown 
in Figure 3.10. In crimping step, 12 rigid plates are used to compress the stent 
onto the balloon by applying enforced displacement load on the rigid plates. In 
spring back step, the 12 rigid plates are removed, allowing a recovery of elastic 
deformation for the crimped stent.  
 
Figure 3.10, Stent-balloon-rigid plate assembly used in simulation. 
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According to the product manual of the Absorb GT1 system, the deployment 
procedure is described as follows (Abbott, 2016): (i) deploy the scaffold slowly 
by pressurizing delivery system in 2 atm increments over 5 seconds, until the 
scaffold is completely expanded; (ii) maintain the pressure for 30 seconds, and 
if necessary, the delivery system can be further pressurized to ensure complete 
apposition of the scaffold to the arterial wall; (iii) deflate the balloon by pulling 
negative on the inflation device for 30 seconds, and confirm the complete balloon 
deflation before removing the delivery system. 
In the finite element simulation of stent deployment, two steps were considered, 
including balloon inflation and deflation steps. In balloon inflation step, pressure 
was applied on the inner surface of tri-folded balloon to expand the stent. 
Following stent expansion, a deflation step was performed to allow free recoil of 
the stent, in which the balloon pressure was removed. It should be noted that the 
specific simulation procedures, including loads and boundary conditions, will be 
introduced in the individual chapters. 
3.3.2 Post-processing of simulation results 
In this study, the whole process of stent crimping and expansion was treated as 
quasi-static problem, and Abaqus/Explicit was used for all simulations. In all 
simulations, the internal and kinetic energies were monitored to make sure that 
the kinetic energy was always less than 5% of internal energy. Automatic time 
increment was used, and the stable time increment was in the order of 10-8 s 
throughout the analysis.  
FDA Guidance 2005 recommends that elastic recoil and dog-boning can be used 
to evaluate the stent performance. The elastic recoil is affected by the 
deformation behaviour of the material and the specific stent structure (Lanzer, 
2007), and dog-boning is a parameter that identifying restenosis induced by 
undesirable mechanical stress on vessel wall (Park, 2008). 
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The recoiling effect can be calculated following the equation (ASTM F2079): 
 𝑆𝑡𝑒𝑛𝑡	𝑅𝑒𝑐𝑜𝑖𝑙	 % = (𝑑L − 𝑑A)𝑑L ×100% (3.4) 
where 𝑑L and 𝑑A represent the diameters in the middle of stent at maximum 
pressure and after deflation, respectively.  
The dogbonig effect is determined by calculating the difference between 
diameters in the middle and at the end, which is described by the equation 
(Migliavacca, 2005): 
 𝑑𝑜𝑔𝑏𝑜𝑛𝑖𝑛𝑔	 % = (𝑑 − 𝑑8)𝑑8 ×100% (3.5) 
where 𝑑 is the average diameter at the end of stent and 𝑑8 is the average 
diameter in the middle of stent. 
Moreover, von Mises stress has been widely used to assess the multiaxial stress 
states on stent, plaque and artery in FE studies (Ju, 2008; Imani, 2015; Eshghi, 
2011), which is also the case for this research. 
3.4 Mesh sensitivity study 
3.4.1 Stent mesh sensitivity 
A simplified Absorb stent model, with three rings connected by bridge struts, was 
used to carry out mesh sensitivity study. The simplified Absorb stent models with 
different mesh densities are shown in  
Figure 3.11. The stent model has a length of 2.6 mm and an outer diameter of 
3.12 mm, and the thickness of strut is 150 µm. The material constitutive model 
used for the Absorb stent is based on biodegradable polymer PLLA, as described 
in the previous section. The stent was meshed using solid hexahedral 8-node 
elements with reduced integration (C3D8R). The mesh densities varied by 
changing the element layers through both width and thickness directions. For 
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instance, mesh density 2×2 represents that there are 2 layers through width 
direction and 2 layers through thickness.  
Stent expansion was simulated by balloon inflation and deflation without 
considering the existence of plaque-artery system. Figure 3.12 shows the von 
Mises stress distribution on the stent with four different mesh densities. Overall, 
high level stresses (red zone) were mainly located at the U-bend regions in all 
four cases. It can be found that high level stress, for stent with finer mesh (i.e., 
4×4 and 6×6), became more localised at the inner and outer surfaces of U-bend 
struts compared to those with coarser mesh (i.e., 2×2 and 2×4). Figure 3.13 
compares the maximum von Mises stress values on the stent with four different 
mesh densities. It is clear that the maximum stress increased with the increase 
of mesh density, and the convergence was considered to be obtained for mesh 
density 4×4. Specifically, the maximum stress was 92 MPa and 94 MPa for stents 
with mesh density 2×2 and 2×4, which was 9% and 7% lower than the converged 
value of 102 MPa for stent with mesh density 4×4 and 6×6.  
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Figure 3.11, Simplified Absorb stent model with different mesh densities, (a) 
2×2, (b) 2×4, (c) 4×4 and (d) 6×6. 
.  
Figure 3.12, The contour plot of von Mises stress on the stent with mesh 
densities of (a) 2×2, (b) 2×4, (c) 4×4 and (d) 6×6. 
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Figure 3.13, Maximum von Mises stress on the stent with four different mesh 
densities. 
Figure 3.14 compares the stent diameter change against balloon pressure during 
free expansion process. Overall, the stent expansion behaviour was very similar 
in all four different cases, and the stent was expanded significantly under a 
pressure of 0.2 MPa. The largest diameter was achieved to be 3.3 mm at peak 
pressure, and subsequently reduced to be around 2.9 mm after elastic recoil. It 
indicated that stent expansion and recoiling behaviour are insensitive to mesh 
densities. 
 
Figure 3.14, Diameter change against pressure for the stent with four different 
mesh densities. 
3.4.2 Plaque-artery mesh sensitivity  
Similarly, a simplified plaque-artery model was used for mesh sensitivity study. It 
has a length of 3 mm, and thicknesses of three layers and plaque are 0.38 mm, 
0.33 mm, 0.29 mm and 0.75 mm, respectively. The plaque-artery was also 
meshed using solid hexahedral 8-node elements with reduced integration 
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(C3D8R). And mesh densities varied by changing the number of element layers 
through the thickness direction of arterial layer and plaque, as shown in Figure 
3.15. It should be noted that the plaque was meshed by twice numbers of 
element layers compared to three individual arterial layers (i.e., intima, media 
and adventitia). For instance, when the arterial layer is meshed with 1 element 
layer, 2 element layers will be generated for plaque through the thickness 
direction. 
 
Figure 3.15, Plaque-artery model with different mesh densities, (a) 1 layer, (2) 2 
layers, (c) 4 layers and (d) 6 layers. 
Figure 3.16 shows the stent diameter change against pressure obtained from 
simulations using four different mesh densities for plaque-artery system. In all 
four cases, stent obtained a diameter of 3.25 mm at peak inflating pressure, and 
then recoiled to be approximately 2.75 mm. It indicated that the mesh densities 
of plaque-artery had little influence on the stent expansion behaviour. 
Figure 3.17 shows the average von Mises stress values on the middle part of 
plaque surface with four different mesh densities. The convergence is achieved 
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for plaque-artery system with 4 layers of elements, and the calculated average 
von Mises stress value is 1.21 MPa, 1.45 MPa, 1.79 MPa and 1.81 MPa for 1 
layer, 2 layers, 4 layers and 6 layers of elements, respectively. 
The von Mises stress distribution on plaque-artery system with different mesh 
densities is shown in Figure 3.18. Overall, von Mises stress value showed a 
gradual increase along the thickness direction (from inner surface of plaque to 
adventitia layer of artery) in all four cases. For mesh with 1 layer of elements, the 
von Mises stress distribution was almost uniform on the inner surface of plaque, 
which didn’t reflect the varied area of contact between stent and plaque-artery 
system during stent expansion. In other three cases, the area of direct contact 
between stent and plaque-artery exhibited higher stresses (red zones), and the 
maximum stress values increased slightly with finer meshes. 
 
Figure 3.16, Stent diameter change against pressure obtained from simulations 
with different mesh densities for plaque-artery. 
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Figure 3.17, The average von Mises stress values over the middle part of 
plaque surface with different mesh densities. 
 
 
Figure 3.18, The contour plot of von Mises stress on the plaque-artery system 
after stent deployment with of (a) 1 layer, (b) 2 layers, (c) 4 layers and (d) 6 
layers of elements. 
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3.5 Conclusions 
In this chapter, the production of finite element models, including stents with four 
different designs, tri-folded balloon and plaque-artery system, was introduced. 
The constitutive material models for each component were also described. The 
material model for stent was defined by stress-strain behaviour of polymer PLLA, 
and the behaviour of tri-folded balloon was assumed to be isotropic and linear 
elastic. The plaque-artery system was treated as hyperelastic material defined 
by hyperelastic strain energy potentials (Ogden for plaque and HGO for arterial 
layers).  
Also, mesh sensitivity studies were carried out for both stent and plaque-artery 
system. Results showed that the stent achieved good convergence for mesh 
density of 4×4, and the plaque-artery showed convergence with 4 layers of 
elements through the thickness direction, in terms of stress distribution and 
maximum/averaged stress values. Moreover, the change of stent diameter was 
not sensitive to mesh densities of stent or plaque-artery system during expansion 
process. In the following chapters, 4×4 mesh density was adopted for stent, and 
4 layers of element through the thickness were applied for three individual arterial 
layers. For the plaque, 8 layers of elements were used through the thickness. 
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Chapter 4 - Finite Element Modelling of 
Crimping and Expansion of Bioresorbable 
Polymeric Stents 
4.1 Intruduction  
Bioresorbable stents have been developed to provide shot-term lumen support 
in plaque-blocked arteries and then disappear within a specific time period, which 
reduces the occurrence of thrombosis, in-stent restenosis and inflammation that 
usually appear after the deployment of metallic stents (Garcia-Garcia, 2014). 
Bioresorbable stents are usually made of biodegradable polymer or magnesium 
alloy. The concept of bioresorbable stent can be dated back to early 1990s, when 
Tamai (2000) reported the first successful implantation of a fully degradable stent 
in human body. Since then, a variety of devices have been developed for 
preclinical and clinical evaluations, such as the Igaki-Tamai stent (Kyoto Medical 
Planning Co. Ltd., Kyoto, Japan), the Absorb (Abbott Vascular, Santa Monica, 
CA, USA), Elixir DESolve (Elixir Medical Corp., Sunnyvale, CA, USA) and REVA 
ReZolve (Reva Medical Inc., San Diego, CA, USA).  
A large amount of clinical studies have been carried out to assess the 
performance of bioresorbable polymeric stents. The Igaki-Tamai stents, as the 
first fully biodegradable coronary stent made of Poly (L-Lactic acid) (PLLA), were 
implanted in 50 patients to evaluate the long-term (>10 years) clinical safety and 
efficacy. Results showed that the major adverse cardiac event rate was similar 
to that of bare metal stent, and low scaffold thrombosis rate (without stent recoil 
and vessel remodelling) was observed in the follow-up trial, which suggested the 
long-term safety of the stents (Nishio, 2012). The Absorb stents, also made of 
PLLA, was firstly applied in the treatment for de-novo coronary artery lesions in 
30 patients. The 2-year follow-up outcomes showed that the stents were 
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absorbed after 2 years, and they were proven to be clinically safe with no cardiac 
deaths or stent thrombosis observed (Serruys, 2009). Recently, a 12-month 
clinical outcome has been published to report the mid-term performance of the 
Absorb stent in the treatment for focal tibial and distal popliteal lesions. It 
revealed that the Absorb stent is safe and free from target lesion 
revascularization (Varcoe, 2016). The novel PLLA DESolve novolimus-eluting 
bioresorbable coronary scaffold (Elixir) has been evaluated in a 2-year clinical 
trial for the treatment of single de-novo coronary lesions in 126 patients. Results 
showed that early luminal growth was observed at 6 months, and the efficacy 
and safety of stents could sustain through 2 years (Abizaid, 2016). 
Over the last two decades, great efforts have been made to study mechanical 
performance of bioresorbable polymeric stents using experimental methods. For 
instance, Grabow et al. (2007) manufactured novel slotted tube stents (made of 
PLLA and PLLA/PCL/TEC) and studied their mechanical properties for peripheral 
vascular applications. They found that pure PLLA stent had recoiling (2.4%) and 
collapse pressure (0.67-1.3 bar), which were comparable to commercial 
peripheral metallic stent (recoiling in a range of 2.5-4.8%, collapse pressures of 
0.8-1.2 bar), due to the adequate mechanical properties of pure PLLA. Welch et 
al. (2009) investigated the influence of thermal treatment on the mechanical 
properties of coil-within-coil PLLA fibre stent. Their results indicated that thermal 
treatment could change the reorientation and realignment of fibre crystalline 
structure, and thereby improved the stress-strain behaviour of PLLA fibre and 
expansive properties of the PLA fibre stent. In 2013, they also fabricated double-
opposed helical stents (made of PLLA) and characterized their mechanical 
properties as a function of stent size and design. Results showed that stent 
design, such as the number of coils in the double helical design and winding 
design in longitudinal direction, made a difference to the mechanical behaviour 
of stent (Welch, 2013).  
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In addition, finite element method also has been used to study the mechanical 
behaviour of stent during deployment. Migliavacca et al. (2005) carried out 
computational study on the free expansion of Cordis BX Velocity stent, and their 
results showed a good matching with the experimental studies in terms of radial 
expansion behaviour and elastic recoil effect. Gervaso et al. (2008) simulated 
expansion of metallic stent using three different inflation methods: (i) impose a 
uniform pressure on stent inner surface, (ii) expand a rigid cylindrical surface by 
displacement control and (iii) model a polymeric deformable balloon. These three 
methods produced similar results of stress distribution on stent, but resulted in 
significantly different deformed shapes of stent. De Beule et al. (2008) evaluated 
the effect of balloon folding on the expansion behaviour of Cypher stent, and they 
found that the mechanical behaviour of tri-folded balloon-expandable stent 
showed the best agreement with both manufacturer's data and experimental 
measurements.  Schiavone et al. (2014) conducted a comparative study on the 
mechanical performance for four metallic stents (e. g. Palmaz-Schatz, Cypher, 
Xience and Endeavor stents), and reported that stent design is one of the major 
factors controlling the stent performance.  
As discussed above, most computational studies focused on metallic stents. 
Computational analysis of bioresorbable polymeric stents, particularly PLLA stent, 
is very limited. Existing research is largely limited to the Absorb stent or simplified 
tubular PLLA stent. For instance, Debusschere et al. (2015) investigated the 
effect of balloon deployment rate on the expansion behaviour of Absorb stent 
using implicit finite element solver, and their results suggested that the stepwise 
balloon inflation method reduced the high level stress generated on expanded 
stent. Pauck and Reddy (2015) evaluated the radial strength, elastic recoil and 
radial stiffness of PLLA coronary artery stent using finite element method. Results 
revealed that both material property (e.g., elastic modulus) and stent design (e.g., 
strut angle, thickness and width) could affect the mechanical behaviour of PLLA 
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stent during expansion. Most recently, Wang et al. (2017) studied the mechanical 
performance of Absorb stent unit by finite element method. They found that the 
stress distribution, radial recoil, stiffness and strength of stent were different 
when crimped or expanded to different diameters. As such, there is a research 
gap in computational investigation of the mechanical behaviour of bioresorbable 
polymeric stents with different designs.  
The chapter aims to investigate the mechanical performance of four typical 
bioresorbable polymeric stents (Absorb, Elixir, Igaki-Tamai and RevaMedical 
stents) during crimping and expansion processes by finite element modelling. A 
comparative study for these four polymeric stents was presented, in terms of 
stress distribution, diameter change against pressure, recoiling effect as well as 
radial stiffness and strength of stent. Furthermore, stent expansion was also 
simulated to study the effect of residual stress generated by crimping procedure 
on the behaviour of bioresorbable polymeric stents. 
4.2 Methodology 
4.2.1 Finite element models and material models 
Four bioresorbable polymeric stents, i.e., Absorb, Elixir, Igaki-Tamai and 
RevaMedical stents, were used in this study. The finite element models of these 
four stents were produced according to the description in Chapter 3. Tri-folded 
balloon was employed to expand the stent in simulations. All four stents were 
considered to be made of biodegradable polymer PLLA, and the tri-folded 
balloon was treated as isotropic and linear elastic material. The material 
behaviour of stent and tri-folded balloon was also introduced in Chapter 3. 
 
4.2.2 Stent crimping procedure 
As described in Chapter 3, crimping and spring back steps were modelled. In 
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stent crimping process, 12 rigid plates were assembled around the stent, and the 
distance between central axis of stent and rigid plate is 1.6 mm.  Both ends of 
the tri-folded balloon were fully constrained because they were fixed on the 
catheter in the actual situation. Interactions between stent and rigid plates, stent 
and tri-folded balloon were considered as surface to surface hard contact, with a 
frictional coefficient of 0.8. A linearly increasing displacement load was applied 
on the surface of 12 rigid plates along radial direction, to squeeze the original 
expanded stent, and the maximum displacement is 1 mm. As a result, all four 
biodegradable polymeric stents were squeezed onto the tri-folded balloon, with 
the same outer diameter of 1.2 mm. The stent-balloon assembly at different 
crimping stages are shown in Figure 4.1. After crimping, an additional step 
(spring back) was added to remove the 12 rigid plates by applying displacement 
load along the opposite direction, which allowed the crimped stent to have elastic 
recovery. 
 
Figure 4.1, Snapshot of stent crimping process. 
4.2.3 Stent expansion procedure 
Following crimping and spring back steps, balloon inflation and deflation were 
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simulated. In balloon inflation step, a linearly increasing pressure was applied on 
the inner surface of the tri-folded balloon to inflate the stent, and the pressure 
increased from 0 to 1.4 MPa. Interaction between inner surface of stent and outer 
surface of tri-folded balloon was defined with a friction coefficient of 0.25 (Ju, 
2008). Following balloon inflation, a deflation step was performed to allow free 
recoil of the stent. It should be noted that residual stress caused by stent crimping 
was considered in the simulation. Then all four commercially available 
bioresorbable stents were simulated in order to compare the performances of 
different stent designs. 
In order to identify the effect of residual stress, expansion of the crimped stent 
was simulated without considering the existence of residual stress. Specifically, 
the crimped stent and balloon assembly was extracted after the spring back 
simulation step, with deformed configuration but free from stress state. Loads 
and constraints were the same as those used for simulations considering 
residual stresses. Again, all four bioresorbable stents were modelled to evaluate 
the mechanical behaviour with and without the existence of residual stress. 
4.2.4 Evaluation of the radial stiffness and strength for stent 
Radial stiffness and radial strength can be used to describe the ability of stent to 
resist collapse under short-term or long-term external loads (US Food and Drug 
Administration, 2010). According to the ASTM standard F3067, the testing 
procedures can be divided into three steps: (i) inflate the stent to a labelled 
diameter; (ii) deflate the balloon; (iii) compress the expanded stent by crimp head.  
Therefore, an additional crimping process (called re-crimping) was added in the 
simulation following the stent expansion. In the re-crimping process, 12 rigid 
plates were again used to compress the expanded stent by linearly increasing 
displacement load. The contact and constraints were the same with those in the 
initial crimping and spring back simulations. 
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The reaction force between stent and rigid plates, and outer diameter of stent 
were measured, to produce radial loading curve of the stent. Radial stiffness and 
radial strength can be calculated from the radial loading curves obtained from 
the re-crimping simulation. Generally, a radial loading curve is a plot of radial 
pressure output as a function of diametric deformation of a stent. The radial 
pressure is expressed as a radial force normalised by the instantaneous stent 
cylindrical area which is calculated by the following equation (ASTM F3067): 
 𝐴 = 𝜋𝐷𝐿	 (4.1) 
where D is instantaneous stent outer diameter, and L is the original stent length.  
Radial stiffness is the slope of the steepest initial linear portion of the radial 
loading curve. Radial strength is defined as the radial pressure at which the stent 
experiences irrecoverable deformation, and it is determined by the parallel 0.1 
mm offset line to the slope line of initial linear portion. 
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4.3 Results and discussions 
4.3.1 Stent crimping  
Figure 4.2 shows the diameter change against radial pressure for four stents 
during crimping process. For all four stents, the Igaki-Tamai stent had a 
significant change of diameter at the relatively low radial pressure. It might be 
because of the smaller surface area (only 7 rings) and the shorter length, which 
makes the stent more flexible. The Absorb and Elixir stents exhibited very similar 
expansion behaviour, due to their similar designs. The RevaMedical stent 
required the relatively high radial pressure for crimping. The stent has the same 
ring design as Absorb and Elixir stents, but with thicker struts that makes it more 
difficult to deform.   
 
Figure 4.2, Diameter change against radial pressure plot for four stents during 
crimping. 
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All four stents were squeezed to a diameter of around 1.2 mm at the end of 
crimping procedure. Figure 4.3 shows the von Mises stress distribution on four 
stents in fully crimped configuration. The maximum von Mises stresses on the 
stents after crimping had very similar magnitude, which was 97.39 MPa, 97.92 
MPa, 96.72 MPa and 98.82 MPa for the Absorb, Elixir, Igaki-Tamai and 
RevaMedical stent, respectively. In all cases, the maximum von Mises stresses 
occurred at the peaks and valleys of U-bend struts, as indicated by the red zones. 
Obviously, the Igaki-Tamai stent had less area with high level stresses compared 
to the other three stents, suggesting it experienced less plastic deformation.  
 
Figure 4.3, The von Mises stress (MPa) contour plot for the (a) Absorb, (b) Elixir, 
(c) Igaki-Tamai and (d) RevaMedical stents in fully crimped configuration. 	
Figure 4.4 shows the von Mises stress distribution on four stents after spring 
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back. The stresses, also called residual stresses, had a reduction due to the 
elastic spring back effects. The residual stresses turned out to be 74.24 MPa for 
Absorb stent, 70.91 MPa for Elixir stent, 81 MPa for Igaki-Tamai stent and 94.01 
MPa for RevaMedical stent. The spring back effects for four stents were 
calculated and shown in Figure 4.5. Specifically, the Igaki-Tamai stent had the 
largest spring back of 30%, which was significantly higher than the other three 
stents. The spring back was 12% for Absorb stent, 15% for Elixir stent, and 10% 
for RevaMedical stent. 
 
Figure 4.4, The von Mises stress (MPa) contour plot for the (a) Absorb, (b) 
Elixir, (c) Igaki-Tamai and (d) RevaMedical stents after spring back. 
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Figure 4.5, Spring back effects for four stents. 
The material properties are the same for all four bioresorbable polymeric stents, 
but different behaviour is obtained during crimping process. It is considered to be 
affected by their individual designs. The Absorb and Elixir stents have the same 
design for U-bend struts, i.e., radius and amplitude, and the same strut thickness, 
but different axial strut spacing. In the results, the von Mises stress distribution 
are very similar during crimping process, while some difference was found 
regarding residual stresses and spring back effects for these two stents. The 
Elixir stent experienced more spring back than the Absorb stent, because of a 
larger axial strut spacing that allowed more recovery of deformation. In addition, 
the Elixir stent has only two axial struts between each two ring units but the 
Absorb stent has three, and therefore the Elixir stent experienced more spring 
back effect and stress loss during the spring back process.  
Similarly, the Igaki-Tamai stent has larger U-bend amplitude and axial strut 
spacing compared to the Absorb and Elixir stents, which ehnhances its flexibility. 
As a result, the Igaki-Tamai stent was able to be crimped under a relatively low 
radial pressure, and also experienced the most severe spring back effect. 
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However, the Igaki-Tamai stent has thicker strut (170 μm) than the Absorb and 
Elixir stents (150 μm), which may benefit its stress resistance. It can be proved 
from the amount of stress loss on the stent after spring back. The stress loss for 
Igaki-Tamai stent is around 15 MPa, whereas the Absorb and Elixir stents 
experienced stress loss of 23 MPa and 27 MPa. The RevaMedical stent has the 
same U-bend strut design as the Absorb and Elixir stents as described in Chapter 
3, but with less spring back effect. It is probably due to the different strut thickness. 
The RevaMedical stent has a strut thickness of 200 μm, much larger than that of 
Absorb and Elixir stents (150 μm). It can be concluded that stent design, in terms 
of U-bend radius and amplitude, strut thickness and axial strut spacing, played 
an important role in controlling the mechanical behaviour of stent during crimping 
process. 
4.3.2 Stent expansion 
Figure 4.6 presents the configurations of the Absorb stent and balloon system at 
different intervals during the inflation process. At zero pressure, the Absorb stent 
takes the crimped shape (Figure 4.6a). When the pressure increases to 0.5 MPa, 
the stent turns out to be in a typical dogbone shape, because the balloon started 
inflation from both ends. The tri-folded balloon is fully inflated at the pressure of 
1.4 MPa, and the dogbone shape disappears for the stent. This phenomenon 
was also reported in the literature (Debusschere, 2015). 
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Figure 4.6, Configurations of the Absorb stent and balloon during the inflation 
process at pressure of 0 MPa (a), 0.5 MPa (b), and 1.4 MPa (c). 
Figure 4.7 shows the stent diameter change against pressure for all four stents 
during the expansion processes. Overall, these four stents exhibited different 
expansion behaviour under the same inflating pressure rate. Obviously, the Igaki-
Tamai stent expanded with the fastest rate and reached saturation much earlier 
than the other three stents. The RevaMedical stent had significant diameter 
enlargement at a pressure of 0.7 MPa, while the Absorb and Elixir stents required 
lower pressures (0.5 MPa and 0.4 MPa) to complete significant expansion. The 
diameters obtained at peak pressure are very close for all four stents, which is in 
a range of 3.3-3.4 mm. The final diameter achieved after balloon deflation is 3.25 
mm for Absorb stent, 3.07 mm for Elixir stent, 2.88 mm for the Igaki-Tamai stent 
and 3.12 mm for the RevaMedical stent. 
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Figure 4.7, Diameter change against pressure plot for four stents. 
Figure 4.8 shows the von Mises stress distribution on stents at peak pressure. 
The red areas have stresses higher than 80 MPa. All four stents turned out to 
have uniformly expanded shapes. Similar to the crimping results, stress 
concentrations were found at the U-bend regions. The maximum von Mises 
stresses were 101.92 MPa for Absorb stent, 102.87 MPa for Elixir stent, 98.48 
MPa for Igaki-Tamai stent and 103.94 MPa for RevaMedical stent.  
Figure 4.9 presents the stress distribution on stents after balloon deflation. 
Similarly, stress loss on stent was observed in all cases. The maximum von 
Mises stress magnitude turned out to be 97.44 MPa for Absorb stent, 100.47 
MPa for Elixir stent, 66.73 MPa for Igaki-Tamai stent, and 100.93 MPa for 
RevaMedical stent. For the Absorb, Elixir sand RevaMedical stents, the 
maximum von Mises stress magnitudes didn’t change significantly, but the area 
of high level stress (in red colour) was less spread on the stents. The Igaki-Tamai 
stent experienced dramatic stress loss, indicating its great flexibility due to the 
large U-bend amplitude and axial strut spacing.   
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The recoiling effects for all four stents are shown in Figure 4.10. The Igaki-Tamai 
stent experienced the most severe recoiling effect (17.0%), while the recoiling 
was significantly lower for Absorb, Elixir and RevaMedical stents, i.e., 6.8%, 
8.8%, and 8.3%, respectively. 
Expansion behaviour of the four stents showed similar trend as that for crimping, 
in terms of the stent diameter change against pressure, stress concentration, as 
well as stress loss, and the recoiling effect after balloon deflation. Therefore, 
stent design also affected the mechanical behaviour of stent during expansion 
process. 
 
Figure 4.8, The von Mises stress (MPa) contour plot for the (a) Absorb, (b) 
Elixir, (c) Igaki-Tamai and (d) RevaMedical stents at peak pressure. 
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Figure 4.9, The von Mises stress (MPa) contour plot for the (a) Absorb, (b) 
Elixir, (c) Igaki-Tamai and (d) RevaMedical stents after balloon deflation. 
	
Figure 4.10, Recoiling effects for four stents after balloon deflation.	 	
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4.3.3 Residual stresses caused by crimping 
Significant amount of residual stresses was generated on the stent during the 
crimping process (see Figure 4.3), and therefore it is important to study how 
these residual stresses will affect the stent behaviour during expansion process. 
The stent expansion behaviour presented above was obtained by taking residual 
stress into account. Simulations of stent expansion were also carried out by 
excluding the residual stress state. Figure 4.11 shows the stent diameter change 
against pressure during expansion process, with and without considering 
residual stress. In the inflation step, it showed that the presence of residual stress 
did affect the expansion rate of stents. All four stents achieved the saturation 
earlier in simulations without considering residual stress. However, the pressure 
levels at expansion saturation showed little difference. The pressure required for 
saturation is around 0.7 MPa for the RevaMedical stent, 0.5 MPa for Absorb stent, 
0.4 MPa for Elixir stent and 0.1 MPa for Igaki-Tamai stent, which were 
approximately the same with the results obtained in the simulations with 
considering residual stress. The stent diameters achieved at peak pressure did 
not change greatly either. For instance, the Absorb stent reached a diameter of 
3.39 mm at peak pressure in the simulation with considering residual stress, and 
achieved a diameter of 3.36 mm in the simulation without considering residual 
stress. In the deflation step, similar trends were observed for stent in simulations 
with or without considering residual stresses, and the final diameters obtained 
after balloon deflation were also very similar for all four stents. For instance, the 
Absorb stent achieved a final diameter of 3.16 mm and 3.164 mm in simulations 
with and without considering residual stress, respectively. As a result, the 
recoiling was 6.8% and 6% for the Absorb stent in the simulations with and 
without considering residual stress.  
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Figure 4.12 shows the recoiling effect obtained from simulations with and without 
considering residual stress for all four stents. A slight difference was observed 
for the Absorb, Elixir and RevaMedical stents, but the difference was only around 
1%. The recoiling for the Igaki-Tamai stent was 17% in the simulation with 
considering residual stress, but it decreased significantly to 12% when the 
residual stress was not considered. This suggested that the effect of residual 
stress should be considered in the study of stent behaviour during expansion 
process. 
 
Figure 4.11, Diameter change against balloon pressure obtained from 
simulations with and without residual stress on stents. 
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Figure 4.12, Recoiling effect obtained from simulations of stent expansion with 
and without considering residual stress. 
 
4.3.4 Radial stiffness and strength 
Figure 4.13 shows the radial pressure-diameter curve for the Absorb stent during 
re-crimping process. The behaviour can be divided into two regions, the initial 
linear behaviour and the follow-on nonlinear behaviour due to increased plasticity.  
For initial linear region, there was a slight non-linear portion when the rigid plates 
started to contact the outer surface of stent, as shown in green box. After the full 
contact was established, the curve became approximately linear. In the linear 
portion of the curve, the stent underwent mainly elastic deformation. Then the 
slope of the steepest linear portion determines the radial stiffness of the stent, 
which is 616 kPa/mm for the Absorb stent. With the increase of plastic 
deformation, the curve trended to become nonlinear. During this region, the radial 
pressure increased relatively slowly with the decrease of stent diameter. The 
interception point between the 0.1 mm offset yield curve and the pressure-
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diameter curve determines the radial strength of the stent, which is 250 kPa in 
this case. 
 
Figure 4.13, Radial loading curve for the Absorb stent during re-crimping. 
Similarly, the radial stiffness and radial strength were also calculated for the other 
three stents (Figure 4.14), with values given in Table 4-1. Obviously, the 
RevaMedical stent presented the highest radial stiffness (708 kPa/mm) and 
strength (318 kPa). The Elixir stent, with similar design to the Absorb stent, 
showed a slightly lower radial stiffness of 538 kPa/mm and a radial strength of 
218 kPa. The calculated radial stiffness and strength are 132 kPa/mm and 73 
kPa for the Igaki-Tamai stent, which are much lower compared to the other three 
stents.  
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Table 4-1, Radial stiffness and radial strength for the four stents. 
 
Overall, the Absorb, Elixir and RevaMedical stents showed a radial stiffness 
comparable to that of a polymeric stent reported by Pauck and Reddy (2015). 
The radial stiffness was approximately 500 kPa for a typical polymeric stent with 
material properties (E = 1.8 GPa, yield stress = 45 MPa), and increased to 1300 
kPa when the material stiffness increased to 3.6 GPa. Their results indicated that 
material modulus affects the radial properties of stents. In this study, four 
bioresorbable polymeric stents exhibited different radial stiffness and strength 
properties, largely due to their individual designs. For instance, the Igaki-Tamai 
stent (with larger U-bend amplitude and axial strut spacing) exhibited the lower 
radial stiffness and strength compared to the other three stents. The 
RevaMedical stent had the same U-bend design (U-bend radius and amplitude) 
as the Absorb and Elixir stents, but with thicker strut. As a result, it showed higher 
radial stiffness and strength than the Absorb and Elixir stents, which suggests 
that the strut thickness also greatly affects the radial property of stent. Therefore, 
it can be concluded that stent design (i.e., U-bend radius and amplitude, strut 
thickness and axial strut spacing) plays an important role in controlling the radial 
stiffness and strength of stents. 
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Figure 4.14, Radial loading plots for (a) Elixir, (b) Igaki-Tamai, and (c) 
RevaMedical stents.	 	
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4.4 Conclusions 
In this chapter, stent crimping and expansion were modelled for four 
commercially bioresorbable polymeric stents, including Absorb, Elixir, Igaki-
Tamai and RevaMedical stent, using finite element method. Due to individual 
designs, these four stents exhibited different mechanical behaviour during 
crimping and expansion processes, in terms of the stress distribution, elastic 
spring back and recoiling effects, stent diameter change against pressure, as 
well as radial stiffness and strength of stents. The effect of residual stress caused 
by crimping on stent expansion was also investigated. Some major conclusions 
are given as follows: 
(I) For Absorb, Elixir and RevaMedical stents, they had very similar 
mechanical performance, (e.g. stress distribution, spring back and 
recoiling effects, radial stiffness and strength), due to the same U-bend 
strut design.  
(II) The Igaki-Tamai stent, with larger U-bend amplitude and axial strut 
spacing, turned out to be less resistant to elastic recoil and recovery.  
(III) Residual stress on the stent caused by crimping was found to affect 
the expansion rate of stents during the expansion process and also 
the recoiling effect after balloon deflation. 
(IV) The radial stiffness and radial strength of stent are influenced by the 
structural designs (e.g. radius and amplitude of U-bend, axial strut 
spacing and strut thickness) and material properties. 
These FE models can be used to simulate the deformation of bioresorbable 
stents during crimping and expansion processes, and the simulated radial 
behavior of polymeric stents show good agreement with those published data. 
Although finite element method is effective in investigating the mechanical 
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behavior of polymeric stents, experimental work is still required to further validate 
these modelling results. 
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Chapter 5 - Deployment of Bioresorbable 
Polymeric Stents in Stenotic Artery 
5.1 Intruduction  
Cardiovascular disease (CVD), particularly coronary heart disease and stroke, is 
one of the leading cause of death in the globe. The 2010 Global Burden of 
Disease study estimated that CVD caused 15.6 million deaths (29.6% of all 
deaths) worldwide, which was two times the deaths caused by cancer (Lozano, 
2012). Statistics showed that more than 4 million Europeans died of CVD every 
year (Townsend, 2015). Moreover, coronary heart disease is the nation’s NO.1 
killer in the United States, and about 492,000 Percutaneous Coronary 
Interventions (PCIs) with stenting were performed in 2010 to deal with 
cardiovascular diseases (American Heart Association, 2010). For coronary heart 
disease, heart’s blood supply is blocked or interrupted due to a build-up of fatty 
substance called plaque in coronary arteries. 
Stents have been developed as very effective medical devices to open blocked 
arteries for regaining of normal flow of flood. Bioresorbable polymeric stents have 
attracted much interest recently, because they can provide short-term lumen 
support in plaque-arteries and then disappear within a period of time, with 
reducing the complications (e.g. thrombosis, in-stent restenosis and 
inflammation) caused by typically metallic stents (Testa, 2016). Nuutinen et al. 
(2003) characterized the mechanical properties of a self-expanded braided PLLA 
stent with a large diameter of 11 mm and a length of 40 mm, and reported that 
the recoiling of stent decreased with the reduction of the size of delivery device 
and the radial stiffness was comparable to those of metallic braided stents. Meng 
et al. (2006) studied the self-expanding property of a helical PLLA stent, and 
results showed that the expanding rate of stent was dependant on the desired 
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diameter and time. Welch et al. (2009) investigated the influence of thermal 
treatment on the mechanical properties of coil-within-coil PLLA fibre stent, and 
results indicated that thermal treatment improved the reorientation and 
realignment of fibre crystalline structure, and further affected expanding 
properties of the PLLA fibre stent.  
It is a challenge to carry out experimental studies on stent due to the tiny size 
and complex geometry, and therefore finite element method has been largely 
used to simulate the deformation of stents, including bioresorbable polymeric 
stents. Pauck and Reddy (2015) conducted a computational analysis to 
investigate the radial strength, recoil and radial stiffness of PLLA coronary artery 
stent. Their results revealed that material stiffness is an important parameter in 
determining the mechanics of polymeric stent, and stent design (e.g., strut angle, 
thickness and width) also affected the mechanical behaviour of PLLA stent. 
Debusschere et al. (2015) used implicit finite element solver to model free 
expansion of stent, and investigated how the balloon deployment rate affects the 
mechanical integrity of the stent by considering viscoplastic effects of stent 
material. Results showed that the direct balloon inflation approach produced 
lower stresses on stent during expansion. Wang et al. (2017) studied the 
mechanical performance of a PLLA stent by experimental and computational 
methods, and they characterized the stress-strain behaviour of polymer PLLA 
and then used in the simulation of stent crimping and expansion. Their results 
revealed that the stent performance, e.g., deformation, stress distribution, radial 
stiffness and strength, and recoiling effect, were dependent on the target 
diameters in expansion. 
To simulate the deployment of stent in diseased artery, it is essential to 
understand the mechanical behaviour of arterial layers and plaque, and choose 
appropriate constitutive models. Generally, coronary artery consists of intima, 
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media and adventitia layers. Stress-strain behaviour in both circumferential and 
axial directions was obtained by performing lumen inflation and axial extension 
testing (Carmines, 1991; Ozolanta, 1998; van Andel, 2003). These studies 
revealed that coronary artery exhibited anisotropic and strong nonlinear 
behaviour in both axial and circumferential directions. Consequently, Holzapfel 
et al. (2000) developed a constitutive model to describe the anisotropic 
mechanical response of arterial tissues, which was extended by Gasser et al. 
(2006) to take distributed collagen fibre orientations into account. The anisotropic 
HGO model has been widely implemented in the computational studies of stent 
deployment in coronary artery, including the simulations presented in this chapter. 
Loree et al. (1994) characterized the stress-strain behaviour using 26 plaque 
specimens obtained from human aortic arteries, which have been widely used to 
calibrate material model for artery.  Generally, a two term Ogden strain energy 
function was used to predict the nonlinear stress-strain behaviour for plaque (Li, 
2006) (Li, 2008) (Sadat, 2010).  
In this chapter, deployment of four bioresorbable polymeric stents, i.e., Absorb, 
Elixir, Igaki-Tamai and RevaMedical stents, within stenotic artery, were simulated 
using finite element method. The study aimed to compare the mechanical 
performance of stents with four different designs during deployment process. In 
particular, stress distribution on stents, change of stent diameter against 
pressure and stent recoiling/dogboning effects were characterized and 
compared across all four designs. Effects of residual stress on stent deployment, 
as well as the stress states on arterial layers and plaques, were also investigated 
in this chapter. 
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5.2 Methodology 
5.2.1 Finite element models and material constitutive models  
Similarly, four bioresorbable polymeric stents, i.e., Absorb, Elixir, Igaki-Tamai and 
RevaMedical stents, were considered and the tri-folded balloon was used to 
expand the stents. Three-layer artery with plaque was considered in the 
simulations. The finite element models of each component were created as 
introduced in Chapter 3. 
The stress-strain behaviour of PLLA was used for stents, and tri-folded balloon 
was treated as isotropic and linear elastic. The anisotropic hyperelastic 
Holzapfel-Gasser-Ogden model was used for three-layer artery, and isotropic 
hyperelastic Ogden model was implemented for plaque. The corresponding 
material parameters were calibrated against experimental data, as described in 
Chapter 3. 
5.2.2 Crimping and expansion of stent in plaque-artery 
Simulation of stent crimping was the same as the description in Chapter 4. The 
stent was crimped onto the tri-folded balloon by applying enforced displacement 
on the 12 rigid plates, and then the rigid plates were removed to allow the elastic 
recovery of crimped stent. Figure 5.1 shows the stent-balloon-plaque-artery 
assembly obtained from the stent crimping process.  
Again, stent expansion procedure consists of inflation step and deflation step. 
The inflation step was performed by applying pressure on the inner surface of 
balloon. The uniform pressure was linearly increasing from 0 to 1.4 MPa. Both 
ends of artery were fully constrained to reflect the constraint imposed by the 
human body environment. Interactions between the artery, stent and balloon 
were modelled as surface to surface hard contacts with a frictional coefficient of 
0.25. The deflation step was modelled by linearly releasing the pressure on the 
inner surface of balloon, which allowed the expanded stent to recoil freely. 
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Interactions between stent, the balloon and the plaque were maintained in this 
step. 
 
Figure 5.1, Crimped stent-balloon-plaque-artery assembly obtained from 
crimping process. 
 
5.3 Results  
5.3.1 Stent expansion  
Figure 5.2 shows the von Mises stress contour plot for four stents at peak inflating 
pressure. It is clear that all four stents showed dogbone shapes, which are 
different from the uniform shapes obtained from free expansion. This is due to 
the existence of plaque. The high level stresses were found at the U-bend 
regions, and the Igaki-Tamai stent experienced less stress concentration (as 
shown by less area of high level stress in red zone) compared to the other three 
stents. This phenomenon was also observed for stent during crimping process. 
The maximum von Mises stress magnitude was approximately 103 MPa for the 
Absorb and Elixir stents, 99 MPa for the Igaki-Tamai stent and 101 MPa for the 
RevaMedical stent.  
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Figure 5.3 shows the von Mises stress contour plot for four stents after balloon 
deflation. All four stents remained the dogbone shapes. Significant stress losses 
on stents were observed in all cases. This is evidenced by the dramatic reduction 
of high level stress areas (>60 MPa) on the stent. Figure 5.4 shows the 
dogboning effects for stents after balloon deflation. The Absorb and Elixir stents 
experienced the most severe dogboning of 35%, while the RevaMedical stent 
had the lowest dogboning of 17%. The Igaki-Tamai stent showed a dogboning of 
23%. 
 
 
Figure 5.2, The von Mises stress (MPa) contour for the four stents at peak 
pressure. 
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Figure 5.3, The von Mises stress (MPa) contour for the four stents after balloon 
deflation. 
 
Figure 5.4, Dogboning effects for the four stents after balloon deflation. 
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Figure 5.5 shows the diameter change against radial pressure for four stents 
during the deployment process. Generally, the stent diameter increases slightly 
during the initial inflation stage, followed by a fast expansion stage and a 
saturation stage with the increasing pressure. However, the four stents 
experienced different expansion rates during balloon inflation process. The Igaki-
Tamai stent expanded with the highest rate and reached saturation earliest (at a 
pressure of 0.2 MPa), while the RevaMedical stent expanded with the lowest rate 
and reached saturation latest (at a pressure of 0.8 MPa). The Absorb and Elixir 
stents showed similar expansion behaviour, and reached saturation at a pressure 
of 0.6 MPa. At the peak inflating pressure, the Igaki-Tamai stent achieved a 
diameter of 2.96 mm, while the RevaMedical stent was expanded to a diameter 
of 2.62 mm. The achieved diameter was 2.68 mm for the Elixir stent and 2.70 
mm for the Absorb stent. After releasing the balloon pressure, stent diameter 
experienced a gradual decrease in all cases, leading to a recoiling effect.  
Figure 5.6 shows the recoiling effects for four stents after balloon deflation. The 
recoiling effect was 17% for the Absorb and Elixir stents, 23% for the Igaki-Tamai 
stent and 15% for the RevaMedical stent. After balloon deflation, the final 
diameter was measured to be 2.22 mm for the Absorb stent, 2.20 mm for the 
Elixir stent, 2.28 mm for the Igaki-Tamai stent and 2.25 mm for the RevaMedical 
stent. 
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Figure 5.5, Diameter change against pressure plot for the four stents during 
deployment. 
 
Figure 5.6, Recoiling effects for four stents after balloon deflation. 
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5.3.2 Stress variation on the plaque/artery 
Figure 5.7 shows the von Mises stress contour plot on the plaque at peak inflating 
pressure during the deployment of four stents. Clearly, high stresses were 
located on the inner surface of the plaque due to the direct contact between the 
outer surface of stent and the inner surface of plaque during stent deployment. 
Stress concentration areas were found at both ends of the plaque due to the 
dogboning effect, especially for the Absorb and Elixir stents. This suggests that 
the Absorb and Elixir stents experienced more severe dogboning effects. For the 
Igaki-Tamai and RevaMedical stents, stress concentration areas were more 
uniformly distributed on the plaque, indicating less dogboning effect. At peak 
inflating pressure, the maximum von Mises stress on the plaque was 3.91 MPa 
for the Absorb stent, 3.83 MPa for the Elixir stent, 5.88 MPa for the Igaki-Tamai 
stent and 3.45 MPa for the RevaMedical stent. The maximum von Mises stress 
also reflects the level of expansion caused by stenting. For instance, the greatest 
expansion was achieved for the Igaki-Tamai stent, so the plaque showed the 
highest stress value. 
Figure 5.8 shows the von Mises stress contour plot on the plaque induced by 
stenting after balloon deflation. Obviously, Stress concentration was still noticed 
at both ends of the plaque. Stress loss was observed on the plaque in all four 
cases, due to the elastic recovery of plaque. The maximum von Mises stress on 
the plaque turned out to be 1.04 MPa for the Absorb stent, 0.89 MPa for the Elixir 
stent, 1.41 MPa for the Igaki-Tamai stent and 1.34 MPa for the RevaMedical stent.  
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Figure 5.7, The von Mises contour (MPa) plot on plaque at peak pressure: (a) 
Absorb, (b) Elixir, (c) Igaki-Tamai and (d) RevaMedical stents. 
Figure 5.9 shows the von Mises stress distribution on the artery at peak inflating 
pressure during the deployment of four stents. It is clear that the artery was 
expanded significantly at the site of plaque. The stress level showed a visible 
gradient from the intima to the adventitia layers of the artery. Stress concentration 
was mainly located at both ends of the inner layer of the artery in all four 
simulations, which suggested that damage might occur at the stress 
concentration sites. The maximum von Mises stress was 15.29 MPa on the artery 
expanded by the Absorb stent, 15.85 MPa by the Elixir stent, 20.19 MPa by the 
Igaki-Tamai stent and 13.79 MPa by the RevaMedical stent.  
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Figure 5.8, The von Mises contour (MPa) plot on plaque after balloon deflation: 
(a) Absorb, (b) Elixir, (c) Igaki-Tamai and (d) RevaMedical stents.	
After balloon deflation, significant amount of stress loss was observed for the 
arteries in all four simulations, as shown in Figure 5.10. The maximum von Mises 
stress reduced to be 0.17 MPa, 0.16 MPa, 0.40 MPa and 0.29 MPa for the artery 
expanded by the Absorb, Elixir, Igaki-Tamai and RevaMedical stents, 
respectively. It suggests that the arterial wall has super elastic property. 
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Figure 5.9, The von Mises contour (MPa) plot on three-layer aretry at peak 
pressure: (a) Absorb, (b) Elixir, (c) Igaki-Tamai and (d) RevaMedical stents. 
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Figure 5.10, The von Mises contour (MPa) plot on the three-layer artery after 
balloon deflation: (a) Absorb, (b) Elixir, (c) Igaki-Tamai and (d) RevaMedical 
stents. 
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5.3.3 Residual stress caused by crimping 
As presented in the free expansion chapter (Chapter 4), there was a significant 
amount of residual stress generated on stent during the crimping process, and it 
is essential and important to investigate how these residual stresses will 
influence the stent expansion during the deployment in stenotic artery. The stent 
diameter change against pressure curves were compared between the 
simulations with and without considering residual stress, as shown in Figure 5.11. 
Firstly, the effect of residual stress was not significant for the Igaki-Tamai stent 
as the dashed line and the solid line nearly overlapped. However, the residual 
stress did affect the expansion behaviour of the other three stents. Generally, the 
deployment of stent can be divided into four stages: the initial expansion stage, 
rapid expansion stage, final expansion stage and recoiling stage. During the 
initial expansion stage, the effect of residual stress was not observed. In the 
second rapid expansion stage, the dashed lines were lower than the solid lines 
in Figure 5.11 (a, b and d), which indicated that the stent experienced a faster 
expansion rate and reached saturation earlier without the consideration of 
residual stresses. During the final expansion stage, the stent could achieve a 
larger diameter at peak inflating pressure when the residual stress was not 
considered. Finally, the stent settled to a larger final diameter after recoiling when 
residual stress was ignored in simulations. 
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The comparison was also made for the recoiling and dogboning effects between 
simulations with and without considering residual stress, as given in Figure 5.12 
and Figure 5.13. Similarly, no difference was observed for the recoiling effect of 
the Igaki-Tamai stent. For the other three stents, the recoiling effects showed a 
slight decrease (around 1%) when the residual stresses were not considered. 
The effect of residual stresses was observed for the dogboning effects of the four 
stents. Specifically, the Absorb and Elixir stents experienced less severe 
dogboning (decrease by 2%) in the simulations without considering residual 
stress. The Igaki-Tamai and RevaMedical stents exhibited more severe 
dogboning (increase by 4%) during the deployment in stenotic arteries without 
taking residual stress into account.  
 
Figure 5.11, Diameter change against pressure with and without considering 
residual stresses: (a) Absorb, (b) Elixir, (c) Igaki-Tamai and (d) RevaMedical 
stents. 
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Figure 5.12, Recoiling effect obtained from simulations with and without 
considering residual stress. 
 
Figure 5.13, Dogboning effect obtained from simulations with and without 
considering residual stress. 
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The stress distribution on stent, plaque and artery were also affected by the 
residual stress caused by crimping, during the stent deployment in stenotic 
arteries. Figure 5.14 shows the von Mises stress distribution on the Absorb stent, 
plaque and artery at the peak inflating pressure, between simulations with and 
without considering residual stress. For the Absorb stent, the maximum von 
Mises stress reduced from 103 MPa to 99 MPa, and the stress concentration 
areas showed a significant decrease when the residual stress was not 
considered. However, the obtained diameters of stent are comparable at peak 
inflating pressure in both simulations, according to Figure 5.11 (a). The Absorb 
stent achieved a diameter of approximately 2.7 mm at peak inflating pressure in 
simulations with and without considering residual stress. There was no significant 
difference observed for the plaque and artery, in terms of stress distribution and 
maximum von Mises stress on the plaque and artery, as shown in Figure 5.14 (b 
and c). Specifically, the maximum von Mises stress was 3.91 MPa and 3.78 MPa 
on the plaque, and 15.29 MPa and 15.56 MPa on the artery for the simulations 
with and without considering residual stress, respectively. The stress 
concentration was located at both ends of plaque. 
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Figure 5.14, The von Mises stress (MPa) contour plot on (a) Absorb stent, (b) 
plaque and (c) three- layer artery at peak pressure with (above) and without 
residual stress (below).	 	
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5.4 Discussions 
In surgery, it should take patient-specific artery into account when choosing stent 
products, because stent implantation induces high stresses on the arterial wall, 
which may generate negative effect such as injury to arterial tissue. Therefore, it 
is important to evaluate the stress state generated in the plaque-artery system 
during stent deployment process. It is a challenge to measure the stresses 
generated in the stent-artery system using experimental methods, due to the 
complicated process and complex geometrical factor. In this chapter, finite 
element method was used to simulate the deployment of bioresorbable polymeric 
stents in stenotic artery, in order to investigate their mechanical behaviours 
during the process. 
Balloon-expandable stents are usually subjected to plastic deformation during 
crimping and expansion processes, so residual stress are generated in these two 
steps (Möller, 2001). Results presented in this chapter and Chapter 3 showed 
that stents produced comparable residual stresses during crimping and 
expansion processes. In this study, the stent expansion behaviour were 
compared in simulations with and without considering residual stress caused by 
crimping. Results showed that less recoiling and dogboning, and larger 
diameters were achieved for stents in simulations without producing higher 
stress levels. This suggests that residual stress caused by crimping should be 
considered in the simulation of stent deployment. After implantation, these 
bioresorbable polymeric stents exhibited a maximum von Mises stress of around 
100 MPa, which is significantly lower than those presented in metallic stents (e.g. 
Palmaz-Schatz. Cypher, Xience and Endeavor), due to large difference in 
material properties. Schiavone et al. (2014) reported that the simulated stress 
after deployment was 720 MPa for Palmaz-Schatz stent, 680 MPa for Cypher 
stent, 780 MPa for Xience stent and 700 MPa for Endeavor stent.  
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Recoiling effects were observed for all stents after balloon inflation, and stents 
experienced different recoiling effects due to their individual designs. Particularly, 
the Igaki-Tamai stent showed the most severe recoiling effects when compared 
to the other three stents. It is because the Igaki-Tamai stent design is made of 
sharper U-bend struts and larger axial strut spacing, which makes it more flexible 
to shrink and expand during crimping and expansion processes. The Absorb and 
Elixir stents have the same U-bends and axial strut spacing, and therefore they 
experienced almost the same recoiling effects. The RevaMedical stent has the 
same U-bend as the Absorb and Elixir stents, but its axial strut has a middle-to-
middle connection that limited the flexibility of stent geometry, thus with the 
smallest recoiling effects. 
The stent diameter change against pressure also showed some differences for 
the four stents. The material properties are the same for all four stents, but they 
required different pressure to achieve the same diameter. For instance, to 
achieve a diameter of 2.5mm, the pressure required is 0.3 MPa for Igaki-Tamai 
stent, 0.6 MPa for Elixir stent, 0.7 MPa for Absorb stent and 1 MPa for 
RevaMedical stent. This indicates that design is an important factor influencing 
the mechanical behaviour of stent. However, all four stents didn’t achieve the 
desired final diameter of 3 mm, and further development work is required to 
improve the stent performance. 
The stress states of stent-artery system also showed some difference during the 
deployment of the four stents. The maximum von Mises stress were very close 
for all four stents during expansion processes, but less stress concentration 
areas were observed for the Igaki-Tamai stent, due to its large axial strut spacing 
and amplitude of U-bends. With the distinct design, the Igaki-Tamai stent 
achieved the largest final diameter after balloon deflation, and thus contributed 
more expansion to the artery. As a result, the artery had the highest stress level 
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during the deployment of the Igaki-Tamai stent. The Absorb and Elixir stents, with 
similar peak-to peak connecting strut designs, caused the same degree of 
expansion to artery. A slightly less expansion of artery was generated during the 
deployment of RevaMedical stent, due to its middle-to-middle connecting strut 
design.  
High level stresses were generated on the plaque during the deployment of stent, 
which should be considered in the computational analysis of stent deployment. 
Timmins et al. (2008) addressed that excessive plaque stresses induced by 
stenting may lead to adverse arterial reaction, damage and even restenosis. 
Bedoya et al. (2006) concluded that stent designs, with large axial strut spacing, 
blunted corners and large amplitudes of U-bends, will produce less stress 
concentration regions on the artery. In this study, the Igaki-Tamai stent, with large 
axial strut spacing but sharp U-bend, generated more severe stress on the 
plaque during its implantation in artery. It can be concluded that stent design 
plays an important role in the stress variation generated on the plaque during 
stent deployment. 
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5.5 Conclusions 
In this chapter, the whole process of stent deployment in diseased artery was 
simulated for four bioresorbable polymeric stents, i.e., the Absorb, Elixir, Igaki-
Tamai and RevaMedical stents. The effect of residual stress caused by crimping 
on the mechanical behaviour of stent during deployment was also studied 
through simulations. 
During stent expansion process, high level stresses were generated on both 
stents and plaques/arteries at peak inflating pressure. Due to the different 
designs, the four stents achieved different diameters at both peak inflating 
pressure and after balloon deflation. They also experienced different recoiling 
and dogboning effects following deployment. As a result, the plaque/artery 
exhibited different stress variation. In simulations without considering residual 
stresses, these stents expanded to slightly larger diameters and subjected to less 
recoiling and dogboning effects, which suggested that the residual stress caused 
by crimping should be considered in the modelling of stent expansion. 
Overall, the modelling approach presented in this Chapter is shown to have the 
capabilities to capture the deformation and stress variation in polymeric stents 
and diseased artery during stent deployment. Also, the modelling approach is 
proved highly efficient in carrying out comparable study for polymeric stents with 
different designs, including the effects of residual stresses caused by stent 
crimping. 
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Chapter 6 - Fatigue Behaviour of 
Bioresorbable Polymeric Stent 
6.1 Introduction 
Stents, as small tubular medical devices, have been widely used in more than 
85% of percutaneous coronary intervention procedures to deal with heart 
disease caused by atherosclerosis (Garg and Serruys, 2010). The short- and 
mid- term complications, such as in-stent restenosis, stent thrombosis and 
inflammation, frequently occur in patients who are treated with stents. Therefore, 
stent materials and designs are being continuously developed and improved over 
recent years to overcome these problems. However, stent fracture, resulting from 
excess deformation, has been reported in a range of clinical studies. Initially, the 
occurrence of stent fractures was reported in 1%-2% of patients implanted with 
drug-eluting stents (Lee, 2007). Recently, some studies showed higher 
incidences of stent fracture. For instance, Shaikh et al. (2008) addressed that 
there was 18.6% of stent fracture observed in 188 patients implanted with drug-
eluting stents over 12-month follow-up. Nakazawa et al. (2009) reported 29% 
incidence of stent fracture in 177 human lesions treated with drug-eluting stents 
over 630 days. The cause of stent fracture is referred to dynamic biomechanical 
loads (i.e., tension, compression, bending and torsion), corrosive environment, 
and stent materials and designs (Bandar, 2013). In particular, fatigue failure, 
caused by cyclic pulsatile blood pressure, plays an important role in the fracture 
of stent. It is because that arterial wall is subjected to approximately 70 times of 
systolic-diastolic pulse in one minute (~40 million times in one year) as the heart 
beats in human body. The US Food and Drug Administration (FDA) highly 
recommends that stents should be designed to survive at least 10 years (108 
cycles) without failure. 
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Therefore, research work is required to assess the fatigue behaviour and lifetime 
of stents under cyclic loading. In order to improve the durability of stent, some 
experimental work has been performed to study fatigue behaviour of stent 
materials, especially metals like stainless steel, Nitinol and cobalt-chromium, and 
their biomedical components. Wiersma and Taylor (2005) carried out fatigue 
tests on 316L stainless steel notched specimens, and predicted 2 million cycles 
of fatigue limit using Smith-Miller approach. In further study, they found that the 
stress-life (S-N) curves of microscopic 316L stainless steel were significantly 
affected by specimen size and geometry (Wiersma, 2006). Weiß et al. (2009) 
investigated fatigue deformation of coronary stent (made of 316L stainless steel) 
by applying radial expansion of 5% for 50 million cycles in a stent tester. Results 
showed that the highly deformed regions were located at the inner and outer 
borders of stent with high internal stresses after cyclic loads. Pelton et al. (2008) 
performed displacement-controlled fatigue tests on Nitinol diamond-shaped strut 
specimens, and their strain amplitude-fatigue (strain-life) results showed that the 
fatigue strain limit is 0.4% for Nitinol strut in high-cycle-fatigue condition.  
Computational approaches have also been used to assess fatigue behaviour of 
metallic stents. Marrey et al. (2006) developed a methodology, combining the 
traditional stress-life analysis and fracture mechanics, to predict fatigue life of L-
605 Co-Cr cardiovascular stent. The approach is useful to estimate the safe 
lifetime of stent and quantify the effect of flaws on stent failure. Li et al. (2010) 
simulated L605 Co-Cr stent deformation under vessel loading and evaluated the 
fatigue life based on Goodman’s rule. Their results showed that dangerous points 
were located at the corner of the ring struts. Azaouzi et al. (2012) carried out 
fatigue life prediction of 316L stainless steel stent by means of two approaches, 
i.e., the well-known Goodman’s Diagram (GD) and the theory of critical distance 
(TCD). They simulated stent deployment in blood vessel, and addressed that 
stent failure may happen during the initial deployment of stent or in the long term 
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of cyclic pulsatile loadings. Also, the TCD approach can be used to predict the 
critical stress magnitude for stent. Barrera et al. (2014) firstly used the Dang Van 
high-cycle-fatigue criterion in life assessment of 316L stainless steel cardiac 
stent subjected to cyclic blood pressure, and their results showed the cyclic 
loading path of stent was in the safe region concerning infinite lifetime. Recently, 
Dordoni et al. (2015) introduced a fatigue criterion based on principal strain 
values in fatigue assessment of Ni-Ti stent, and this criterion was calibrated by 
experimental data from fatigue testing.  
However, almost all existing work focused on metallic stents, such as Co-Cr, 
stainless steel and Ni-Ti stents, and there is a lack of study on the fatigue 
behaviour of polymeric stents. Therefore, the objective of this chapter is to study 
the stress/strain distribution and fatigue behaviour of polymeric stent using finite 
element method. 
6.2 Methodology 
6.2.1 FE models and constitutive models for stent and artery 
The Elixir stent was chosen to study the fatigue behaviour of bioresorbable 
polymeric stent. Stent deformation was modelled after the deployment in stenotic 
artery, by considering systolic-diastolic blood pressure loading. FE models of 
Elixir stent and stenotic artery were obtained from the simulation of stent 
deployment in diseased artery, as shown in Figure 6.1. The constitutive models 
and parameters remained the same as those used in the previous chapters. 
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Figure 6.1, Model of the deployed stent and artery system. 
6.2.2 Simulation setup 
In order to study fatigue behaviour of stent under blood pressure, two additional 
steps, i.e., pre-loading and systolic-diastolic cyclic loading steps, were added 
following the deployment of stent. During these two steps, contact between stent 
and balloon was removed while contact between stent and artery remained. Both 
ends of artery were still fully constrained over the process. As shown in Figure 
6.2, blood pressure was firstly applied on the inner surfaces of both stent and 
artery by linearly increasing to 0.01 MPa (diastolic value), and then diastolic-
systolic cyclic loading was imposed.  
Normally, the realistic blood pressure has an average value of 100 mmHg 
(0.0125 MPa), with fluctuating between a diastolic value of 80 mmHg (0.01 MPa) 
and a systolic value of 120 mmHg (0.015 MPa). In this study, the diastolic-systolic 
blood pressure was modelled in a realistic waveform, which was obtained from 
open resource (see Figure 6.3).  
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Figure 6.2, Simulation procedure for stent under fatigue. 
 
 
Figure 6.3, Blood pressure in the realistic waveform.	 	
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6.3 Results  
6.3.1 Stress/strain analysis 
Figure 6.4 shows the von Mises stress distribution on the stent at different steps, 
i.e., deployment, pre-loading, systole and diastole. Overall, high stress gradient 
occurred in all steps, ranging between 1 MPa and 100 MPa. There was a 
significant reduction of high level stress on stent during pre-loading step (from 
101MPa to 94 MPa), whereas the stress difference between systole and diastole 
was not that significant. Also, high level stresses (red zones) were mainly found 
at the inner corner of U-bends, and low stresses (blue zones) occurred at the 
middle of bridge struts. The results suggested that the inner corners of stent U-
bends exhibited high risk of fatigue failure. 
 
Figure 6.4, Contour plot of von Mises stress (MPa) on stent at the end of (a) 
deployment, (b) pre-loading, (c) systole and (d) diastole steps. 
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Figure 6.5 shows the change of contact area between stent and artery as a 
function of step time. Initially, the contact area showed a sudden drop, because 
stent experienced further elastic recoil due to the deactivation of contact between 
balloon and stent. During the pre-loading step, both stent and artery were 
expanded further by the applied blood pressure, which resulted in a rapid 
increase of contact area between each other. Afterwards, the contact area 
exhibited lower increasing rate and finally achieved a stable stage under the 
cyclic systolic-diastolic blood pressure. 
 
Figure 6.5, Contact area between artery and stent as a function of step time. 
During the cyclic systolic-diastolic loading step, the maximum von Mises stress 
was located at critical element A and the maximum equivalent plastic strain 
occurred at critical element B, as shown in Figure 6.6. In order to investigate the 
fatigue behaviour of stent, stress and strain variations of these two elements are 
required. Figure 6.7 shows the von Mises stress variation against step time for 
the critical element A subjected to cyclic systolic-diastolic loading.  It is clear that 
the von Mises stress showed a significant fluctuation with the cyclic systolic-
diastolic loading and then tended to stabilize at cycle 5. The maximum and 
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minimum stabilized stresses were 100 MPa and 92 MPa respectively. 
 
Figure 6.6, Stent model showing locations of critical elements A and B with 
maximum von Mises stress and with maximum equivalent plastic strain, 
respectively. 
 
Figure 6.7, Diagram of von Mises stress variation for critical element A during 
systolic-diastolic cyclic loading process. 
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Figure 6.8 shows the equivalent plastic strain variation of critical element B as a 
function of step time. During balloon inflation step, a large increase was observed 
for equivalent plastic strain because the stent was severely expanded to provide 
mechanical support in plastic region. Afterwards, the equivalent plastic strain 
maintained at a stabilized value of 2.7 during both deflation and cyclic loading 
steps, which demonstrated the occurrence of elastic shakedown. 
 
Figure 6.8, Equivalent plastic strain for critical element B at different steps. 
6.3.2 Fatigue analysis 
Fatigue life prediction is of importance because cyclic load may lead to a failure 
of component at much lower stress compared to that under monotonic loading 
condition. Stress-life (S-N) method is usually used to determine the fatigue life of 
materials and components. The fatigue testing data of polymer PLLA, studied in 
this thesis, is not available in the open resources, and therefore the S-N curves 
of several other polymers were considered to estimate the fatigue life of Elixir 
stent (Averett, 2008; Osswald, 2015), as shown in Figure 6.9. The red line 
represents the stress amplitude of critical element on stent under cyclic systolic-
diastolic loading condition, and the black lines illustrate the existing fitted S-N 
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curves of polymers, including EP, PET, PLA, PS, PMMA, PP, PE and PTFE. The 
fatigue limits can be obtained for EP, PS and PP from the diagram, which were 
20 MPa, 10 MPa and 5 MPa respectively. The S-N curve of PLA did not exhibit 
a saturation stage, and therefore the specified fatigue limit couldn’t be 
determined. However, the fatigue limit of PLA can be assumed to be between 
polymer EP (20 MPa) and PP (5 MPa). The stress amplitude of critical element 
A can be calculated from the variation of von Mises stress, which was 4 MPa. It 
was even lower than the fatigue limit of PP (5MPa), so it suggested that critical 
element A was located within infinite life stress zone. It should be noticed that the 
fatigue life prediction was performed based on testing data up to 107 cycles. 
 
 
Figure 6.9, Stress amplitude vs. cycles to failure (S-N) curves for EP-epoxy, 
PET-polyethylene terephthalate, PLA-poly (lactic acid), PS-polystyrene, PMMA-
polymethyl methacrylate, PP-polypropylene, PE-polyethylene and PTFE-
polytetrafluoroethylene. 
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The above analysis is only valid when the mean stress is zero. In FE analysis, a 
significant level of mean stress was obtained for stent due to excess deformation 
in the deployment stage. Consequently, the Goodman analysis method can be 
considered to assess the fatigue life of stent. The Goodman’ rule combines the 
mean stress and stress amplitude, which is defined by: 
 
𝜎𝑆 + 𝜎8𝑆 = 1 (6.1) 
where  𝜎8 and 𝜎 represent the mean stress and stress amplitude of applied 
cyclic stress, and 𝑆 and 𝑆 are the fatigue limit (fatigue strength) and ultimate 
tensile strength of the material. The ultimate tensile strength of PLLA was taken 
as 105 MPa.  
The mean stress and stress amplitude of all elements can be obtained from the 
FE analysis of stent deformation during cyclic systolic-diastolic loading. They are 
plotted in the Goodman’s diagram, as shown in Figure 6.10. The blue and orange 
slanting lines illustrate the fatigue limit lines of PLLA, which were determined by 
estimating the fatigue limit in a range of 10 MPa and 20 MPa. Generally, the zone 
below fatigue limit line means safe zone. The green square symbols represent 
the level of mean stress and stress amplitude of all elements and the red triangle 
symbol represents the critical element A which has the highest level of mean 
stress and stress amplitude. It can be observed that a large number of elements 
experienced high mean stress and stress amplitude during the cyclic systolic-
diastolic loading. A group of elements are already located in the dangerous zone 
based on the estimated fatigue limit lines. These elements showed higher risks 
of fatigue failure than other elements. 
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Figure 6.10, Goodman diagram for the Elixir stent. 
 
6.4 Discussions 
Firstly, it is clear that high stress occurred at the inner corner of stent U-bends 
and low stress was distributed at the bridge struts during cyclic systolic-diastolic 
loading. This phenomenon was also reported in the study of fatigue of metallic 
stents. For instance, Li et al. (2010) studied the Co-Cr stent and found that the 
high stress areas were distributed in the curvatures of stent rings whereas 
minimal stress regions happened at the middle position of bridge struts. They 
predicted that the dangerous position of stent structure was located at the 
curvature of rings due to the high stress levels, which was also verified by fatigue 
experiments. As discussed in the previous chapter, stress concentration 
occurred at the curvature (corner) of stent U-bends and high residual stress was 
generated during stent crimping and deployment processes. Thus, residual 
stress caused by stent expansion imposes a high level of mean stress, and acts 
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as a key factor influencing the fatigue resistance of the stent structure in cyclic 
loading condition.  
Fatigue life of stents usually refers to 107 cycles due to the typical annual heart 
beating of 4×107 cycles/year. In this study, the fatigue life was assessed against 
a life of 107 cycles using the S-N curves of selected polymers, and therefore the 
prediction is valid for at least a period of one year (Figure 6.10). The result is 
meaningful because the Elixir stent will degrade after one year. Certainly, fatigue 
behaviour of polymer can also be affected by environment, temperature and 
frequency of loading (Osswald, 2015). However, this study didn’t consider the 
effect of temperature and frequency because the corresponding fatigue test data 
was not available. Therefore, in order to achieve comprehensive understanding 
of stent fatigue, further work is required, especially fatigue testing of PLLA and 
its structural components. 
Moreover, the Goodman’s rule was used to conduct fatigue life prediction for 
stent, by evaluating the mean stress and stress amplitude distribution. In the 
Goodman’s diagram, the fatigue limit line was determined by fatigue strength and 
ultimate tensile strength of the material. This study did a fatigue life prediction of 
polymeric stent based on the stress state of all elements, and highlighted that 
there is a risk of fatigue failure in the U-bend regions due to high levels of mean 
stress and stress amplitude. But for metallic stent (e.g. L605 Co-Cr alloy or 316L 
stainless steel), FE simulations suggested that there was no risk of fatigue failure 
under the systolic-diastolic loading condition (Li, 2010; Azaouzi, 2012). This may 
due to the difference in material properties. The L605 Co-Cr alloy and 316L 
stainless steel have significantly higher fatigue strength (300 MPa and 115MPa) 
and ultimate tensile strength (1390 MPa and 580 MPa), compared to polymer 
PLLA. This suggests that material properties, such as fatigue strength and 
ultimate tensile strength, also play an important role in the fatigue resistance of 
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stents. On the other hand, it may due to the difference in the applied cyclic 
systolic-diastolic loads. Some of them considered the cyclic load that was applied 
on the outer surface of stent without an artery, and others included artery model 
but only applied cyclic loading on artery. In this study, cyclic systolic-diastolic load 
was imposed on both the stent and artery because the stent was subjected to 
both the interaction from artery and the pressure from blood flow in reality.  
6.5 Conclusions 
Stent deformation was simulated after deployment in stenotic artery, under cyclic 
systolic-diastolic blood pressure loading. The maximum von Mises stress and 
stress amplitude was found at the inner corners of stent U-bends, indicating a 
risk of fatigue failure. The Goodman’s method was used to carry out a fatigue life 
prediction for polymeric stent, and results suggested potential fatigue failure at 
the U-bend regions of stent. However, the fatigue assessment has some 
limitations due to the lack of testing data for polymer PLLA, and therefore further 
work is required in terms of the material characterization and fatigue testing. 
  
164 
 
Chapter 7 - Stent-Artery Interaction during 
Degradation and Vessel Remodelling 
7.1 Introduction 
Bioresorbable stents, made of Poly (lactic-acid) (PLLA), are to provide temporary 
mechanical support for arterial lumen and then gradually absorbed in human 
body due to their biodegradable properties. The duration that the polymeric 
stents provide the mechanical support is called functional time, and the duration 
for the stent to degrade is referred as disappearance time (Lyu and Untereker, 
2009). One of the great advantages is that there is no need to remove the stents 
for an additional surgical intervention. Moreover, the use of bioresorbable stents 
can reduce the risk of long-term complications such as late stent thrombosis and 
inflammation. However, there is a challenge controlling the functional time and 
disappearance time, and it is very important to understand the degradation of 
biodegradable polymers. 
Polymer degradation can be divided into different types, such as thermal, 
mechanical and chemical degradation, and chemical hydrolytic degradation is 
mostly considered in study of polymeric implants. PLA possesses natural 
hydrophilic characteristic that is affected by surrounding temperature and 
moisture (Karlssion and Ndazi, 2011). There is a large amount of experimental 
work devoted to the characterization of hydrolytic degradation of PLA/PLLA. 
Agarwal et al. (1998) characterized the degradation of PLA in abiotic and biotic 
environments by measuring the production/evolution of CO2, weight loss and 
molecular weight change, and it was found that hydrolysis of ester linkage is the 
primary degradation mechanism for PLA. Zhao et al. (2008) studied the 
hydrolytic degradation behaviour of PLLA and its nanocomposites 
(PLLA/MWNTs) by measuring the weight loss as a function of exposed time in 
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sodium hydroxide solution, and their results showed that the degradation rate of 
PLLA can be accelerated through adding MWNTs. Gaona et al. (2012) studied 
the in vitro hydrolytic degradation of porous PLLA/PCL blend membranes during 
a period up to 65 weeks. Results showed that membrane weight kept decreasing, 
but molecular weight and elastic modulus increased slightly during the initial 11 
weeks and then decreased significantly for PLLA/PCL(80/20) specimen. 
The experimental studies of degradation behaviour for PLLA scaffold were also 
widely carried out. Gong et al. (2007) investigated the in vitro degradation 
behaviours (i.e. weight loss, water uptake, molecular weight and morphology) of 
porous PLLA scaffold during 39 weeks period, and found that the porous PLLA 
scaffold suffered degradation at 37 °C in vitro at a slow rate due to its highly 
porous structure. The in vitro degradation behaviour of PLLA scaffolds were 
studied by Liu et al. (2014), who reported that PLLA porous scaffolds displayed 
reduction in mechanical properties (compressive modulus and strength), weight 
loss and molecular weight during a degradation time of 200 days. Rodrigues et 
al. (2016) carried out an in vitro degradation study of porous PLA scaffold 
immersed in phosphate-buffered saline solution for 8 weeks. The study revealed 
that there was no significant change for molecular weight, but compressive 
properties (i.e. compressive modulus and stress at yield) of the scaffolds 
maintained constant during the initial 6 weeks and increased significantly at week 
8. Zamiri et al. (2010) conducted the in vitro degradation testing of PLLA and 
PLLA/PLGA braided stents, and their results showed that the mass loss is very 
limited for PLLA braided stents up to 25 weeks while 64% mass loss was found 
for PLLA/PLGA braided stents. Grabow et al. (2007) conducted in vitro 
degradation study for a PLLA stent prototype in a deployed shape, and they 
found that collapse pressure increased firstly within 12 weeks and then deceased, 
while the molecular weight showed a gradual and steady reduction during the 24 
weeks.  
166 
 
Mechanical properties (i.e. ductility, toughness and strength) of biodegradable 
polymers change significantly during degradation, due to hydrolytic chain 
scission at molecule level (Vieira, 2011). It is of importance to understand the 
mechanical behaviour of bioresorbable polymeric stents during degradation 
period, especially the simulation and prediction of stent performance during 
degradation under loading conditions. 
Efforts have been made to develop constitutive models to describe the 
mechanical behaviour of biodegradable polymers during degradation. Rajagopal 
et al. (2007) developed a strain-induced degradation model for polymeric solids 
to study simple shear and bending behaviour of polymeric beams. In the model, 
they mainly considered the mechanical causes (i.e., deformation) for degradation 
by ignoring the influenced of temperature, oxygen diffusion and UV radiation. 
Their results showed that the degradation rate of polymeric beam was 
significantly affected by initial strain level in shear response, and the inner and 
outer fibres of the beam underwent faster degradation due to the higher strain in 
bending response. Soares et al. (2008) proposed a fully nonlinear constitutive 
model for degradable polymer by introducing a scalar variable that combined the 
degradation parameter and mechanical parameter (i.e., shear modulus) together. 
They modelled the creep and stress relaxation in responses to different constant 
stretches/stresses, and results showed that the mechanical behaviour of polymer 
was significantly affected by degradation. However, experimental work was 
required to validate the model. Vieira et al. (2011) tried to combine a hyperelastic 
model (Neo-Hookean or Mooney-Rivlin) with hydrolytic damage to predict the 
mechanical behaviour of biodegradable polymers during hydrolytic degradation 
process, and the numerical results were proven to be in good agreement with 
the tensile test data for PLA/PCL fibres. Later, they also proposed a 3D time-
dependent model based on Bergstrom-Boyce model, which was calibrated by 
fitting the experimental stress-strain data for PLA/PCL blend, to simulate the 
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deformation of biodegradable polymer under different strain rates.  Results 
showed that the model could simulate the time-dependent response of polymer, 
and predict the stress-strain behaviour of PLA/PCL blend over 8-week 
degradation period. But the model was limited to devices with small thickness 
and independence of temperature, stress state and other environmental 
conditions (Vieira, 2014).  
On the other hand, several follow-up studies of clinical trials reported that vessel 
remodelling was observed following the bioresorbable stent implantation in 
humans and animals, by multiple invasive imaging methods, such as multislice 
CT, angiography and Intravascular Ultrasound (IVUS). Ormiston et al. (2008) 
reported that the BVS (bioresorbable vascular scaffold) Absorb stent showed an 
angiographic in-stent loss of 0.44 mm and an overall 16.8% reduction of lumen 
area at 6-month follow-up after implantation in 30 patients. Serruys et al. (2009) 
addressed the trail outcomes of Absorb after 2-year follow-up, in which the 
angiographic in-stent late loss was 0.48 mm and the lumen area increased from 
5.19 mm2 (at 6 months) to 5.47 mm2 due to the decrease in plaque size. Similarly, 
in 2010, Serruys et al. evaluated the efficacy of Absorb for treatment of de novo 
coronary artery stenosis in 45 patients.  At 6-month follow-up, the mean lumen 
area reduced by 3.1% (from 6.60 mm2 to 6.37 mm2) according to IVUS analysis. 
At 2-year follow-up, the mean lumen area showed an increase (from 6.37 mm2 
to 6.85 mm2) (Ormiston, 2012). Also, Serruys et al. (2011) successfully implanted 
57 Absorb stents in 56 patients, and the 12-month follow-up results showed that 
there was a slight increase for the mean lumen area from 6.31 mm2 (Post-PCI) 
to 6.33 mm2. Recently, they reported 5-year follow-up results after BVS stent 
implantation, and they concluded that the mean lumen area tended to increase 
from 6 months to 1 year and 5 year whereas the plaque media showed a 
regression (Serruys, 2016). Moreover, progressive lumen gain was also 
observed in porcine coronary arteries after BVS implantation (Lane, 2014). They 
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addressed that the lumen area retained stable from 1 to 6 months and then 
showed a progressive increase from 12 to 42 months. Therefore, vessel 
remodelling occurred in terms of lumen gain after stent implantation, which 
should be considered in the study of stent-artery interaction. 
So far, most computational work focused on the development and validation of 
material constitutive models to predict the stress-strain behaviour of degradable 
polymer, mainly by combing the existing hyperelastic or elastoplastic models with 
hydrolytic mechanism. There is a lack of computational study in predicting the 
stent-artery interaction as a result of mechanical property change during the 
degradation process. The objective of this chapter is to study the stent-artery 
interaction during stent degradation, as well as vessel remodelling, using finite 
element method. Degradation process was modelled by incorporating the 
change of material property as a function of time, for which a series of nonlinear 
stress-strain response were constructed based on the experimental 
measurement of radial stiffness and strength for polymeric stents over 2-year 
degradation. Vessel remodelling was realised by changing the size of plaque and 
vessel manually, according to the clinical data in literature. Then the variation of 
stresses in stent and artery were presented and discussed. 
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7.2 Calibration of stress-strain curves during degradation 
The stress-strain behaviour of biodegradable polymer shows a change during 
degradation process. In this section, the stress-strain curves of PLLA at different 
degradation time points were calibrated against the experimental measurements 
of radial strength and stiffness for a commercial polymeric stent.  
7.2.1 Radial strength and stiffness of stent 
Firstly, it is necessary to introduce the experimental procedure determining the 
radial strength and stiffness of the stent using the MSI RX550 Radial Force Tester.  
As shown in Figure 7.1, the entire procedure can be divided into five steps: (I) 
sample preparation, (II) sample pre-conditioning, (III) scaffold deployment, (IV) 
scaffold measurement and (V) radial strength & stiffness test. In step I, the 
catheter-balloon-scaffold system was removed from packaging, and then 
microscope was used to check the crimped scaffold and balloon in good 
condition or not. In step II, the delivery system was soaked in water bath at 37°C 
for pre-conditioning for at least 2 minutes. In step III, scaffold deployment in an 
expansion block was performed by balloon inflation. The balloon inflation and 
deflation procedures were completed in the water bath at 37°C. Afterwards, the 
expanded scaffold was removed from the water bath, and the length was 
measured. Finally, in step V, the expanded scaffold was inserted into crimp head, 
and compressed to the nominal diameter by displacement loading of crimp head.  
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The loading pressure-diameter graph was obtained from the compression 
process, and the radial strength and stiffness were determined from the graph 
according to ASTM F3067-14. Specifically, as shown in Figure 7.2, the black line 
is the pressure-diameter curve. The blue line (modulus) is consistent with the 
linear portion of pressure-diameter curve, and the radial stiffness is determined 
by the slope of the modulus line. The radial strength is determined by the 
interception of 0.1 mm offset yield line (red line) and pressure-diameter curve. 
According to the method above, the measured radial strength and radial stiffness 
(normalised against the values at day zero), for bioresorbable polymeric stent at 
different degradation time points were summarized in Table 7-1. It should be 
pointed out that the actual values for radial strength and stiffness are confidential 
and so they are not presented here. 
 
 
Figure 7.1, Flow chart of testing procedures for radial strength and stiffness of 
stent. 
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Figure 7.2, Pressure-diameter graph obtained from the experimental testing. 
 
Table 7-1, Normalised radial strength and stiffness of a commercial polymeric 
stent. 
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7.2.2 Calibration of stress-strain curves for PLLA during the degradation 
The full procedure for calibrating PLLA stress-strain curves was shown in Figure 
7.3. The PLLA stress-strain behaviour was treated as model input. Then the 
simulation was performed to evaluate radial strength and stiffness of stent, 
according to the experimental testing method described above. Specifically, the 
stent crimped in the 1st crimping step, in which the displacement loading was 
applied on 12 rigid plates to compress the original stent on to the balloon. 
Afterwards, the crimped stent was expanded by balloon inflation, followed by 
balloon deflation to allow stent recoil. The 2nd crimping was subsequently 
modelled to produce the radial pressure-diameter curve, which was used to 
determine the radial strength and radial stiffness of the stent. It is an iteration 
process, i.e., tuning the stress-strain curves until the simulated radial strength 
and stiffness match the measured ones. 
Specifically, radial strength and radial stiffness of the virgin Elixir stent were 
obtained from the simulations using the original PLLA stress-strain curve in 
Chapter 4. The PLLA stress-strain curves at different degradation time points 
were artificially constructed, and then used as input to produce radial strength 
and stiffness results. The target is to match the simulated stent stiffness and 
strength with the experimental measurements in Table 7-1 by tuning the 
constructed stress-strain curve. The process is an iteration process based on 
trial and error. Here, the radial strength and stiffness, normalised to the virgin 
state (i.e., zero-time point), were used for fitting the stress-strain curves of PLLA 
at different degradation time points (Table 7-1). 
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Figure 7.3, Flow chart of calibrations for PLLA stress-strain curves. 
7.3 Modelling of stent-artery interaction during degradation  
The calibration work in Section 7.2 was mainly to obtain the stress-strain 
behavior change of stent material as a function of degradation time, by matching 
the experimental measurements of radial stiffness and strength for a commercial 
PLLA stent. Then, the calibrated series of stress-strain curves of PLLA was used 
as input to simulate the deformation and stress variation of polymeric stents 
during degradation process. As a result, the stress variation over time was mainly 
caused by the change of material properties during degradation. The physical 
and chemical processes of stent degradation were not simulated in this PhD 
project, as the research was focused on the change of mechanical properties of 
polymeric stents during degradation, which is the aim of this thesis. 
Figure 7.4 shows the full simulation procedures to investigate the stent-artery 
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interaction during degradation process. Firstly, pre-processing was performed to 
implant the stent in stenotic artery. In the pre-processing procedure, crimping, 
spring back, inflation and deflation steps were simulated, with implementing the 
original PLLA stress-strain behaviour. The geometry and mesh for the stent and 
artery/plaque were the same as that described in the previous chapters, including 
boundary and loading conditions. 
Subsequently, stent degradation process was modelled by changing the PLLA 
stress-strain behaviour as a function of degradation time. The change in PLLA 
stress-strain behaviour was controlled by a field variable. The field variable was 
associated with the mechanical property of polymer PLLA, and the mechanical 
property of PLLA varied with the change of field variable values. In simulation, 
additional ten steps were created after stent deployment. The stress-strain 
curves calibrated at ten different time points were defined in the input file, in 
association with ten different field variable values. The change of PLLA stress-
strain behaviour over degradation time was realised through the change of field 
variable value in each degradation step. At the same time, cyclic blood pressure 
was applied to capture the pulsatile vasomotion of artery. In order to simulate the 
systolic-diastolic fluctuations, a pressure in realistic waveform fluctuating 
between 80 mmHg and 120 mmHg (see Figure 6.3 in Chapter 6), was applied 
on the inner surface of stent and artery, and 10 cycles were modelled in this study. 
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Figure 7.4, Flow chart for the full simulation procedures. 
7.4 Modelling of stent-artery interaction during vessel 
remodelling 
Generally, lumen areas are measured by intravascular ultrasound method, which 
showed an increase over 2-year period of degradation. This is referred as vessel 
remodelling. In this study, vessel remodelling was realised by changing the lumen 
diameter of artery-plaque system manually, according to the clinical data in 
literature. According to Serruys et al. (2009), the minimal lumen area increased 
from 3.92 mm2 at 6 months to 4.34 mm2 at 2 years for patients implanted with 
Absorb stents. It was also reported that the increase of lumen area was caused 
by the plaque regression while vessel size remained unchanged. By translating 
the lumen area gain to diameter change, it was found that the lumen diameter 
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was increased by 5.2% over two years (compared to 6 months). This percentage 
of increase has been used in this study to simulate the effect vessel remodelling 
on stent-artery interaction. Specifically, the plaque-artery configuration obtained 
directly from the simulation of stent deployment was taken as a reference state 
(day 0), which gave a lumen diameter of 2.3 mm. Over two years, lumen diameter 
increased to 2.42 mm (5.2% increase) while the vessel size remained unchanged 
(see Figure 7.5 and Table 7-2).  
Here, lumen area reduction observed at 6 months was not considered (assuming 
no change of lumen area over 6 months). The geometry of remodelled artery-
plaque system was then created by manually reducing the plaque thickness to 
give an increased lumen diameter. Then the manually constructed artery-plaque 
model, with the implanted stent inside, was used to simulate the stent-artery 
interaction after vessel remodelling over 2 years. Again, cyclic systolic-diastolic 
blood pressure was applied to the stent-artery system. It should be noted that 
the degraded stress-strain curve calibrated for 792 days was used for simulation 
of stent-artery interaction. For the reference state (i.e., 0 day or immediately after 
deployment), the original stress-strain curve was used for simulation of stent-
artery interaction. Also the residual stresses/deformations generated from stent 
deployment were excluded in the simulations, due to limitation of the approach. 
 
 
Figure 7.5, Schematic of vessel and lumen diameters for artery-plaque system. 
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Table 7-2, Values of vessel diameter and lumen diameter used in simulations. 
 
  
178 
 
7.5 Results  
7.5.1 PLLA stress-strain behaviour over degradation 
Figure 7.6 shows the radial pressure-diameter curve obtained from simulation of 
re-crimping process for the Elixir stent, using the original PLLA stress-strain 
behaviour (i.e., no degradation). The dashed line followed the linear portion of 
the pressure-diameter curve, and the dash dot line is the 0.1 mm offset line. As 
a result, the calculated radial stiffness and strength are 4625 mmHg/mm and 
1900 mmHg, respectively, for the Elixir stent with the original PLLA stress-strain 
behaviour. Following a similar method, the radial stiffness and strength values 
for the stent, obtained using calibrated PLLA stress-strain curves at different 
degradation time points, were shown in Table 7-3, which are in good agreement 
with the experimental data. 
 
Figure 7.6, Radial pressure-diameter curve obtained from re-crimping process 
for Elixir stent. 
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Table 7-3, Radial strength and stiffness data obtained from simulations for the 
Elixir stent. 
 
 
Figure 7.7, Constructed PLLA stress-strain curves for Elixir stent at different 
degradation time points. 
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Figure 7.7 shows the back calculated PLLA stress-strain curves for the Elixir stent 
at different degradation time points. The red line with square symbols refers to 
the original stress-strain behaviour for PLLA. Overall, there was no significant 
change in the Young’s modulus, because of small difference was observed for 
the radial stiffness of stent that mainly controlled by Young’s modulus of polymer. 
While the yield stress had a significant increase in the early times (up to 365 days) 
due to the recrystallization of polymer, and then decreased quickly. 
7.5.2 Stress variation on the stent over degradation 
Figure 7.9 shows the contour plot of von Mises stress on the stent over 
degradation time. Clearly, high level stresses (red zones) were mainly located at 
the corners of U-bend struts, especially in the middle and dogboning parts of the 
stent structure. The mechanical strength of stent material became weaker and 
weaker caused by stent degradation, and therefore stress concentration spread 
towards both ends of stent. The maximum von Mises stress values on the stent 
was 101.93 MPa, 120.39 MPa, 116.68 MPa, 66.70 MPa and 43.67 MPa at 
degradation time of 0 day, 189 days, 365 days, 659 days and 729 days, 
respectively.  
Figure 7.8 shows the variation of maximum von Mises stress on the stent over 
the degradation time of 729 days. It could be concluded that the maximum von 
Mises stress increased up to 365 days and then decreased quickly, 
corresponding to the change in stress-strain behaviour of stent material. 
Between 30 days and 365 days, no significant difference was observed for the 
maximum stress value on the stent, because the stress-strain behaviour of stent 
material was very similar over this period. Beyond 365 days, the stress started 
to reduce, with dramatic reduction after 545 days. Specifically, the maximum von 
Mises stress reduced from 115.16 MPa at 545 days to 43.67 MPa at 729 days. 
Significant stress loss indicated that the biodegradable stent might lose 
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mechanical integrity after 545 days, when it was likely absorbed by human body. 
 
 
Figure 7.8, Maximum von Mises stress on the stent over degradation time. 
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Figure 7.9, The von Mises stress (MPa) distribution on the stent at degradation 
time of (a) 0 days, (b) 189 days, (c) 365 days, (d) 659 days and (e) 729 days. 
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7.5.3 Stress variation in the plaque-artery system over degradation 
 
Figure 7.10, The contour plot of von Mises stress (MPa) on plaque at a 
degradation time of (a) 0 days, (b) 189 days, (c) 365 days, (d) 659 days and (e) 
729 days. 
Figure 7.10 shows the contour plot of von Mises stress on the plaque over 
degradation time. The maximum stress showed a continuous decrease over 
degradation, which was 0.852MPa, 0.829 MPa, 0.819 MPa, 0.765 MPa and 
0.531 MPa at a degradation time of 0 day, 189 days, 365 days, 659 days and 
729 days, respectively. Also, the area with high level stress (red zone) exhibited 
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a decrease over stent degradation. As a result, the stress concentration shifted 
towards both ends of plaque, which was strong contact with the stent due to the 
dogbone shape. 
 
 
Figure 7.11, The contour plot of von Mises stress (MPa) on the intima layer at a 
degradation time of (a) 0 days, (b) 189 days, (c) 365 days, (d) 659 days and (e) 
729 days. 
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The contour plots of von Mises stress on the intima, media and adventitia layers 
were shown in Figure 7.11 to Figure 7.13, respectively.  
For the intima layer, the maximum von Mises stress increased significantly for 
the segment covered with plaque (i.e., from 0.265 MPa at day 0 to 0.274 MPa at 
day 189), followed by a gradual decrease over the rest period of time (i.e., 0.270 
MPa at 365 days, 0.251 MPa at 659 days and 0.167 MPa at 729 days). The 
stress in the intima layer was concentrated over the plaque-covered segment, 
especially at both ends due to stent dogboning.  
For the media layer, no difference was found for the maximum von Mises stress 
over degradation time up to 365 days, with a value maintained at approximately 
0.02 MPa. After 365 days, the maximum von Mises stress reduced to 0.019 MPa 
at day 659 and 0.015 MPa at day 729. Again, the area of high level stress also 
reduced and shifted towards both ends of the plaque-covered segment.  
For the adventitia layer, both the maximum von Mises stress value and the stress 
concentration area were similar at a degradation time of 189 days, 365 days, 659 
days and 729 days. Specifically, the maximum von Mises stress had a magnitude 
of 0.008-0.009 MPa, and the stress concentration areas were again found at both 
ends of plaque-covered segment. 
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Figure 7.12, The contour plot of von Mises stress (MPa) on the media layer at 
degradation time of (a) 0 days, (b) 189 days, (c) 365 days, (d) 659 days and (e) 
729 days. 
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Figure 7.13, The contour plot of von Mises stress (MPa) on the adventitia layer 
at degradation time of (a) 0 days, (b) 189 days, (c) 365 days, (d) 659 days and 
(e) 729 days. 
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Figure 7.14 shows the change of the maximum von Mises stress on the plaque-
artery system over degradation time. It could be concluded that the maximum 
von Mises stress on the plaque-artery system had a continuous reduction over 
degradation process. The first significant decrease of stress was observed at day 
30, from 0.96 MPa at day 0 to 0.866 MPa at day 30, which might be due to the 
contact loss between stent and artery caused by applied blood pressure. After 
601 days, another significant decrease in the maximum von Mises stress 
occurred in the plaque-artery system. It might be caused by additional contact 
loss due to more elastic recoil, because the yield stress reduced significantly with 
the change of stress-strain behaviour of stent material. It indicated that stress 
loss could be achieved for both plaque and arterial layers from the results above, 
which might benefit vessel revascularization after stent implantation. 
 
Figure 7.14, Maximum von Mises stress in plaque-artery system over 
degradation time. 
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7.5.4 Effects of vessel remodelling 
Figure 7.15 shows the contour plot of von Mises stress on the stent at 0 day and 
729 days after 10 cycles of pulsatile blood pressure. At 0 day, there is no vessel 
remodelling and the stress-strain behaviour of the stent was taken as the original 
one. At 729 days, the plaque-artery system experienced vessel remodelling via 
plaque regression, with increased lumen diameter. The stress-strain behaviour 
used for stent simulation was the one at 729 days by considering material 
degradation. Again, high level stresses were concentrated at the inner and outer 
corners of U-bend struts, especially at the stent ends which represented the main 
contact zone between stent and artery due to dogboning. In addition, stress loss 
was observed on the stent over degradation time due to the loss of modulus. But 
the magnitude of stress loss was only marginal (only 3 MPa), as the blood 
pressure imposed limited deformation to the stents. It should be noted that 
residual stresses generated from stent crimping/expansion were not considered 
due to the model limitation.  
Figure 7.16 shows the contour plot of von Mises stress on the plaque at 0 day 
and 729 days after 10 cycles of pulsatile blood pressure. With the regression of 
plaque, the stress reduction was observed on the plaque, which was around 
0.008 MPa. Stress concentrations were located at both ends of the plaque, and 
stress on the inner surface was higher than that on the outer surface. It indicated 
that stress loss occurred on the plaque during vessel remodelling. 
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Figure 7.15, The contour plot of von Mises stress (MPa) on the stent at 0 day 
and 729 days after 10 cycles of pulsatile blood pressure. 
 
Figure 7.16, The contour plot of von Mises stress (MPa) on the plaque at 0 day 
and 729 days after 10 cycles of pulsatile blood pressure. 
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Figure 7.17, The contour plot of von Mises stress (MPa) on the intima, media 
and adventitia layers during at 0 day and 729 days after 10 cycles of pulsatile 
blood pressure. 
Figure 7.17 shows the stress distribution on individual arterial layers at 0 day and 
729 days after 10 cycles of pulsatile blood pressure. Overall, stress distribution 
was symmetric for all three individual layers. High level stresses were mainly 
concentrated at both ends of arterial layers, corresponding to the stress 
concentration on the stent. For intima layer, stress loss was observed due to 
vessel remodelling, which was 0.009 MPa. For media layer, stress loss was only 
around 0.001 MPa. For adventitia layers, no difference was observed for the 
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maximum stress. 
Figure 7.18 shows the variation of maximum von Mises stress on the plaque and 
three arterial layers at major degradation time points. The lumen diameter was 
taken as 2.36 mm and 2.40 mm for day 545 and day 659, respectively, which 
were calculated based on a linear increase from day 0 (2.3 mm) to day 729 (2.42 
mm). It can be concluded that the maximum stress on the plaque and intima 
decreased gradually, whereas no difference was observed for media and 
adventitia layers. Specifically, the stress loss on plaque was 0.005 MPa at 545 
days, 0.006 MPa at 659 days and 0.008 MPa at 729 days. The stress loss in 
intima layer was 0.005 MPa, 0.007 MPa and 0.009 MPa at 545 days, 659 days 
and 729 days, respectively. These results revealed that plaque and intima layer 
were affected by vessel remodelling in terms of mechanical deformation. 
 
Figure 7.18, Variation of maximum stress over degradation time for plaque and 
arterial layers. 
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7.6 Discussions 
From the constructed stress-strain behaviour of PLLA, we can see that both the 
yield stress and modulus had an increase up to a period of 15 months, 
corresponding to the increase of radial strength and radial stiffness for stent in 
experiments. It indicated that the radial strength and stiffness of stent is mainly 
controlled by the yield stress and Young’s modulus of stent material. In the view 
of material, the initial increase of yield stress and Young’s modulus might be 
caused by the recrystallization of biodegradable polymer PLLA due to the water 
absorption and temperature increase (from room temperature 20°C to human 
body temperature 37°C). It was reported that crystallization can significantly 
improve the mechanical strength and stiffness of PLLA in literature (Perego, 
1996). For instance, the amorphous PLLA presents a tensile strength of 55-59 
MPa whereas the crystalline PLLA has a tensile strength of 60-70 MPa. In 
addition, they also pointed out that PLLA could be potential material candidate 
for applications at a temperature of 40°C or higher, because the crystallization 
can significantly improve the mechanical properties. Subsequently, the radial 
strength of stent reduced quickly after 365 days, but the significant reduction in 
radial stiffness occurred after 659 days. It suggested that the yield stress of PLLA 
was more sensitive to hydrolysis degradation compared to Young’s modulus. 
Stress loss was observed for both stent and plaque-artery system in the 
simulation of stent-artery interaction by changing the stress-strain behaviour of 
stent material and applying pulsatile blood pressure. For stent, the maximum von 
Mises stress reduced to 43 MPa at 729 days (~2 years), indicating the loss of 
mechanical integrity and support due to stent degradation. As reported by 
Serruys et al. (2009) in a clinical follow-up study, the bioresorbable everolimus-
eluting stent was fully absorbed at 2 years as revealed by means of multi-imaging 
approaches including echogenicity, virtual history and optical CT. For the plaque-
artery system, relatively high von Mises stress (0.96 MPa at 0 day) was 
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generated when the stent was implanted and expanded, which may lead to injury 
on artery. Then, the von Mises stress on the plaque-artery system became lower 
and lower (reduced to 0.53 MPa at 729 days) over degradation time when 
subjected to pulsatile blood pressure, which may benefit the healing process of 
the artery from a clinical point of view. 
Long-term lumen gain has been reported after stent implantation in a series of 
clinical trial studies (Serrys, 2009; Serrys, 2010; Serrys, 2011 and Serrys, 2016). 
The intravascular ultrasound examination showed that significant increase 
occurred to the mean luminal area and minimal luminal area between 6 months 
and 2 years, whereas significant decrease was found in plaque area and volume, 
and therefore they addressed that the lumen gain (vessel remodelling) was 
caused by a decrease in plaque size without change in vessel size. Plaque 
regression was considered to cause the luminal area enlargement in the study. 
As a result, stress loss was observed for both stent and plaque-artery system 
(especially for plaque and intima arterial layer) in the simulation with considering 
the plaque regression, which suggested that vessel remodelling via plaque 
regression should be considered in assessing the mechanical deformation of 
stent-artery interaction over degradation time. 
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7.7 Conclusions 
Stent-artery interaction was simulated by considering the change of stent 
material property and the vessel remodelling via plaque regression over 
degradation in this chapter. The von Mises stress variation on the stent was 
consistent with the change of yield stress of stent material, whereas the stress 
change in the plaque-artery system depended on the tissue layers. Stress loss 
was observed for stent and plaque-artery system during vessel remodelling via 
plaque regression, which indicated that vessel remodelling also played an 
important role in the mechanical deformation of stent and plaque-artery system. 
It should be noted that residual stresses in the stent-artery system, caused by 
stent deployment, were unable to be considered in simulations of stress variation 
due to vessel remodelling, so the results need to be interpreted cautiously. 
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Chapter 8 - Poly (lactic-acid) and Poly 
(butylene succinate) Blends for Stent 
Application-Testing and Modelling 
8.1 Introduction 
Synthetic polymers are of importance in modern science and technology as they 
are essential to our daily life with a wide range of applications in various fields 
such as packaging, agriculture, food, consumer products and medical devices. 
In the past few decades, considerable attention has been given to the 
biodegradable polymers due to their unique biodegradability, enhanced 
biocompatibility as well as flexible physical and mechanical properties. In 
particular, biomedical applications of biodegradable polymers generate an 
enormous amount of interest in research. Biodegradable polymer is a specific 
type of polymer that breaks down into natural by-products such as gases (CO2, 
N2), water, biomass and inorganic salts after its intended purpose. Applications 
can be found in drug delivery systems, surgical implants and other medical 
applications. Amongst, Poly-lactic acid (PLA) attracted most of the interest. PLA 
is a semi-crystalline thermoplastic polymer with high strength and modulus, and 
has been widely used in medical implants in the forms of rods, plates, pins as 
well as meshes (Pulapura and Kohn, 1992). In addition, PLA can be easily 
processed into a wide range of products by extrusion, injection moulding, 
compression moulding as well as film and sheet casting (Lim, 2008). PLA can 
come under the stereo-isomeric forms such as Poly-l-lactic acid (PLLA) and Poly-
d-lactide (PDLA), with minor difference in thermal properties (e.g. melting 
temperature, glass transition temperature and crystallinity). 
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Significant amount of research has been conducted to study the mechanical 
properties of biodegradable polymer PLA. For instance, Bartkowiak-Jowsa et al. 
(2011) carried out uniaxial tensile tests to characterize the stress-strain 
behaviour of several biodegradable polymers, including poly-lactide (PLA), poly-
caprolactone (PCL), poly (L-lactide) (PLLA) and poly (lactide-co-glycolide) 
(PGLA). Their results showed that PLA (PLLA) is a typical brittle material, with 
relatively high Young’s modulus but limited deformation at failure when compared 
to PCL/PGLA. In fact, mechanical brittleness or poor elongation (≤ 3%), and low 
strength of PL(L)A has limited its medical applications considerably. As such, 
some other polymers (i.e. PCL and PES) have been proposed to fabricate PLA 
blends for improved mechanical properties. Liang et al. (2013) investigated the 
tensile mechanical properties of PLLA/PCL/nano-CaCO3 composite and 
evaluated the effects of blend composition on their mechanical properties. Their 
results showed that PCL content is helpful to improve the ductility of PLLA 
composite but with a sacrifice of the strength. Lu et al. (2007) examined the 
tensile mechanical properties of PLLA/PES composites by tensile testing and 
observed that the Young’s modulus increased significantly with the increase of 
weight fraction of PES but with a dramatic decrease of the elongation at break. 
In addition, the increase of temperature can also affect the ductility of the PLA. 
Rezgui et al. (2005) investigated the mechanical behaviour of PLA upon 
stretching at 50°C, and found that PLA underwent extensive plastic deformation, 
due to a dramatic reduction of yield stress, followed by a progressively increasing 
strain hardening. It has also been proved that the mechanical properties of PLA 
are less dependent on the molecular weight. For example, the tensile strength 
rises 20% only when the molecular weight increases from 107,000 to 550,000 
g/mol (Vroman and Tighzert, 2009). As reviewed by Hamad et al. (2015), PLA 
has good mechanical properties, especially tensile Young’s modulus and tensile 
strength, but limited elongation at break and low impact strength, when 
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compared to other traditional polymers. To improve its ductility, PLA can be 
blended with polymeric tougheners (e.g., PCL, PBS, PPC and PHA) and the 
effects can be controlled by varying size, volume fraction, substructure and 
inherent property of the dispersed toughening phase (Liu and Zhang, 2011). 
Rasal et al. (2010) reported that surface- and bulk- modification strategies could 
be used to toughen PLA, but usually associated with a loss of tensile strength or 
modulus. They also pointed out that the development of PLA-nanocomposites 
may be a promising approach to improve PLA properties. 
Numerical methods have also been widely applied to understand, evaluate and 
predict the mechanical deformation of biodegradable polymers by means of a 
variety of material models. For instance, the Bergström-Boyce viscoelastic model 
can be used to simulate the performance of polymers undergoing large 
deformation (Bergström and Boyce, 1998). The hyper-elastic constitutive 
relationship, such as the Neo-Hookean and the Mooney-Rivlin models, was used 
by Vieira et al. (2011) to predict the mechanical deformation of PLA and PCL 
blend. Vieira et al. (2014) also performed a parametric study based on the 
adapted Bergström-Boyce model for PLA-PCL blend to simulate three-
dimensional time-dependent mechanical deformation during hydrolytic 
degradation. The adapted model was proved to be able to simulate more relevant 
phenomena such as stress relaxation, creep and inelastic strain measured 
experimentally. Muliana and Rajagopal (2012) modified a quasi-linear 
viscoelastic (QVL) model to analyse the response of nonlinear viscoelastic 
biodegradable polymer PLLA by considering the change of material parameters 
during degradation process. They identified that the stress-strain response was 
less sensitive to strain rates which agreed with experimental results. So far, 
modelling of biodegradable polymers has been mostly carried out by considering 
the elastic/viscoelastic deformation and the effects of degradation on the elastic 
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properties of the polymers. There is limited research on modelling of 
biodegradable polymer PLA by considering the viscoplastic deformation, i.e., 
rate-dependent plastic deformation, which is critically important for accurate 
capture of the material behaviour, especially in modelling of loading-bearing 
components and devices such as PLLA stents which rely on plastic deformation 
to function properly.  
The present chapter aims to study the potential in improving the ductility of PLA 
by blending with PBS in various weight ratios. Polybutylene Succinate (PBS) is 
one of the newest biopolymers under development, and belongs to 
biodegradable aliphatic polyester. It has high crystallinity, a melting point of about 
90°C~120°C and a glass transition temperature of around -45~-10°C (Foin, 2014; 
Papageorgion, 2007). Moreover, PBS has good material processability, even 
better than PLA, and can be easily processed at relatively low cost as compared 
with other biodegradable polymers (Kanemura, 2012). Zhao et al. (2005) studied 
the biodegradation behaviour of PBS under controlled composting conditions, 
and found it degraded very slow initially and then got accelerated. Chieng et al. 
(2010) reported that the strength and modulus of PBS can be increased by 
blending with poly (butylene adipate-coterephthalate) (PBAT) and organo-
modified montmorillonite (OMMT). Similarly, Okamoto et al. (2003) prepared 
PBS/layered-silicate nanocomposites by melting extrusion, and results showed 
that there was significant improvement in tensile modulus but with a compromise 
of tensile yield strength. 
Specifically, PLA/PBS blends, with weight ratios at 90/10, 70/30, 50/50, 30/70 
and 10/90, were produced by roller mixing at melting condition. Thermal 
properties were characterized by Differential Scanning Calorimetry (DSC) for the 
various PLA/PBS blends produced. The crystalline morphology of the PLA/PBS 
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blends was studied by Optical Microscopy. Mechanical properties were studied 
by uniaxial tensile testing, and strain rate effect was characterized. Also, an 
elastic-plastic model with rate dependence was applied to simulate the 
viscoplastic deformation of stent, in which testing data were used as model input. 
8.2 Methodology 
8.2.1 Raw materials 
Both poly (lactic-acid) (PLA) (Ingeo PLA 4043D, NatureWorks LLC) and poly 
(butylene succinate) (PBS) (RJ503S, Hangzhou Ruijiang Chemical Co. Ltd.) 
were purchased for this study. PLA 4043D is a type of biopolymer, and its melting 
temperature is in the range of 145-160°C. The density is 1.24 g/cm3, and tensile 
strength is about 110 MPa. PBS RJ503S has a melting point in the range of 110-
116°C and a density of 1.20-1.28 g/cm3. The tensile strength is relatively low (35-
45 MPa) but the elongation at break can be as high as 300%. Both polymers 
were provided in the form of pellets. 
PLA 4043D is not for medical purpose, but its tensile strength and elongation at 
break are considered to be very close to that of PLA polymer in medical grade. 
Considering that polymer PLA in medical grade is far too expensive, polymer PLA 
4043D was used as an alternative in this research. Polymer PBS (RJ503S) was 
chosen in the research because it is very ductile (elongation at break ≥300) and 
used to overcome the brittleness of polymer PLA through blending. However, the 
tensile strength of PBS is limited (35-45 MPa), so the weight ratio in the blend 
should be controlled in order to achieve required mechanical strength.  
8.2.2 Preparation of PLA/PBS blends and specimens 
To prepare PLA/PBS blends, PLA and PBS pellets were pre-dried in the oven at 
the temperature of 80°C for at least 12 hours. They were then melted and mixed 
in HAAKE Polylab OS mixer for 10 minutes at a mixing speed of 60 rpm and 
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under a temperature of 195°C. PLA/PBS weight ratios of 90/10, 70/30, 50/50, 
30/70 and 10/90 were considered. 
To produce PLA/PBS specimens, PLA/PBS film (80×80×1 mm3) were firstly 
obtained from PLA/PBS blends by compression moulding method. The 
temperature for compression moulding depended on the melting points of both 
materials. Those films were further cut into dog-bone specimens. Pure PLA and 
PBS specimens were also prepared as control. These dog-bone specimens were 
used for mechanical testing to investigate mechanical properties. The 
dimensions for the PLA/PBS dog-bone specimens followed the testing Standard 
ISO-527-2-5A (see Figure 8.1 and Table 8-1). 
 
 
Figure 8.1, Sketch for the dog-bone specimen. 
Table 8-1, Dimensions for dog-bone specimen (corresponding to Figure 8.1). 
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8.2.3 Characterization of PLA/PBS blends 
8.2.3.1 Differential scanning calorimetric (DSC) 
TA instruments DSC 2010 differential scanning calorimeter was used to evaluate 
the thermal behaviour of PLA/PBS blends. Non-isothermal run was performed 
for PLA, PBS and their blends. The materials were heated to 200°C at a rate of 
10°C /min, cooled down to room temperature at the same rate, and then reheated 
to 200°C in DSC system. Crystallisation temperature, degree of crystallinity and 
melting temperature of the blends were identified from the DSC curves. The 
degree of crystallinity was calculated by the following equation: 
 𝜒9 	 % = ∆𝐻8  − ∆𝐻9 ∆𝐻8 ,L×𝑊  ∗ 100	 (8.1) 
 𝜒9x¡	 % = ∆𝐻8x¡∆𝐻8x¡,L×𝑊x¡ ∗ 100	 (8.2) 
where 𝑊 and 𝑊x¡is the PLA and PBS weight fraction in the blend system, ∆𝐻9  is the enthalpy of crystallization for PLA, and ∆𝐻8L is the heat of fusion for 
100% polymer crystal (∆𝐻8 ,L=93.0 J/g and ∆𝐻8x¡,L= 210.0 J/g). 
8.2.3.2 Optical microscopy analysis 
Leica DMRX microscope was used to examine the crystalline structure of the 
pure PLA, PBS and their blends. Material samples were heated to melt fully into 
very thin film on a hot stage at the temperature of 200°C, and then squeezed 
between cover glasses. They were then put into the oven at a temperature of 
80°C for 30-minute crystallization, and finally quenched to room temperature 
(20°C). 
8.2.4 Mechanical testing 
Mechanical properties were evaluated by uniaxial tensile testing on dog-bone 
samples at room temperature. Instron machine (Instron 2716-010, maximum 
load 50kN) was used for the experiments with a loading rate of 10 N/min. Stress-
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strain behaviour of the blends was obtained to extract the elastic modulus, tensile 
strength and elongation at break. In particular, to study the viscous behaviour, 
strain-controlled tests were also carried out for the blended PLA/PBS specimens 
(70/30, 50/50 and 30/70) under three strain rates, i.e., 0.01/s, 0.001/s and 
0.0001/s.  
8.2.5 Finite element modelling  
To study the effect of loading rate on mechanical deformation of stent, Elixir stent 
was chosen for finite element simulations of crimping and expansion processes. 
The whole model setup was the same as developed in the previous chapter. 
Three different loading times were applied in the simulations of stent crimping 
and expansion, i.e., 1s, 0.1s and 0.01s. A time-dependent plastic model 
(available in Abaqus) was used for the stent in which the testing data was used 
as model input. 
 
8.3 Results and Discussions 
8.3.1 DSC analysis 
Generally, DSC analysis is an effective method for the measurement of melting 
temperature and crystallization for semi-crystalline polymer. Figure 8.2 shows 
DSC diagrams for pure PLA, pure PBS and their blends. In terms of endothermal 
process, it can be noticed that there is only one peak occurred in the endothermal 
process for either pure PLA or PBS sample, which is at about 148°C and 108°C, 
respectively. All other blends exhibit two melting peaks in the endothermal 
process, which are around 100~120°C and 140~160°C, respectively.  
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Figure 8.2, DSC thermal diagram for PLA, PBS and their blends including both 
endothermal and exothermal processes. 
 
 
 
 
An example is given in Figure 8.3 (a) to indicate the method for calculation of 
melting temperature and heat flow for PLA/PBS (70/30) blend. It can be 
concluded from these thermal diagrams that polymer PLA and PBS are 
immiscible by mechanical mixing method. While in the exothermal process, pure 
PLA and PLA/PBS (90/10) blend have definitely slow crystallization process, 
which can hardly be captured in the DSC thermal diagrams. Figure 8.3 (b) gives 
an example for the calculation of crystallization temperature and heat flow for 
PLA/PBS (70/30) blend. The crystallization temperature of pure PBS is 
calculated as 77°C. In particular, there are two exothermal peaks in the PLA/PBS 
(70/30) blend. Therefore, it might be considered that PBS composition would 
improve PLA crystallization behaviour.  
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Figure 8.3, Example of melting temperature (a), crystallization temperature (b) 
and heat flow calculation for PLA/PBS blend (70/30). 
Thermal properties of pure polymer and their blends are summarized in Table 
8-2 and Table 8-3. It is clear that the crystallinity of PLA in the blend increased 
from 19.35% to 24.64% with the addition of 30% PBS, and then slightly 
decreased with the further increase of PBS content. On the other hand, as shown 
in Table 8-3, the crystallinity of PBS was compromised by the blending with PLA. 
For PLA/PBS (90/10) blend in Table 8-3, there was no significant exothermal 
peak in the DSC diagram (as the light blue line shown in Figure 8.2), so the 
relevant values were missing. It might be due to the very limited PBS composition 
in this blend, which makes it difficult to be characterized in the DSC testing. 
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Table 8-2, Thermal properties of content PLA in the blends. 
 
 
Table 8-3, Thermal properties of content PBS in the blends. 
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8.3.2 Optical microscopy analysis 
 
Figure 8.4, Optical microscopy images for PLA/PBS blends: (a) PLA; (b) 
PLA/PBS (90/10); (c) PLA/PBS (70/30), (d) PLA/PBS (50/50); (e) PLA/PBS 
(30/70); (f) PBS. 
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In order to characterize what happened to the PLA/PBS blend system, optical 
microscopy analysis was conducted to observe the crystalline morphology and 
the results are shown in Figure 8.4. It is clear that the crystal of pure polymer 
PLA is small in size and quite uniformly dispersed in terms of distribution (see 
Figure 8.4a). The PBS crystal is also small in size but with a rather non-uniform 
distribution (see Figure 8.4 f). Moreover, the crystal in the PLA/PBS blends tends 
to increase in size with the addition of PBS content. In particular, it clearly shows 
that the crystal in PLA/PBS (70/30) blend tends to have a bigger size and good 
spreading. It could be considered that the addition of PBS content aids with the 
crystallization process of polymer PLA, leading to altered mechanical properties 
(Yokohara and Yamaguchi, 2008; Stoyanova, 2014).  
8.3.3 Mechanical properties of PLA/PBS blends 
Figure 8.5 shows the stress-strain curves of the PLA/PBS blends with various 
weight ratios. It should be noted that three specimens were tested for each blend, 
and the mean values were used to produce this stress-strain diagram. Pure PBS 
and blends with more than 50% of PBS such as PLA/PBS (10/90) and PLA/PBS 
(30/70) showed distinctive ductile behaviour, with the occurrence of necking 
behaviour (Figure 8.6). While pure PLA and blends with less than 50% of PBS 
such as PLA/PBS (90/10) and PLA/PBS (70/30) showed the nature of brittle 
fracture, with no sign of necking phenomenon. 
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Figure 8.5, Uniaxial tensile stress-strain curves for PLA/PBS blends tested at a 
loading rate of 10 N/min. 
Furthermore, tensile modulus, elongation and strength were obtained from the 
stress-strain curves, and presented in Figure 8.7, with a normalisation to those 
of pure PLA. As shown in Figure 8.7 (a), pure PLA polymer shows the highest 
tensile modulus (around 1.8 GPa), and the tensile modulus of PLA/PBS (90/10, 
70/30) blends were reduced to 1.6 GPa and 1.4 GPa, respectively. Further 
decrease in modulus was obtained with the addition of more PBS. These results 
are similar to the results obtained from PLA/PBS blends prepared by either melt 
spinning technique or Haake RHeomix OS mixer. The elongation of pure PLA is 
really limited (8%) and further improved by the blending with ductile PBS polymer, 
as shown in Figure 8.7 (b). Specifically, the elongation increased to 12.5% and 
15.4% for the addition of 10% and 30% PBS, respectively. Tensile strength of 
PLA/PBS blends exhibits the same trend as the tensile modulus (see Figure 8.7c). 
All results reveal that the brittleness of pure PLA can be improved by blending 
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with ductile PBS using mechanical mixing technique, but with a compromise of 
tensile modulus and strength. 
 
 
Figure 8.6, Failed PLA/PBS dog-bone specimens after tensile testing: (a) a 
PLA; (b) PLA/PBS (90/10); (c) PLA/PBS (70/30), (d) PLA/PBS (50/50);(e) 
PLA/PBS (30/70); (f) PLA/PBS (10/90); (g) PBS. 
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Figure 8.7, Tensile properties for PLA/PBS blends as a function of PLA weight 
percentage with normalisation against pure PLA: (a) tensile modulus; (b) 
elongation; (c) tensile strength. 
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8.3.4 Rate dependent behaviour  
Figure 8.8 shows their tensile stress-strain curves for PLA/PBS blends with 
weight ratios of 70/30, 50/50 and 30/70 at two different strain rates, i.e., 0.0001/s 
and 0.01/s. It is clear that the strain rate has an effect on the stress-strain 
behaviour of PLA/PBS blends, demonstrating the time-dependent deformation 
nature of the material, i.e., an increase of stress with the increase of strain rate. 
This time-dependent or viscous behaviour needs to be considered properly in 
the design and manufacturing of components and devices made of PLA/PBS 
blend, including computational modelling.  
 
 
Figure 8.8, The rate dependent stress-strain behaviour of PLA/PBS blends 
obtained from experiments. 
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8.3.5 Effect of loading rate on stent behaviour 
8.3.5.1 Viscoplastic material model for stent 
 
Figure 8.9, Experimental and simulated stress-strain behaviours of blend 
PLA/PBS (70/30) for different strain rates. 
A time-dependent elastic-plastic model, available in Abaqus, was used for stent. 
Isotropic hardening was implemented by the description of yield stress as a 
function of plastic strain. Strain rate dependence was defined by inputting yield 
stress ratios as a function of equivalent plastic strain rates. The yield stress ratio 
is the ratio of the yield stress at nonzero strain rate to the static yield stress. Here, 
the stress-strain response of PLA/PBS (70/30) at strain rate of 0.0001/s was 
regarded as the static behaviour. These inputs were extracted from the stress-
strain behaviours of blend PLA/PBS (70/30) at a strain rate of 0.0001/s, 0.001/s 
and 0.01/s. The capability of the model was evaluated by simulating the response 
of a single 3D element subjected to displacement-controlled load at the three 
strain rates (i.e., 0.0001/s, 0.001/s and 0.01/s). As shown in Figure 8.9, the model 
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captured very well the time-dependent stress-strain behaviour that was 
measured experimentally. 
8.3.5.2 Effect of loading rate on stent crimping 
Three different loading rates (i.e., 1 mm/s, 10 mm/s and 100 mm/s) were applied 
to simulate the rate effect on the mechanical behaviour of stent during crimping. 
Figure 8.10 compares the von Mises stress contour plot of Elixir stent in fully 
crimped configuration under different loading rates. Obviously, high level stress 
area (red zone) increased dramatically when the loading rate was increased from 
1 mm/s to 100 mm/s. The maximum von Mises stress magnitude also increased, 
from 88.87 MPa to 92.47 MPs and 93.99 MPa when the loading rate increased 
from 1 mm/s to 10 mm/s and 100 mm/s, respectively. 
 
 
Figure 8.10, The von Mises stress (MPa) contour plot for the Elixir stent in fully 
crimped configuration, with a loading rate of (a) 1 mm/s, (b) 10 mm/s and (c) 
100 mm/s. 
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Figure 8.11 shows the equivalent plastic strain contour plot of the Elixir stent in 
fully crimped configuration achieved under three different loading rates. Again, 
the maximum equivalent plastic strain magnitude increased with the increase of 
loading rate, with a value of 0.91, 1.21 and 1.22 for the loading rate of 1 mm/s, 
10 mm/s and 100 mm/s, respectively. Moreover, the maximum equivalent plastic 
strain occurred at the peaks and valleys of the stent U-bends in all cases. 
 
Figure 8.11, The equivalent plastic strain contour plot for the Elixir stent in fully 
crimped configuration, with a loading rate of (a) 1 mm/s, (b) 10 mm/s and (c) 
100 mm/s. 
In the followed spring back step, the rigid plates were removed to allow crimped 
stent to recover elastically. Figure 8.12 shows the von Mises stress contour plot 
of the Elixir stent after spring back under three different loading rates. Significant 
stress loss was observed for stent in all cases, and the maximum von Mises 
stress magnitude reduced to be 59.40 MPa, 62.17 MPa and 73.25 MPa for the 
loading rate of 1 mm/s, 10 mm/s and 100 mm/s, respectively. In terms of stress 
distribution, the area of high level stress increased with the increase of loading 
rate. Figure 8.13 shows the spring back effect of stent under different loading 
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rates. Different amount of elastic deformation recovery was obtaiend for the Elixir 
stent, which was 12 %, 14% and 16% with a loading rate of 1 mm/s, 10 mm/s 
and 100 mm/s, respectively.  
 
Figure 8.12, The von Mises stress (MPa) contour plot for the Elixir stent after 
spring back, with a loading rate of (a) 1 mm/s, (b) 10 mm/s and (c) 100 mm/s. 
 
Figure 8.13, Spring back effect of the Elixir stent at different loading rates. 
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8.3.5.3 Effect of loading rate on stent expansion 
Similarly, three different loading rates (i.e., 1.4 MPa/s, 14 MPa/s and 140 MPa/s) 
were used to model stent expansion via balloon inflation and deflation. Figure 
8.14 shows the change of stent diameter against pressure for the Elixir stent 
during the expansion process, with different rates of inflation. Initially, the stent 
started to expand from both ends and formed a dog-bone shape, so the diameter 
in the middle part increased very slowly. When the pressure was high enough to 
expand the whole stent, rapid stent expansion happened and the diameter 
increased significantly. After the rapid stent expansion, the dog-bone shape 
disappeared and then the stent expansion reached a saturation stage. Finally, 
the expanded stent underwent elastic recovery leading to a slight decrease of 
the diameter during the balloon deflation process. 
It is clear that the loading rate did not affect the stent behaviour during the initial 
stage of stent expansion. However, the pressure required for the rapid expansion 
was different, i.e., 0.3 MPa, 0.4 MPa and 0.5 MPa for the loading rate of 1.4 
MPa/s, 14 MPa/s and 140 MPa/s, respectively. This led to a stent diameter of 
3.37 mm, 3.38 mm and 3.40 mm at peak inflating pressure under the three 
loading rates.  
Figure 8.15 gives recoiling effect for the Elixir stent under three different loading 
rates. The recoiling effect is very similar for 1.4 MPa/s and 14 MPa/s loading 
rates, which is around 6.5%. However, the recoiling showed a significant 
decrease when the loading rate increased to 140 MPa/s, which was only 2.5 %. 
The difference can also be found from the curve of stent diameter change against 
pressure (Figure 8.14).  
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Figure 8.14, Diameter change against pressure for the Elixir stent during 
expansion. 
 
 
Figure 8.15, Recoiling effect of the Elixir stent at different loading rates. 
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Figure 8.16 shows the von Mises stress contour plot for the stent at peak inflating 
pressure under three different loading rates. The maximum von Mises stress 
magnitude was 70.29 MPa, 74.60 MPa and 88.15 MPa for a loading rate of 1.4 
MPa/s, 14 MPa/s and 140 MPa/s, respectively. Again, similar trend was found for 
the maximum von Mises stress magnitude, increasing with the increase of 
loading rate. Stress distribution was generated very uniformly on the stent at 
loading rate of 1.4 MPa/s and 14 MPa/s, with stress concentration at the peaks 
and valleys of U-bends. However, high level stress areas were mainly located at 
two ends of stent for the fastest loading rate of 140 MPa/s. After recoiling, the 
stent released some stress to accommodate elastic recovery, and the maximum 
von Mises stress magnitude reduced to 65.00MPs, 65.02 MPa and 71.51 MPa 
for a loading rate of 1.4 MPa/s, 14 MPa/s and 140 MPa/s, respectively, as shown 
in Figure 8.17. 
 
Figure 8.16, The von Mises stress (MPa) contour plot for the Elixir stent at peak 
pressure, with a loading rate of (a) 1.4 MPa/s, (b) 14 MPa/s and (c) 140 MPa/s. 
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Figure 8.17, The von Mises stress (MPa) contour plot for the Elixir stent after 
recoiling, with a loading rate of (a) 1.4 MPa/s, (b) 14 MPa/s and (c) 140 MPa/s. 
 
8.4 Conclusions 
In this chapter, mechanical and thermal properties of PLA, PBS and their blends 
were characterized by experimental method. PLA/PBS blends were obtained by 
mechanical mixing technique, and dog-bone specimens were manufactured by 
compression moulding. Thermal properties of PLA/PBS blends were identified 
by DSC, and results showed that the crystallinity of PLA/PBS blends increased 
with the addition of PBS content. The mechanical properties of PLA/PBS blends 
were studied by conducting tensile testing, and results showed that the 
brittleness of pure PLA can be improved by blending with ductile PBS using 
mechanical mixing technique, but with a loss of stiffness and strength. The tensile 
tests at different strain rates confirmed the rate-dependent plastic deformation 
nature of the blends, i.e., an increase of stress with the increase of strain rate. 
This study help further understand the mechanical behaviour of PLA from an 
experimental point of view. 
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The study also modelled the stent crimping and expansion, by using the elastic-
plastic model with rate dependency. Results showed that loading rate affected 
the stent deformation, such as stress distribution, stress concentration, diameter 
change, and spring back/recoiling effects. All results suggest that loading rate 
should be considered as a factor in the clinical practise of stent crimping and 
deployment. 
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Chapter 9 - Conclusions and Further Work 
9.1 General conclusions 
In this thesis, mechanical behaviour of bioresorbable polymeric stents, including 
the Absorb, Elixir, Igaki-Tamai and RevaMedical stents, were investigated using 
the finite element method. In Chapter 1, the general background was introduced, 
e.g., what is a stent and why we need stents. The aims and objectives of this 
thesis were also identified.  
In Chapter 2, literature review was presented, including the development of stent, 
materials for bioresorbable stents, experimental and computational studies on 
stents. Stents have been developed from the bare-metal stents (BMSs), to drug-
eluting stents (DESs) and bioresorbable stents (BRSs) over the last three 
decades. Corrodible metallic alloys and biodegradable polymers are considered 
to be the major material candidates for BRSs. The bioresorbable metallic stent 
has the comparable mechanical properties to permanent metallic stent, but the 
fast degradation rate limits the required functional properties. The bioresorbable 
polymeric stent has a reasonable degradation rate, but its mechanical property 
is not comparable to metallic stent. In vitro experimental studies were carried out 
to investigate the radial and longitudinal flexibility of stents, with a focus on the 
comparison between commercial stents with different designs. Degradation 
behaviour of stents was characterized by in vivo and in vitro experimental 
approaches, in terms of weight loss and molecular weight change. The safety 
and efficacy of biliary stent was also evaluated in a large amount of in vivo studies. 
However, experimental research on stents was still limited due to the complexity 
of the stent design and the difficulty in simulating realistic human body 
environment. Computational studies have been widely carried out to study the 
mechanical behaviour of stent during expansion, especially for metallic stents. 
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Stress distribution, stent diameter change against pressure, and 
recoiling/dogboning effects were studied based on the computational analysis. 
Comparative studies were conducted to evaluate the effect of stent designs and 
stent expansion methods on the mechanical behaviour of stents, and results 
showed that both stent designs and stent expansion methods played important 
roles in controlling stent performance. The fatigue behaviour of metallic stents 
was also studied by finite element modelling, and fatigue lifetime prediction was 
carried out by stress/-strain-life approach and fracture-mechanics approach. 
Numerical models were developed to investigate the degradation behaviour of 
polymeric stents, but little research was carried out to study the corresponding 
mechanical response of stent and artery over degradation times.   
In Chapter 3, general methodology was introduced for the finite element 
modelling of stent expansion. Firstly, the finite element models of stent, tri-folded 
balloon and plaque-artery were created using Abaqus CAE and NX software. 
The constitutive material models for each component were described. The 
stress-strain behaviour of stent and tri-folded balloon were taken from published 
papers, and the material models of arterial layers and hypocellular plaque were 
calibrated against experimental data. Subsequently, a description was given for 
the actual crimping and expansion procedures of stents, based on which multiple 
simulation steps were created to model stent deployment, including stent 
crimping, balloon inflation and deflation. Post-processing of simulation results 
were also presented, according to FDA guidance and ASTM standard. Finally, 
mesh sensitivity studies were carried out for both stent and plaque-artery system, 
to ensure that the convergences were achieved in the simulations of stent 
expansion. Results showed that good convergence was achieved for the stent 
with a mesh density of 4×4. Similarly, convergence was also achieved for the 
plaque-artery meshed with 4 and 8 layers of elements through the thickness 
direction of each arterial layer and the plaque, respectively. The change of stent 
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diameter was not sensitive to mesh densities of the stent or plaque-artery system 
during the expansion process. 
Chapter 4 compared the mechanical behaviour of four bioresorbable polymeric 
stents (Absorb, Elixir, Igaki-Tamai and RevaMedical) during crimping and free 
expansion processes, in terms of stress distribution, diameter change against 
pressure, spring back and recoiling effects, as well as radial stiffness and 
strength of stents. The effect of residual stresses caused by crimping was also 
identified during the stent expansion. Results showed that four stents exhibited 
significantly different behaviour, due to their individual designs. Stent, with larger 
U-bend amplitude and axial strut spacing, showed more flexibility and generated 
less stress concentration in expansion but resulted in a higher recoiling effect. 
The radial stiffness and strength of stent were highly dependent on the strut 
thickness of the stent, and thicker strut benefited the radial properties of the stent. 
Residual stresses on the stent caused by crimping were found to affect the 
expansion behaviour of stent, such as expansion rate and recoiling effect. These 
results highlighted the importance of stent design on the stent performance. 
In Chapter 5, a comparative study was performed to evaluate the mechanical 
behaviour of both stent and plaque-artery by modelling the deployment of the 
four polymeric stents in the stenotic artery. Also, the effect of residual stress 
caused by crimping was characterized. Overall, stents exhibited dogbone shapes 
and achieved smaller diameters during expansion, due to the existence of plaque 
and artery. Stents, with thicker and curved axial struts, showed smaller recoiling 
and dog-boning effects but limited radial flexibility. Stress concentration areas 
were generated at the corner regions of U-bend struts, and stent with larger U-
bend amplitude and axial strut spacing experienced less stress concentration. 
High level stresses were also observed on the plaque and artery during stent 
deployment, located at both ends of the plaque layer. Stress variations on the 
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plaque and artery were greatly dependent on the expansion of stent, which can 
be used to assess the injury of artery caused by stenting. In addition, stents 
gained slightly larger diameters and experienced less recoiling and dog-boning 
effects in simulations without considering crimping-caused residual stresses. 
This study indicated that an improved understanding of stent performance can 
be achieved by considering the existence of residual stress and plaque-artery in 
the simulation of stent deployment. 
The fatigue behaviour of the Elixir stent was investigated in Chapter 6, by 
considering the pulsatile systolic-diastolic blood pressure. High stresses 
occurred at the inner corners of stent U-bends, and low stresses were observed 
at the middle part of stent struts. The Elixir stent achieved a stabilized stage after 
applying 5 cycles of pulsatile blood pressure, with a stable stress variation 
between 92 MPa and 100 MPa. Both the classical stress-life method and 
Goodman’s rule were used to carry out fatigue lifetime prediction for the Elixir 
stent, and results showed that U-bend regions of stent had high risks of fatigue 
failure under the pulsatile systolic-diastolic blood pressure. However, this fatigue 
assessment has limitations due to the lack of fatigue testing data for 
biodegradable polymer PLLA. 
In Chapter 7, the stent-artery interaction during degradation and vessel 
remodelling were studied, by considering the change of mechanical property for 
stent material and plaque regression. The stress-strain curves of stent material 
PLLA at different degradation time points were calibrated against experimental 
data for a commercial polymeric stent. The yield stress of material PLLA showed 
a significant increase after 1 month and maintained high values for up to 15 
months, and then decreased gradually. The Young’s modulus also maintained an 
almost constant level for up to 22 months, and only showed a dramatic decrease 
at 24 months. The changes of yield stress and Young’s modulus corresponded 
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well to the changes of radial strength and stiffness of the stent, which suggested 
that the radial strength and stiffness of stent were highly dependent on the yield 
stress and Young’s modulus of stent material. Over degradation times, the stress 
variation on the stent showed an increase firstly before a gradual decrease, 
which was consistent with the change of yield stress for the stent material. 
However, the stress on the plaque and arterial layers showed a continuous 
decrease over stent degradation. During vessel remodelling via plaque 
regression, both stent and plaque exhibited stress loss. Stress loss was also 
observed for the intima layer of artery, but no significant difference was found for 
the media and adventitia layers. This study identified the stress variation on the 
plaque and arterial layers during stent degradation and vessel remodelling, which 
can help understand the long-term stent-artery interaction after the stent 
deployment. However, the residual stresses in the stent-artery system were not 
considered due to the limitation of simulations, and therefore further work is 
required to evaluate the results. 
Chapter 8 presented an experimental study on the mechanical and thermal 
properties of PLA and PBS blends, and also the effect of strain rate on stent 
expansion behaviour using finite element method. DSC results showed that the 
crystallinity of PLA/PBS blends increased by the addition of PBS content. The 
brittleness of pure PLA can be improved by blending with ductile PBS, but with a 
sacrifice of stiffness and strength. A significant difference was observed for the 
stress-strain behaviour in the plastic region, which suggested the rate-dependent 
plastic deformation nature of the PLA/PBS blend. This rate effect was considered 
in the simulation of the stent expansion. Results showed that stents exhibited 
different mechanical behaviour under different loading rates, in terms of stress 
distribution, diameter change and spring back/recoiling effects. With the increase 
of loading rate, stents experienced more expansion with less recoiling effect but 
resulted in higher stresses. These results suggest that the loading rate should be 
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considered as a factor in the clinical practise of stent implantation. 
9.2 Summary of key achievements 
Ø Through simulation of stent expansion with and without diseased artery, it 
can be seen that stent design (radius of U-bend strut, axial strut spacing and 
strut thickness) greatly affects the mechanical behavior of stents and arterial 
layers, such as stress distribution, diameter change against pressure, 
recoiling/dogboning effects and radial stiffness and strength, during stent 
deployment. 
Ø Based on fatigue analysis after stent deployment, it can be concluded that 
the U-bend regions of polymeric stents possess a high risk of fatigue failure 
due to the cyclic pulsatile blood pressure. This is different from metallic 
stents which are generally safe from fatigue failure. 
Ø For the first time, stress loss was quantified for the stents, plaque and arterial 
layers during stent degradation and vessel remodeling, and the results 
provide important insights into stent-artery interaction during stent 
degradation process. 
Ø Experimental studies showed that the stress-strain behavior of PLA/PBS 
blend is rate-dependent, and subsequent simulations showed that the 
mechanical behavior of polymeric stent is sensitive to loading rates during 
crimping and expansion processes. These results suggested that loading 
rate should be considered as a factor in the clinical practice of stent 
implantation. 
Ø The modelling approaches developed in this thesis are proved effective and 
important to study the deformation of stent-artery system during the 
processes of stent deployment and stent degradation, which can be used as 
efficient tools to help with stent design, material processing and clinical 
practices. 
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9.3 Further work 
9.3.1 Experimental work 
As reviewed in Chapter 2, bioresorbable polymeric stents are mostly made of 
biodegradable polymer PLLA with high molecular weight. However, the 
mechanical properties of biodegradable PLLA are highly dependent on the 
synthesis method and material processing. The stress-strain curve of PLLA used 
in this study was obtained from literature, in which high-molecular-weight PLLA 
specimens were used to perform uniaxial tensile tests. In fact, mechanical 
behaviour of the actual material used for commercial polymeric stent is still not 
available. Therefore, mechanical tension and compression tests are required to 
investigate the actual material behaviour of bioresorbable polymeric stent, and 
this will help better evaluate stent performance by choosing more accurate 
material models in simulations. Fatigue test is also needed to obtain stress-life 
curve for high-molecular-weight PLLAs, which is very important to perform the 
fatigue lifetime assessment for commercial polymeric stents. 
Further work is also required to develop bioresorbable polymeric stents with 
performance comparable to commercial drug-eluting stents. The bioresorbable 
polymeric stents may suffer from insufficient radial strength to support arterial 
wall and prevent elastic recoil, because the mechanical property of polymers is 
weaker than metal. In order to improve the radial strength, bioresorbable 
polymeric stents are optimized in geometries by increasing the strut width and 
thickness. But with thicker and wider struts, the range of dilatation and 
deliverability are limited. As discussed in Chapter 4, the radial strength of stent 
can be improved by increasing the material stiffness. Then improving the material 
properties of polymers, through material synthesis and processing, should be an 
effective approach to enhance the radial properties of polymeric stents. For 
instance, ring-opening polymerization method can be used to produce high-
molecular-weight PL(L)A with good mechanical properties. Material blending and 
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thermal treatment are effective to improve the material stiffness of polymers. 
9.3.2 Modelling work 
As presented in Chapter 5, significant high stresses were generated on the 
plaque-artery system after the deployment of stent. It means that there is a high 
risk of arterial wall damage caused by stenting. Therefore, damage mechanisms 
of plaque and arterial layers need to be considered and implemented in the 
modelling of the stent deployment in a diseased artery, in order to evaluate any 
acute damage of arterial walls. The evaluation of arterial wall damages can 
benefit the prediction of the clinical outcomes of stents, because arterial wall 
damage may result in some clinical complications like stent thrombosis and 
restenosis. It can also provide a more comprehensive understanding for stent 
performance.  
Moreover, vessel remodelling study is also required to investigate the healing 
process of injured vessel walls after stent deployment. Generally, vessel 
remodelling acts in the geometry and mechanical property, and it is caused by 
histological structure changes and external loads. In this study, vessel 
remodelling was modelled by changing vessel geometries (increase the lumen 
diameter), without considering the evolution of mechanical property and its 
intrinsic residual stresses. In the further work, material property change and 
residual stresses should be implemented for plaque-artery systems in the 
simulation of stent-artery interaction during vessel remodelling. 
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